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SUMMARY 
This project focuses on the Virus Infectivity Factor protein of HIV-1 and its relief of 
the block to virus replication exerted by the APOBEC3G component of the innate 
immune response.  
Virus Infectivity Factor (vif) is an accessory gene of HIV, deletion of which leads to 
large drops in virus infectivity. This decrease in infectivity was found to be due to 
APOBEC3G, an inhibitor of HIV replication which is constitutively expressed in 
peripheral blood mononuclear cells (PBMCs), the natural host cells for HIV in 
humans. Vif is indispensable to block the inhibitory effects of APOBEC3G thereby 
allowing normal viral replication to continue inside the host. This recognition of the 
critical role played by Vif in the viral replication cycle has centred studies on 
characterising the interactions of Vif with both APOBEC3G as well as other virus 
encoded proteins.  
Stimulation of proteasomal degradation of APOBEC3G is currently believed to be 
the primary anti-APOBEC3G effect induced by Vif. However recent reports, 
particularly those showing that Vif remains able to block the inhibitory actions of 
degradation resistant APOBEC3G, question the validity of this hypothesis. The 
recognition that both APOBEC3G and Vif become incorporated into HIV particles 
through an interaction with the precursor of the virion structural proteins, Pr55GAG 
has raised the possibility that they may compete with each other for this 
incorporation. Using techniques such as mammalian two-hybrid assays, sucrose 
gradient analysis of GAG virus-like particles (VLPs) and confocal imaging, the 
interactions of these proteins with Pr55GAG have been analyzed and the results 
obtained indicate that Vif competes with APOBEC3G for Pr55GAG binding leading to 
its displacement and exclusion from the budding HIV virions. This potentially 
important pathway for Vif activity and its significance in the development of novel 
antiretroviral drugs in the future will be discussed. 
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1.1 History of HIV 
 
The origin of HIV was from non-human primates in sub-saharan Africa. The virus is 
believed to have crossed the species barrier and infected humans sometime in the late 
19th or early 20th century (Worobey et al, 2008). The current HIV epidemic is known 
to have started in the late 1970s. Prior to this time, nothing was known about the 
virus due to the silent spread and slow evolution of infection.  
The first indications of this new infection came in 1981 in Los Angeles and New 
York when there was a sudden unexplained increase in cases of two very rare 
diseases: Kaposi’s sarcoma and Pneumocystis Carinii pneumonia especially among 
homosexuals and intravenous drug users (Gottlieb et al, 1981; Hymes et al, 1981; 
Masur et al, 1981). The affected individuals appeared to have become immune-
compromised thus rendering them susceptible to relatively avirulent organisms and 
malignancies. The term Acquired Immune Deficiency Syndrome (AIDS) was first 
coined by the CDC, Atlanta in 1982 to explain the occurrence of these uncommon 
diseases in a cluster in high-risk groups. 
In 1983, Luc Montagnier’s team at the Pasteur Institute in France isolated a virus 
from an African patient with persistent generalised lymphadenopathy as the 
causative agent of AIDS and named it Lymphadenopathy associated Virus (LAV) 
(Barré-Sinoussi et al, 1983). Later in 1984, Robert Gallo in the U.S confirmed the 
isolation of a retrovirus from AIDS patients and called it Human T-Lymphotropic 
Virus III (HTLV-III) (Popovic et al, 1984). The International Committee on 
Taxonomy of Viruses gave a new generic name Human Immunodeficiency Virus 
(HIV) for these viruses in 1986 (Coffin et al). 
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The first blood test for AIDS became available in 1985 and was based on the 
detection of antibodies to the virus in patient sera. Up until that point, the infection 
could only be diagnosed on the basis of characteristic opportunistic infections and 
malignancies. Following the availability of laboratory based diagnosis of infection, it 
quickly became clear that these terminal cases constituted only a minuscule 
proportion of the people infected with the virus. Following its recognition, the HIV 
epidemic has continued to rise and it has become one of the greatest threats to human 
health and well being. At the same time, there has been a lot of effort to study the 
virus, its mode of infection, its prevention and options for treatment. These efforts 
have led to a huge database of information which has increased our understanding 
both about the virus and the disease it causes. 
 
1.2 Classification 
 
The Human Immunodeficiency Virus (HIV) belongs to the Genus Lentivirus, which 
is a part of the Family Retroviridae. It is classified in Class VI of The Baltimore 
Classification of Viruses, it being a single stranded, positive sense RNA virus with 
an envelope that produces a DNA intermediate in its replication cycle. Two types of 
HIV are known, HIV-1 which originated in equatorial Africa and is closely related to 
a virus infecting Chimpanzees and HIV-2 which is confined to West Africa and is 
similar to a virus infecting Sooty Mangabey, an Old World Monkey (Gao et al, 1999; 
Reeves & Doms, 2002). HIV-1 is highly transmissible and is the major cause of the 
global HIV pandemic while HIV-2 has much lower transmissibility and is largely 
confined to West Africa. 
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1.3 Epidemiology 
 
HIV was unknown less than 40 years ago. So dramatic has been the spread of the 
epidemic that it has led to almost 25 million deaths worldwide since it started in the 
late 1970s. Currently there are almost 33 million people worldwide who are living 
with HIV. 
According to the latest UNAIDS report published in 2008, the annual number of new 
infections declined from 3.0 million in 2001 to 2.7 million in 2007. On the other 
hand, almost 2.0 million people died of AIDS in 2007 as compared to 1.7 million in 
2001. 
Globally, the epidemic has now stabilised but the number of new infections and 
AIDS related deaths are still unacceptably high. The number of people living with 
HIV is also steadily rising. This is due to a continued increase in the number of new 
infections particularly in economically less developed regions accompanied by the 
life-prolonging effects of anti-retroviral therapy.             
The HIV Epidemic has been disproportionately concentrated in sub-saharan Africa 
with 35% of the new HIV infections and 38% of AIDS deaths in 2007 occurring in 
that region (Fig.1.1). Almost 67% of the people living with HIV are also 
concentrated in sub-saharan Africa (2008 UNAIDS report). 
In the UK, an estimated 83000 people were living with HIV at the end of 2008 with 
almost one-third of these people being unaware of their infection. During 2008, there 
were 7298 new cases of HIV diagnosed in the UK (2009 HPA report). 
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Figure 1.1 Status of the global HIV epidemic in 2007, 2008 UNAIDS report: The HIV epidemic is disproportionately concentrated in 
southern Africa with the highest adult prevalence in that region (15-28%). 
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1.4 Routes of transmission  
 
HIV is transmitted between humans in three main ways: 
1.4.1 Blood or blood products 
Cause of infections in intravenous drug users and people receiving blood 
transfusions.  
1.4.2 Mother to child transmission 
This mode of infection is important in an HIV infected pregnant woman. 
Transmission of the virus occurs primarily during child birth or in the immediate 
post-natal period. 
1.4.3    Sexual intercourse 
Unprotected sexual intercourse is the most common route of infection. 
 
1.5 Antigenic variation and diversity of HIV 
 
HIV is a highly mutable virus. There are a lot of antigenic differences observed in 
the HIV genome from different isolates. Not only are HIV isolates obtained from 
different geographical areas different but isolates obtained from different individuals 
in the same region or more significantly isolates obtained from different sites of the 
same individual at the same time are also different (Ananthanarayan & Paniker, 
2000). These variations are believed to occur due to the nature of the reverse 
transcription process which lacks an error correction mechanism. 
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As described in section 1.2, HIV has been classified into two types i.e. HIV-1 and 
HIV-2 based on molecular and antigenic differences. HIV-1 and HIV-2 were 
transferred to humans from two distinct simian viruses and hence have low sequence 
identity. 
HIV-1 strains belonging to group M have been classified into genetically distinct 
subtypes or clades designated from A to K and these cause a majority of HIV-1 
infections worldwide. Some isolates from West Central Africa don’t fall under group 
M and are designated as group O (Outlier). In addition, some isolates found in 
Cameroon don’t fall in either group M or O and hence have been designated as group 
N (New). Recently a new virus strain derived from gorillas has also been found in 
Cameroon which doesn’t belong to any of these three groups. This strain has been 
designated as belonging to a new group P (Plantier et al, 2009). 
The HIV-1 subtypes show differentiated geographical distribution. Subtype A is the 
most common and is prevalent worldwide. Subtype B predominates in the Americas 
and Europe. Subtypes A, C and D are common in Africa while subtypes E, C and B 
are common in Asia, with subtype C being the most prevalent clade in India and 
China. 
 
1.6 Evolution of HIV infection 
 
The natural course of HIV infection can be divided into the following stages (Fig. 
1.2) (Ananthanarayan & Paniker, 2000): 
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1.6.1 Acute HIV infection 
In the 3-6 week period following initial HIV infection, about 50% of the infected 
individuals experience low grade fever, headache, malaise and lymphadenopathy. 
These symptoms resolve spontaneously after a relatively short time (< 2-3 weeks). In 
some people, this stage may be completely absent. Tests for HIV antibodies are 
generally negative initially but may become positive later in this stage. Hence this 
stage is also referred to as ‘seroconversion illness’. The symptoms during this period 
occur as a result of both the immune response as well as virus multiplication. 
1.6.2 Latent infection 
Every infected individual whether he/she goes through the first phase or not 
experiences the second stage of HIV infection. This stage which comprises 
symptomless chronic infection may last up to several years. In this phase, viral 
multiplication proceeds normally but due to the immune response mounted against 
the infection the viral load is kept under control thus preventing any clinical 
manifestations. However, the immune system is not capable of clearing the infection 
completely resulting in a simultaneous gradual decrease in CD4+ T cell count. 
1.6.3 Persistent generalised lymphadenopathy 
This is defined as the presence of enlarged lymph nodes, at least 1 cm in diameter, in 
two or more non-contiguous extrainguinal areas which persist for at least 3 months in 
the absence of any other illness or medication. This stage may progress to full blown 
AIDS. 
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1.6.4 AIDS related complex (ARC) 
During this phase, infected individuals suffer from various symptoms such as fatigue, 
loss of weight, diarrhoea and unexplained fever. Due to their immunocompromised 
state, minor opportunistic infections such as herpes zoster, oral candidiasis, 
salmonellosis and tuberculosis are fairly common. Many of the ARC patients 
progress to full blown AIDS in a few months. 
1.6.5 AIDS 
This stage represents the end stage of the illness and involves the irreversible 
breakdown of the immune system. As the immune system becomes weak, 
opportunistic infections and malignancies become more common. Patients are 
vulnerable to infections such as Pneumocystis carinii, Mycobacterium tuberculosis, 
Salmonella and Cytomegalovirus and malignancies like Kaposi’s sarcoma and 
lymphomas. The severity of AIDS depends on the type of infection or malignancy 
present. 
 
1.7 Diagnostic tests for HIV 
 
Different types of diagnostic tests are employed for the detection of HIV infection in 
humans (Ananthanarayan & Paniker, 2000). They are as follows: 
1.7.1 Detection of virus antigen 
The p24 antigen capture essay (ELISA) is the most common technique used for the 
detection of HIV p24 proteins in patient serum. If the patient gets infected with a 
large dose of infectious material, the antigen becomes positive as early as 2-3 weeks  
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Figure 1.2 Clinical course of an untreated HIV infection: As the CD4 T-cell 
count decreases in the acute stage of HIV infection, the plasma viral load increases. 
In the latent phase of HIV which can last as long as 10-15 years, the plasma viral 
load remains low as the virus remains dormant. During the corresponding period, the 
CD4 count starts dropping gradually. In the AIDS-related complex stage, the CD4 
count becomes very low and viral load starts to increase again as the immune system 
can’t control the infection. A number of opportunistic infections may occur during 
this period due to the immunocompromised state. Patients in this stage of infection 
usually proceed to full-blown AIDS in a couple of months. AIDS represents the end 
stage of the infection and complete breakdown of the immune system. (Figure 
modified from Pantaleo G et al ,1993). 
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after exposure. However if the infective dose is small, it may take up to 4-6 weeks 
for the appearance of p24 in the patient’s serum. The p24 antigen is positive in the 
beginning of infection, becomes negative in the latent phase and resurfaces again at 
the end-stage of disease. 
1.7.2 Detection of viral load 
The viral load after infection mirrors p24 antigen levels. It is high immediately 
following infection in the first stage of the disease. Later, it becomes low in the latent 
stage and rises again in the end-stage of disease. The diagnostic technique employs 
incubation of the patient’s lymphocytes with uninfected lymphocytes and 
Interleukin-2. The presence of HIV is detected by reverse transcriptase activity and 
positive viral antigens. However, this test can’t be used for large scale diagnostic 
screening as it gives many false negative results. In addition, due to the risks 
associated with working with infectious virus, this test can only be employed in labs 
with suitable containment facilities. 
1.7.3 Polymerase chain reaction 
This test is the gold standard for the diagnosis of HIV at all stages of the infection. 
However, it is too expensive to be used routinely as a screening test for HIV 
infection. In this technique, the patient’s lymphocytes are lysed and proviral 
DNA/RNA is amplified using primers specific for relatively constant regions of the 
HIV genome. The amplified products are characterised using nucleic acid 
hybridisation. It is a very sensitive test and if done with proper controls, the proviral 
DNA can be detected at a frequency of 1 copy per 10,000 cells. 
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1.7.4 Detection of the virus antibody in patient’s serum 
Antibody detection is the simplest and most commonly used diagnostic method for 
detection of HIV infection. However, it may take up to several weeks for antibodies 
to develop to detectable levels in serum. This period during which the antibody titres 
are negative but the person is infectious is called the ‘window period’. The tests 
employed for detecting antibodies against HIV can be divided into two types:  
1.7.4.1 Screening antibody capture assay (ELISA) 
Antigens representing all groups and subtypes of HIV-1 and HIV-2 obtained from 
HIV grown in T-lymphocyte cell lines or by recombinant techniques are coated onto 
the wells of ELISA micro titre plates. The patient’s serum is incubated with the 
antigens and if the serum is positive for HIV antibodies, it can be detected 
colorimetrically using anti-human immunoglobulin as the secondary antibody. This 
test is highly sensitive but not so specific and can yield many false positives. 
However, it is easy to perform and is used on a large-scale for screening patients. 
1.7.4.2 Confirmatory assay (Western blot) 
In this test, HIV proteins are separated using SDS-PAGE and blotted onto 
nitrocellulose membranes. The blots are probed by test sera and enzyme-conjugated 
anti-human immunoglobulin is used as a secondary antibody. The western blot is a 
very specific test and is usually used to confirm results obtained in a screening 
antibody capture ELISA.  
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1.8 Treatment of HIV infection 
The treatment of HIV infection involves a three-pronged strategy: 
1.8.1 Prevention and prophylaxis of opportunistic infections and malignancies 
As the immune system of an HIV infected individual becomes compromised, the 
person becomes susceptible to numerous opportunistic infections and malignancies. 
Diagnosing them without delay and initiating proper treatment of these infections is 
important in improving the health of an individual. 
1.8.2 Specific anti-HIV drugs 
In addition to the treatment of opportunistic diseases, it is of utmost importance to 
keep the HIV infection itself under control. Hence regular monitoring of the CD4+ T 
cell count and viral load (viral RNA levels) of the patient is recommended. If the 
CD4+ T cell count drops below 350/mm3 or viral load increases, treatment with 
specific anti-retroviral drugs is initiated. There are more than 20 Food and Drugs 
Administration (FDA) approved drugs currently targeting HIV and they can be 
divided into 5 groups: 
1.8.2.1 Nucleoside reverse transcriptase inhibitors (NRTIs): e.g. Zidovudine (AZT), 
Lamivudine (3TC), Didanosine (ddI).  
Mechanism of action: NRTIs as their name suggests are nucleoside analogues. AZT 
is a thymidine analogue, 3TC is a cytidine analogue and ddI is an adenosine 
analogue. They get incorporated into viral cDNA by mimicking nucleotides and 
compete with the deoxyribonucleotides within the cells (Perno et al, 1988; Sarafianos 
et al, 2009). The only structural difference is that they lack a 3’OH group on the 
deoxyribose sugar. This leads to the 5’-3’phosphodiester bond needed to extend the 
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DNA chain not being formed. This process is called chain termination. However, 
before they can prematurely terminate the formation of viral cDNA, nucleoside 
analogues need to be activated to nucleotides by phosphorylation (Furman et al, 
1986). This step is carried out within the cell by cellular kinases. Thus NRTIs act 
during the reverse transcription process and prematurely terminate the formation of 
viral cDNA thereby inhibiting HIV replication. 
1.8.2.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs): e.g. Delavirdine 
(DLV), Efavirenz (EFV), Nevirapine (NVP). 
Mechanism of action: NNRTIs are chemically different from NRTIs and do not 
require cellular kinases to activate them. All NNRTIs though chemically different 
interact at the same site on HIV-1 reverse transcriptase. They bind to a region of the 
p66 subunit of the HIV-1 RT p66/p51 heterodimer called the NNRTI binding pocket 
thus inhibiting the enzyme from completing reverse transcription. It is important to 
note here that NNRTIs cannot bind to HIV-2 RT and hence can’t inhibit HIV-2 
replication (De Clercq, 1998). 
1.8.2.3 Protease inhibitors (PI): e.g. Indinavir (IDV), Nelfinavir (NFV), Amprenavir 
(APV). 
Mechanism of action: The HIV-1 protease cleaves the polyprotein precursors 
Pr55GAG and Pr160GAG-POL into smaller proteins resulting in the reorganisation of the 
virion structure by a process called maturation. Maturation of the virus particle 
during or just after budding is critical for subsequent virus infectivity. PIs are 
synthetic analogues of the phenylalanine-proline cleavage site on Pr55GAG (Debouck, 
1992). They act on the viral protease and prevent the cleavage of the polyprotein 
precursor thereby blocking the process of maturation and infectivity of nascent 
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virions. Thus the primary action of PIs is to prevent subsequent waves of infection 
and they have no effect on the cells harbouring intergrated proviral DNA (Flexner, 
1998). 
1.8.2.4 Fusion or entry inhibitors: e.g. Enfuvirtide (T-20), Maraviroc (MVC). 
Mechanism of action: There are currently two approved entry inhibitors with 
different targets but each affecting the process of viral entry into the cell. 
a) Maraviroc – It is a selective CCR5 antagonist and small-molecule inhibitor which 
inhibits HIV-1 gp120 binding to CCR5, thus preventing gp160-CCR5-mediated cell-
cell fusion and therefore inhibits HIV entry into cells (Dorr et al, 2005). It is an 
allosteric inhibitor which interacts with the hydrophobic pocket in the 
transmembrane helices of CCR5 and changes the conformation of the extracellular 
loops thus disrupting the gp120 binding site (Tilton & Doms, 2010). 
b) Enfuvirtide – It is a 36-mer oligopeptide whose sequence corresponds to the HR2 
region of gp41. It interacts with the HR-1 trimeric region of gp41 and prevents the 
association between HR2 and HR1. The association between HR1 and HR2 is 
essential to proximate the viral and cellular membrane and form a viral pore for entry 
into the cell cytoplasm (discussed in greater detail in sections 1.10.1.3 and 1.11.1). 
Enfuvirtide inhibits this final step of viral entry and thus prevents infection (Tilton & 
Doms, 2010). 
1.8.2.5 Integrase inhibitors: e.g. Raltegravir (RAL). 
Mechanism of action: Integration of the HIV DNA into the host chromosomal DNA 
is a multi-step process catalysed by the viral enzyme integrase. It involves interaction 
of the enzyme with the viral DNA, formation of a stable pre-integration complex, 
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transfer of the complex from the cytoplasm to the nucleus and finally the integration 
of the viral DNA into the host genome. Integrase inhibitors act on the active sites 
within the integrase and prevent the viral strand transfer into the host thus preventing 
the cells from forming an integrated provirus. As the viral DNA can’t integrate, it is 
targeted by the cellular DNA repair mechanisms and rendered inactive (Cocohoba & 
Dong, 2008). 
The treatment strategy used with these drugs is called Highly Active Anti-retroviral 
Therapy (HAART). The principle behind this strategy is administering a combination 
of 2 or more drugs concurrently can significantly delay the development of viral 
resistance. If the same drugs were to be given individually and sequentially, the onset 
of resistance would be much quicker. Although HAART is not a cure for HIV, it can 
significantly increase the life span of people infected with the disease. 
1.8.3 General health management of the patient 
When a patient is diagnosed with HIV, it becomes very important to remove some of 
the misconceptions about the disease. Hence counselling is an important part of 
treatment. In addition, nutritional guidance and treatment compliance are two 
significant arms that need to be explained in detail to the patient.  
Thus regular health check-ups, adhering strictly to treatment regimens and proper 
nutrition can help the patient control HIV infection for many years enabling him/her 
to lead an almost normal life. 
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1.9 Structure of the HIV virion 
 
The HIV particle is an approximately 120nm spherical particle with an outer 
envelope made up of lipid (Fig. 1.3). 72 spikes made up of proteins gp120 and gp41 
project from the envelope. Inside of the envelope, lies the layer of matrix protein, 
also called p17. Lining the spherical matrix protein from inside is the toroidally 
shaped nucleocapsid, whose predominant constituent is p24, the serologic marker of 
HIV replication. The nucleocapsid also contains three enzymes Reverse 
Transcriptase (RT), Protease (PR) and Integrase (IN) which are essential for viral 
replication (Gelderblom et al, 1988; Haseltine, 1991). In addition it contains two 
identical functional strands of viral genetic material which is single stranded positive 
sense RNA. Hence retroviruses are unusual as the sole examples of genetically 
diploid viruses. 
1.10 Genes and gene products of HIV 
HIV genome consists of 9181 bases of linear single stranded RNA. As shown in 
figure 1.4, the integrated provirus encodes 9 proteins. At either end are Long 
Terminal Repeats (LTR) involved in the initiation of transcription and viral 
replication.  
The genes of HIV can be classified as follows: 
1.10.1 Structural genes / viral proteins 
1.10.1.1 Gag 
The Gag gene of HIV encodes a polyprotein precursor, Pr55GAG (named on the basis 
of its molecular weight, 55 kDa) (Fig. 1.4). Pr55GAG is on its own capable of self- 
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Figure 1.3 Diagram to illustrate the structure of the HIV virion: The outermost 
layer is made up of lipids. From this layer project 72 spikes made up of the envelope 
glycoproteins gp120 and gp41. The envelope is lined from the inside by the matrix 
protein (p17) layer. The innermost toroidal core is made up predominantly of the 
capsid protein (p24). The capsid encloses two identical strands of viral genetic 
material, single stranded positive sense RNA along with the viral enzymes Reverse 
Transcriptase, Protease and Integrase. (Courtesy: HIV InSite) 
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assembly to generate immature Gag virus-like particles even in the absence of other 
viral proteins or genomic RNA (Gheysen et al, 1989; Karacostas et al, 1989). The 
structural proteins of HIV have to perform two very contrasting functions if HIV is 
to replicate successfully in its host cells. On the one hand, they have to disassemble 
into small proteins and help direct the viral genetic material to the nucleus during the 
post-entry phase while on the other hand during the post-integration phase they have 
to form ordered multimerised structures capable of localising to the cytoplasmic 
membrane, initiating assembly of the progeny virus particles and their subsequent 
budding from the cell surface. These dual functions are achieved by Pr55GAG first 
performing the assembly function and later being cleaved into subcomponent 
proteins by the viral enzyme protease (Freed, 1998).  
During or shortly after budding Pr55GAG is cleaved into matrix (MA or p17), capsid 
(CA or p24), nucleocapsid (NC or p7) and p6 (Henderson et al, 1992). Two spacer 
peptides p2 and p1 are also generated from the cleavage process (Sheng & 
Ericksonviitanen, 1994). These latter two small peptides assist in the ordered 
cleavage and maturation of virus particles (Pettit et al, 1994). The process of 
cleavage of Pr55GAG into different fragments is called maturation as it results in 
many morphological changes in the newly released virus particles. MA remains 
attached to the inner surface of the viral membrane while CA forms a conical core 
around the NC-viral RNA complex (Gelderblom et al, 1988). The end result of 
maturation is the formation of fully infectious HIV particles capable of invading 
other cells. The functions of the individual fragments generated as a result of 
cleavage are discussed below: 
MA is formed from the cleavage of the N-terminal region of Pr55GAG. The N-
myristoylated MA protein has been implicated in directing Pr55GAG to the plasma 
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membrane and initiating particle assembly (Bryant & Ratner, 1990; Gheysen et al, 
1989; Gottlinger et al, 1989; Hermida-Matsumoto & Resh, 2000). It also plays a role 
in Env incorporation into the budding virus particles which is demonstrated by the 
fact that multiple amino acid substitutions (Dorfman et al, 1994b) and single residue 
mutations (Freed & Martin, 1995b) in HIV-1 MA block Env incorporation into the 
HIV particles. In the post-entry stage of the viral life cycle MA has been found to be 
a part of the pre-integration complex which is responsible for transporting viral DNA 
produced by reverse transcription of the viral genome to the nucleus (Bukrinsky et al, 
1993b; Gallay et al, 1995; Miller et al, 1997).  
CA or p24 is the second sequential product of Pr55GAG cleavage. The conical shell 
which protects the viral RNA is made up predominantly of CA. The C terminal 
domain of CA contains a highly conserved sequence, the major homology region 
(MHR), which has been shown to be involved in Gag oligomerisation (Dorfman et 
al, 1994a; Zhang et al, 1996). CA has also been shown to be involved in the 
incorporation of Gag-Pol precursor into the budding HIV virions thus enabling RT, 
PR and IN to be incorporated into the virion (Smith et al, 1993; Srinivasakumar et al, 
1995). The N-terminal domain of CA has been reported to be essential in the specific 
incorporation of Cyclophilin A (Cyp A) in the virion (Franke et al, 1994; Thali et al, 
1994). Virions lacking Cyp A show early post-infection defects (Thali et al, 1994). 
While mutations in the C-terminal region of CA disrupt Gag-Gag interactions and 
thus efficient release of the progeny particles, mutations in the N-terminal region 
cause no such decrease in the efficiency of release of HIV virions (Freed, 1998). By 
contrast, these mutations are known to disrupt the normal core condensation process 
thus interfering with the viral maturation and subsequent infectivity (von Schwedler 
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et al, 1998). Thus the N-terminal region of CA is essential for the proper functioning 
of the viral machinery at early times post-infection. 
NC or p7 is the third cleavage product of Pr55GAG. NC contains two zinc-finger 
motifs within its sequence. These motifs are essential for the specific binding and 
thus incorporation of the viral RNA into the budding virion (Aldovini & Young, 
1990; Schwartz et al, 1997; Zhang & Barklis, 1997). NC has also been shown to 
have a role in the process of RNA dimerisation (Darlix et al, 1990; Derocquigny et 
al, 1992) and thus thermodynamic stabilisation of the RNA structure through a 
process called RNA maturation (Feng et al, 1996b). The N terminal ‘I’ (Interaction) 
domain of NC has been implicated as playing a role in efficient virus assembly and 
release (Bennett et al, 1993; Jowett et al, 1993) . In addition to its role as a part of the 
Gag precursor, the mature NC protein is also involved in important steps in the viral 
replication cycle. It is essential for the binding of tRNALys3, the primer for HIV-1 
reverse transcription, to the primer binding site located near the 5’ end of the HIV 
genome (Barat et al, 1993; Derocquigny et al, 1992). Thus NC plays a role in the 
initiation of reverse transcription and efficient strand transfer (Allain et al, 1994) 
during the reverse transcription process. 
The final product of Pr55GAG cleavage is p6. It is located at the C-terminal end of the 
Pr55GAG sequence. Mutations in p6 have been shown to hamper efficient release of 
HIV virions pointing to a role for p6 in the late budding stage which is discussed in 
detail in section 1.11.5 (Gottlinger et al, 1991). The viral accessory protein Vpr has 
been shown to get incorporated into HIV virions through a specific interaction with 
the p6 domain of Pr55GAG (Kondo et al, 1995), with the C-terminal domain of p6 
being implicated in this function (Paxton et al, 1993). Thus Gag plays a very 
important role in the replication cycle of the virus. 
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1.10.1.2 Pol  
The pol gene products are translated following a low-frequency ribosomal frame-
shifting event that results in the formation of a 160 kDa precursor Pr160GAG-POL, 
which contains the viral enzymes protease (PR), reverse transcriptase (RT) and 
integrase (IN) in addition to Pr55GAG (Fig. 1.4) (Jacks et al, 1988; Wilson et al, 
1988). The ratio of synthesis of Pr55GAG to Pr160GAG-POL is approximately 20:1 
(Jacks et al, 1988; Wilson et al, 1988) .  
Cleavage of the Gag-Pol precursor into component Pol proteins is brought about by 
the aspartic protease PR (Peng et al, 1989). Dimerised PR first cleaves itself out of 
the precursor and subsequently fragments the Pr160GAG-POL in an ordered process 
which ultimately results in the formation and release of fully infectious HIV particles 
(Graves et al, 1988; Mous et al, 1988). Inhibition of PR has no effect on the 
formation and release of virus particles but the process of viral maturation is affected 
resulting in the production of non-infectious virions. For the HIV replication cycle to 
be successful, it is critical that the stoichiometry of component Gag and Gag-Pol 
proteins is correct (Felsenstein & Goff, 1988). Hence the rate at which PR cleaves 
these protein precursors into mature proteins is very important. A small change in the 
amount of PR causes a huge difference in the quantity of the final products of 
cleavage ultimately affecting viral infectivity and morphology (Frankel & Young, 
1998). 
The second pol product is reverse transcriptase (RT). It is a heterodimer which has 
RNA and DNA dependent DNA polymerase as well as RNase H enzyme activities 
(Goff, 1990; Sarafianos et al, 2009). The heterodimer consists of two asymmetric but 
related subunits p66 and p51. The p51 subunit is cleaved from p66 by the viral 
protease after the formation of a p66/p66 homodimer (Sluis-Cremer et al, 2004). The 
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p66 subunit is 560 residues long, consists of two domains, polymerase and RNase H 
and acquires a right hand conformation when in solution (Sarafianos et al, 2009). The 
polymerase domain is composed of four sub-domains consisting of fingers (residues 
1-85 and 118-155), palm (residues 86-117 and 156-236), thumb (residues 237-318) 
and the RNaseH connection (residues 319-426) (Jacobomolina et al, 1993; 
Kohlstaedt et al, 1992). All the enzymatic activities of RT are exhibited by the p66 
subunit. In contrast, the p51 subunit plays a more structural role. It is 440 residues 
long and stabilizes the heterodimer (Herschhorn & Hizi, 2010). Interestingly the p51 
and p66 share the same four domains (fingers, palm, thumb and connection) and also 
fold in a similar way but the relative position of the domains in the two subunits is 
different resulting in a different tertiary structure (Herschhorn & Hizi, 2010). The 
nucleic acid binding cleft of RT is composed primarily of the p66 fingers, palm, 
thumb, connection and RNase H domains. However the base of the binding cleft is 
made up of the connection and thumb domains of p51 (Sarafianos et al, 2009). 
Nucleic acids bind RT is such a way that they are simultaneously in contact with 
both the polymerase and RNase H active sites. Upon binding of a nucleic acid the 
p66 thumb changes its conformation from ‘closed’ where it is in contact with the 
fingers to ‘open’ where it moves 30° away from them (Hsiou et al, 1996; Rodgers et 
al, 1995). This initiates the process of reverse transcription that is discussed in detail 
in section 1.11.2.  The end result of the reverse transcription process is the formation 
of a double-stranded cDNA copy of the HIV genome from single-stranded positive 
sense RNA (Gilboa et al, 1979). RNase H is essential for the cleavage of the RNA 
associated with the first DNA strand synthesised thereby allowing the single stranded 
DNA to synthesise its complementary strand (Hansen et al, 1988). The first DNA 
strand is primed by the RNA primer tRNALys3 and the second strand by the 
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polypurine tract which is resistant to digestion by RNase H (Pullen & Champoux, 
1990; Schultz & Champoux, 2008). As RT has no proof reading activity, reverse 
transcription is an error prone process resulting in the introduction of a number of 
changes into every new copy of the genome synthesised (Bebenek et al, 1989).  
The third and final product of pol is integrase (IN). IN integrates proviral DNA into 
the genomic DNA of the host cell. IN possesses two major catalytic activities namely 
3’ processing involving endonucleolytic cleavage at 3’-hydroxyl ends of the viral 
genome and strand transfer involving integration of the processed viral DNA into 
host DNA by trans-esterification (Delelis et al, 2008). The protein has 3 domains: 1) 
The N-terminal domain contains the zinc-binding site involved in multimerisation 
which is essential for IN function (Zheng et al, 1996) (2) the central catalytic domain 
which is critical for IN activity and 3) The C-terminal DNA binding domain which is 
significant for the stability of pre-integration complexes (PIC) (Delelis et al, 2008). 
1.10.1.3 Env 
The env gene encodes the glycoprotein precursor gp160, which is cleaved by the host 
protease enzyme furin into two proteins SU/gp120 and TM /gp41 (Fig. 1.4) (Freed & 
Martin, 1995a).  
Glycoprotein precursor gp160 is synthesised and co-translationally glycosylated on 
the rough endoplasmic reticulum (ER) and is transferred into the lumen of the ER. 
The stop transfer sequence is located in the central portion of the transmembrane 
domain of gp160. The glycosylation of the gp160 monomers by addition of high 
mannose sugars shortly after synthesis is followed by the oligomerisation of the 
individual precursor molecules. Oligomerisation is said to be essential in the transfer 
of the precursor from the ER to the golgi complex (Willey et al, 1991).  Once in the 
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golgi complex, some of the ER acquired high mannose oligosaccharide side chains 
are converted to more complex hybrid/terminally glycosylated forms and gp160 is 
proteolytically cleaved into gp120 and gp41 (Freed & Martin, 1995a; Willey et al, 
1988). The Env glycoprotein is extensively glycosylated with 24 glycosylation sites 
present in gp120 and 4 sites within the gp41 sequence. Carbohydrates amount to 
almost 45-50% of the final molecular weight of the fully formed Envelope 
glycoprotein (Allan et al, 1985).  The cleavage of the Env glycoprotein precursor at 
the golgi complex is inefficient and is catalysed by a host protease at a Lys/Arg-X-
Lys/Arg-Arg motif that is highly conserved in viral Env glycoprotein precursors 
(McCune et al, 1988). The cleavage is said to be catalysed by furin or a furin-like 
cellular protease (Hallenberger et al, 1992). Following cleavage into gp120 and 
gp41, the non-covalently associated oligomeric proteins are transported to the plasma 
membrane where they get incorporated into the budding progeny virions.  
These proteins remain associated with the lipid bilayer of cells infected with HIV as 
well as projecting from the virion surface as spikes. SU lies on the outer surface of 
the lipid bilayer and is important in CD4 receptor recognition, cell attachment and 
entry (Klatzmann et al, 1984; Sattentau & Moore, 1991).  TM is embedded within 
the lipid bilayer and is involved in virus-host cell membrane fusion and entry 
(Gallaher et al, 1989; Kowalski et al, 1987). 
Env plays a major role in the viral entry process (section 1.11.1) and getting an 
insight into the domain organisation of Env is critical to understanding the process of 
viral entry. The gp120 unit consists of five conserved (C1-C5) and five variable (V1-
V5) domains (Starcich et al, 1986). The conserved regions contain many domains 
which are critical for binding to host cells. In contrast, the variable regions (V1-V4) 
form exposed loops and play a role in countering the humoral immune response by 
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constantly changing epitopes. In addition, V1/V2 and V3 play a very important role 
in gp120 binding to the co-receptor (Tilton & Doms, 2010). The gp41 unit consists 
of a large exracellular ectodomain, a transmembrane domain spanning the viral 
membrane and a cytoplasmic domain on the inside of viral membrane. The 
ectodomain consists of an N’terminal fusion peptide and two heptad repeat regions 
(HR1 and HR2) which are critical for the fusion process (Dubay et al, 1992; Tilton & 
Doms, 2010).  
The growing genetic divergence between different HIV isolates can be attributed 
primarily to sequence variation in env (Lynch et al, 2009). Env is a major target for 
the humoral immune response against HIV and many neutralising antibodies are 
generated in humans against gp120. However the virus evades the antibody response 
by altering the gp120 sequence to generate antibody escape mutants (Frost et al, 
2005). 
1.10.2 Regulatory genes 
In addition to Gag, Pol and Env which are the proteins expressed by all retroviruses, 
complex retroviruses like HIV also encode other regulatory and auxiliary proteins 
which perform diverse functions in vivo.  
1.10.2.1 Tat (Transcriptional activator) 
HIV-1 Tat acts as a transactivator of various viral and cellular genes (Ju et al, 2009; 
Mahlknecht et al, 2008). The tat mRNA is modified post-transcriptionally by a 
double splicing event (Fig. 1.4) (Pugliese et al, 2005; Romani et al, 2010). Two 
important functional domains of Tat have been identified, the first is the N-terminal 
cysteine rich activation domain involved in interactions with various cellular factors 
and the second is the arginine-rich RNA binding domain involved in nuclear 
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localisation and binding to the transactivation response element (TAR) of the LTR 
(Rana & Jeang, 1999; Romani et al, 2010). Tat is known to influence mRNA 
transcription and elongation. Tat recruits cellular proteins to relieve the repression of 
viral LTR so that the viral promoter can induce expression of the viral genes 
(Richman et al, 2009). It binds to the RNA stem loop structure TAR located at the 5’ 
end of all initiated viral RNA transcripts, recruiting the cellular cyclin T1 and CDK9 
proteins in the process and resulting in the phosphorylation of the C-terminal domain 
of RNA polymerase II which potentiates the enzyme to synthesise full-length HIV 
transcripts (Williams et al, 2006; Zhou et al, 2003). 
1.10.2.2 Rev (Regulator of viral expression) 
Rev is known to regulate the switch between early expression of the Tat, Rev and 
Nef proteins of HIV and the later Rev-dependent expression of Gag, Pol, Env, Vif, 
Vpr, Vpu and the production of viral genomic RNA for packaging into newly formed 
virions (Fig. 1.4) (Cullen, 1992; Emini, 2002). This switch is accomplished by 
allowing the nuclear export of partially spliced and unspliced viral mRNAs (Malim 
et al, 1989). Thus early viral transcripts produced in the absence of Rev are spliced 
resulting in the expression of Tat, Rev and Nef (Fig. 1.4). As the amount of Rev 
increases it prevents the splicing and activates the export of unspliced viral mRNAs 
and late expression of viral structural proteins (Fig. 1.4). Rev interacts with the Rev 
response element (RRE) located in the env sequence to promote the stability of the 
unspliced mRNAs, their export from the nucleus and their translation into proteins 
(Malim et al, 1989).  
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1.10.3 Accessory genes 
In addition to the various structural and regulatory genes discussed above, the HIV 
genome also contains four other genes which although they are dispensable for 
growth in tissue culture systems, have been shown to be critical for the establishment 
of a successful infection in vivo (Trono, 1995). The genes vif, vpr, nef and vpu are 
collectively called the accessory genes of HIV. Of these four only Nef has Rev-
independent expression early in the regulatory phase of infection. Vif, Vpr and Vpu 
are expressed late in a Rev-dependent fashion during the structural protein phase of 
viral gene expression (Fig. 1.4). 
1.10.3.1 Nef 
Nef is an N-terminally myristoylated accessory protein of HIV-1 produced at all 
stages of viral replication and packaged non-specifically into HIV virions in low 
amounts (Li et al, 2005). It serves as an adapter protein and diverts host cellular 
proteins to perform functions that aid virus replication in host cells (Geyer et al, 
2001). Nef is known to downregulate the cell surface expression of both CD4 
(Garcia & Miller, 1991) and Class-1 MHC molecules (Schwartz et al, 1996). This is 
achieved by internalisation followed by lysosomal degradation of these molecules 
which in turn leads to inhibition of CTL-mediated lysis of HIV-1 infected cells and 
aids viral pathogenesis (Collins et al, 1998). Nef enhances viral infectivity by aiding 
`uncoating of the virion core and proviral DNA synthesis (Aiken & Trono, 1995; 
Bukovsky et al, 1997). Nef may also be responsible for cellular activation and in turn 
disease progression through cellular kinases Pak2 (Raney et al, 2005; Renkema et al, 
1999) and Hck (Foster & Garcia, 2008; Ye et al, 2004). Nef also regulates 
cholesterol trafficking by binding to newly synthesised cholesterol and transporting it 
to the site of viral budding in HIV-infected cells (Li et al, 2005; Zheng et al, 2003). 
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Cholesterol has been shown to be important in the HIV life cycle as depletion of 
cellular cholesterol leads to a decrease in HIV particle production (Maziere et al, 
1994). Thus Nef performs a number of important functions allowing viral replication 
to continue normally inside host cells. 
1.10.3.2 Vpr 
Vpr is a small basic nuclear protein expressed from a singly spliced mRNA (Fig. 1.4) 
(Emini, 2002; Li et al, 2005). It is expressed late in the viral replication cycle but is 
present in the early post-entry phase as it is incorporated into the budding progeny 
HIV virions through a direct interaction with the carboxy-terminal p6 domain of the 
Pr55GAG precursor (Bachand et al, 1999; Le Rouzic & Benichou, 2005). Vpr is 
efficiently packaged into the progeny virions with a Vpr:Gag ratio of 1:7 (Muller et 
al, 2000). After entry into host cells, the viral capsid gets uncoated and the single 
stranded genomic RNA is reverse transcribed to produce double-stranded DNA. The 
viral cDNA then associates with many viral and host cellular proteins to form the 
viral pre-integration complex (PIC) (Le Rouzic & Benichou, 2005). Vpr is a part of 
the PIC and enhances the transport of viral DNA from the cytoplasm to the nucleus 
for subsequent integration in non-dividing cells (Heinzinger et al, 1994). Another 
important function of Vpr is that of inducing the arrest of infected proliferating T 
cells in the G2 phase of the cell cycle (Jowett et al, 1995). The HIV-1 LTR is more 
active in the G2 phase of the cell cycle and thus Vpr creates a favourable 
environment for the efficient transcription of viral genes by inducing cell cycle arrest 
(Goh et al, 1998). 
1.10.3.3 Vpu 
Vpu is produced late in the replication cycle and is translated from a vpu-env 
bicistronic mRNA (Fig. 1.4) (Nomaguchi et al, 2008; Schwartz et al, 1990). It is not  
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Figure 1.4 Gene organisation of HIV with the mechanism of expression of the 
early and late genes in the replication cycle: The HIV-1 integrated provirus 
encodes 9 genes in total, 3 of which the gag, pol and env are the basic genes present 
in all retroviruses. In addition, HIV encodes 2 regulatory genes; tat and rev and 4 
accessory genes; vif, vpr, vpu and nef.  Rev acts as a switch to modulate the 
expression of the various genes at the right time in the HIV replication cycle through 
its interaction with the Rev response element (RRE) located in the env sequence to 
promote the stability of the unspliced mRNAs, their export from the nucleus and 
their translation into proteins. The first viral RNAs to be transcribed in the absence of 
Rev are spliced and hence the first viral proteins to be expressed are Tat, Rev and  
Nef as they are synthesised from fully spliced mRNAs and are referred to as early 
gene products. The level of the regulatory protein Rev determines the splicing of the 
RNAs. Thus Rev is responsible for the transition from the early regulatory phase of 
HIV infection where it directs the splicing of the majority of viral RNAs to the late 
structural phase of infection where it directs the transcription of partially spliced as 
well as full-length mRNAs which are translated into the structural proteins of HIV 
responsible for virion assemly. The late gene products of HIV are Gag, Pol, Env, Vpr, 
Vif and Vpu. 
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packaged into virions but is found only in virus infected cells (Nomaguchi et al, 
2008). Vpu is made up of two distinct domains, an N-terminal transmembrane 
domain and a cytoplasmic domain (Schubert et al, 1996). The cytoplasmic domain of 
Vpu, together with Nef and Env, is involved in the down-regulation of CD4 at the 
cell surface. While Nef enhances clathrin-mediated endocytosis of CD4 molecules at 
the cell surface and forwards them to the lysosomes for degradation and Env forms a 
complex with the newly synthesised CD4 in the ER, Vpu targets the CD4 in the Env-
CD4 complex mediating its subsequent degradation in the ER (Garcia & Miller, 
1991; Sattentau & Moore, 1991; Willey et al, 1992). This releases Env from the CD4 
complex and allows its proper incorporation into virions. Vpu is indispensible for 
normal virion release from HeLa cells, monocyte-derived macrophages and primary 
T-cells (Vpu-dependent cells) (Klimkait et al, 1990). By contrast, Vpu is not required 
for efficient virion release from 293T, COS and Vero cells (Vpu- independent cells) 
(Nomaguchi et al, 2008). Thus the virion release function of Vpu is cell type 
dependent. It has been shown recently that Vpu is required to counteract the host-
cellular virion release inhibitor Tetherin, with the N-terminal transmembrane domain 
being involved in this function. This is discussed in greater detail in section 1.12.3 
(Neil et al, 2008). 
1.10.3.4 Vif 
The Virus Infectivity Factor (vif) is one of the accessory genes of HIV (Strebel et al, 
1987). It codes for the Vif protein which is a 192 amino acid long 23kDa 
phosphorylated protein conserved among all primate and most other lentiviruses. Vif 
is expressed at late stages of the viral replication cycle and is found in both the 
nucleus and cytoplasm of the infected host cell (Goncalves et al, 1994). It co-
localises with the Gag protein in the core of the HIV virion (Bardy et al, 2001). The  
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characteristic properties and functions of Vif are discussed in greater detail later in 
this chapter. 
 
1.11 The replication cycle of HIV-1 
 
The HIV replication cycle can be divided into the following stages (Emini, 2002) for 
simplistic understanding of the mechanisms involved (Fig. 1.5): 
1.11.1 Virus entry and cell tropism 
HIV-1 is primarily known to infect CD4+ T-cells and macrophages which are its host 
cells in humans. Infection of dendritic and langerhans cells of the macrophage 
lineage is important for the transmission of virus infection as these cells are involved 
in the presentation of antigen to T-cells (Knight et al, 1990; SotoRamirez et al, 
1996). In addition, HIV also infects macrophages and microglial cells in the central 
nervous system (Johnson, 1995).  The viral envelope surface glycoprotein gp120 is 
crucial for the attachment of virus to its receptors. The process of viral entry requires 
the presence of the CD4 cell surface receptor (Stein et al, 1987) and at least one of 
the G-protein coupled co-receptors (GPCRs) with spanning seven-transmembrane 
regions on the surface of host cells (Feng et al, 1996a). The GPCRs play a crucial 
role in viral tropism to certain cell types.  
Most HIV strains which are able to infect cultured T-cell lines through an interaction 
of gp120 with the cellular receptor CD4 and co-receptor CXCR4 are called T-tropic 
or X4 viruses (Bleul et al, 1996; Feng et al, 1996a). These viruses also induce 
syncytia and hence are called ‘Sycytia Inducing (SI)’ viruses and are usually seen in 
late stage HIV disease when the immune system is waning (Connor et al, 1997; 
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Tersmette et al, 1988). On the other hand, some viruses use CCR5 as their 
chemokine co-receptor for entry and don’t induce syncytia in T-cell lines (Deng et al, 
1996; Dragic et al, 1996; Tersmette et al, 1988). These viruses are called Non-
syncytia Inducing (NSI) or M-tropic (macrophage-tropic) or R5 viruses (Coakley et 
al, 2005). R5 HIV-1 is the characteristic strain found in the early asymptomatic stage 
of the infection; it lasts throughout the disease and is the predominant strain 
transmitted between individuals (Schuitemaker et al, 1992). Some isolates are able to 
bind with both CCR5 and CXCR4 with equal efficiency and hence are called R5X4 
strains (Doranz et al, 1996). Although other chemokine receptors are also present on 
the surface of cells, all of the known strains of HIV-1 use CCR5 and/or CXCR4 as 
their co-receptors for attachment and entry (Choe et al, 1996; Doranz et al, 1996). 
T-tropic viruses can infect both resting and activated T-cells. However there is a 
post-entry block to virus replication in resting T-cells and so replication does not 
occur in these cells (Bukrinsky et al, 1991; Stevenson et al, 1990). Similarly X4 
viruses can infect macrophages but again virus replication cannot proceed normally 
due to a block at the post-entry level (Schmidtmayerova et al, 1998). M-tropic 
viruses can infect macrophages and activated T-cells but not resting T-cells due to 
the low expression of CCR5 on the surface of these cells (Bukrinsky et al, 1991; 
Spina et al, 1995).  
HIV entry into the cell is a multi-step process. The intial interaction between HIV 
and the target cell may be facilitated by positively charged domains on gp120 and 
negatively charged proteoglycans on the cell surface or by specific interactions with 
DC-SIGN on the dendritic cell surface (Geijtenbeek et al, 2000; Tilton & Doms, 
2010). These proteins don’t play a role in viral entry into the cell but do increase the 
efficiency of the process. The first specific stage of viral entry involves an interaction 
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between viral gp120 and the CD4 cellular receptor. The domain structure of Env has 
been discussed in detail in section 1.10.1.3. The epitopes within gp120 involved in 
this interaction are highly conserved and are discontinuous in the protein sequence 
(Kwong et al, 1998). The binding of gp120 to CD4 induces a dramatic 
conformational change in gp120 which enhances its binding affinity for the 
chemokine co-receptors (Wu et al, 1996). Later, gp120 interacts with either CXCR4 
or CCR5. Thus the gp120-CD4 interaction is a pre-requisite for the formation and 
exposure of the co-receptor binding site. Binding of gp120 to the co-receptor results 
in further conformational change in Env which in turn leads to the exposure of the 
hydrophobic fusion peptide of gp41 and its insertion into the host cell plasma 
membrane (Tilton & Doms, 2010). Following insertion, the heptad regions HR1 and 
HR2 of gp41 undergo an energetically favourable structural rearrangement bringing 
the transmembrane region of gp41 which is embedded in the viral membrane into 
close proximity to the fusion peptide which is now inserted into the host cell 
membrane. This re-positioning of gp41 results in the formation of the fusion pore 
and entry of the capsid into the cell (Chan & Kim, 1998; Kwong et al, 1998; Stein et 
al, 1987; Tilton & Doms, 2010). 
1.11.2 Reverse Transcription  
Following entry of the viral core into the cytoplasm of the target cell, the process of 
reverse transcription (RTN) converts the ssRNA of the input viral genome to dsDNA 
(Fig. 1.5) (Gilboa et al, 1979). Reverse transcriptase (RT) is the enzyme which 
carries out the whole process after associating with the viral genomic RNA and a 
primer to initiate RTN. HIV-1 specifically uses host cell tRNALys3 as a primer for 
RTN (Kleiman et al, 1991). The 3′ 18 nucleotides of this tRNA are complementary 
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to a site near the 5’ end of the HIV-1 RNA genome known as the primer binding site 
enabling the hybridisation of the tRNA to this site (Ratner et al, 1985). 
The first stage of RTN involves synthesis of the viral (-) DNA strand from the (+) 
strand RNA genome. The 5’ end of the viral RNA genome consisting of the 5’ 
unique sequence (U5) and the 5’repeat region (R) is synthesised by extending the 3’-
OH end of the tRNA primer (Herschhorn & Hizi, 2010). As RT reaches the end of 
the genome, its RNase H activity hydrolyzes the genomic RNA strand from the 
newly synthesised RNA/DNA hybrid. This leaves the (-) sense DNA strand 
designated as (-) strand strong stop DNA (sssDNA) which has sequences which are 
complementary to the identical repeat (R) sequences  located at both the 5’ and 3’ 
ends of the viral RNA genome. The (-) sssDNA then hybridizes to the 3’ end R 
sequences of the viral genomic RNA, this process being designated first (-) strand 
transfer (Luo & Taylor, 1990; Peliska & Benkovic, 1992). After the DNA hybridizes 
to the 3’ end R sequence of the genomic RNA, the (-) strand DNA synthesis 
proceeds and the copied RNA is degraded simultaneously by the RNase H activity of 
the RT (Sarafianos et al, 2009). 
Some purine-rich sequences show high resistance to degradation by RNAse H. One 
such sequence called the Major Polypurine Tract (PPT) is located at the 3’ end of the 
viral genome and serves as the primer for the synthesis of second (+) strand DNA 
(Rausch & Le Grice, 2004). All retroviruses use the 3’PPT as the primer for (+) 
strand DNA synthesis but some retroviruses such as HIV-1 also have additional 
PPTs, the most notable of which is the central PPT (cPPT) located in the centre of 
the genome in the IN coding sequence (Charneau et al, 1992). HIV-1 uses both of 
these PPTs as primers for the initiation of second (+) strand synthesis. 
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 (+) strand DNA synthesis begins at the PPT and proceeds by copying the (-) DNA 
strand to its 5’end. RNAse H removes the primer tRNA from the RNA/DNA duplex 
and this facilitates second strand transfer where the partially synthesised (+) DNA 
strand anneals with the (-) DNA strand at the complementary primer binding site 
segments (Peliska & Benkovic, 1992). The (+) and (-) DNA strand synthesis is then 
completed by each strand serving as a template for the other. The end result is the 
generation of dsDNA containing an LTR at either end. 
1.11.3 Nuclear import of proviral DNA and integration 
Once the dsDNA is synthesised, it gets incorporated into a complex with other viral 
proteins namely RT, IN, NC, MA and Vpr (Bukrinsky et al, 1993b; Heinzinger et al, 
1994). This complex is called the pre-integration complex (PIC). For the virus 
replication to start, the newly formed PIC should be transported to the nucleus (Fig. 
1.5). This is achieved by distinct nuclear localisation signals (NLS) on both MA and 
Vpr whose function though synergistic, is independent of each other (Bukrinsky et 
al, 1993a; Heinzinger et al, 1994). The PIC can be imported through the nuclear pore 
into the nucleus without the destruction of the nuclear membrane, which helps HIV-1 
to replicate in even terminally differentiated and static cells, a feature that favours 
efficient viral replication and spread (Emini, 2002). 
Following transport of the PIC to the nucleus, IN undergoes a series of steps to 
catalyse integration of the proviral DNA into the host chromosome. The first step 
involves endonucleolytic cleavage of a dinucleotide from the 3’ end of each strand 
leaving the viral DNA with 3’ CAOH overhangs referred to as 3’ processing (Delelis 
et al, 2008; Katz & Skalka, 1994). The next step designated DNA strand transfer 
involves cleavage of the host chromosome by nucleophilic attack from the 3’ 
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hydroxyl overhangs of the viral DNA and subsequent ligation of the viral DNA to 
the 5’ end of the target DNA at the cleavage site. The gaps generated in the target 
DNA as a result of the integration are repaired by host enzymes (Frankel & Young, 
1998; Miller et al, 1995). The end result is flanking of the integrated proviral DNA 
with 5 base pair repeats of the target site DNA (Delelis et al, 2008). 
1.11.4 Viral gene expression 
Following integration of proviral DNA into the host cell genome, HIV-1 uses the 
cellular machinery for its replication. Host RNA Polymerase II is responsible for 
transcribing the DNA into mRNAs which are either translated into viral proteins or 
are incorporated into the progeny virions as viral genomic RNA (Emini, 2002). The 
rate of transcription depends on cellular transcription factors such as NF-κB, NFAT-
1 and AP-1, particularly in the early transcription phase prior to the expression of Tat 
(Kingsman & Kingsman, 1996). Cellular activation signals result in these 
transcription factors binding the LTR and initiating viral RNA transcription (Cullen, 
1991). After the expression of Tat, the efficiency of viral transcription increases 
(Laspia et al, 1989). For the whole transcription process to proceed smoothly there 
needs to be a dynamic collaboration and balance between the host transcription 
factors mentioned above and the viral regulatory proteins Tat and Rev. The first viral 
mRNAs to be transcribed are spliced; this results in the first HIV proteins to be 
synthesised being Tat, Rev and Nef since they are expressed from fully spliced 
mRNAs and are referred to as early gene products of HIV. The level of the 
regulatory protein Rev determines the splicing of the RNAs (Malim et al, 1989). 
Thus Rev is responsible for the transition from the early regulatory phase of HIV 
infection where it directs the splicing of the majority of viral RNAs to the late 
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structural phase of infection where it directs the transcription of full-length mRNAs 
which are translated into the structural proteins of HIV responsible for virion 
assembly (Cullen, 1992).  
1.11.5 Virion assembly and release 
Pr55GAG is responsible for mediating the assembly and release of progeny HIV-1 
from host cells (Gheysen et al, 1989). The precise sequence of events leading to HIV 
assembly has not been determined and many events are said to occur simultaneously 
within the infected cell. Different regions of Pr55GAG perform different critical 
functions during particle assembly. MA is responsible for Gag targeting, membrane 
binding and Env incorporation (Bryant & Ratner, 1990; Dorfman et al, 1994b). The 
C-terminal region of CA along with the N-terminal I domain of NC is believed to 
mediate Gag multimerisation (Jowett et al, 1993; Zhang et al, 1996). The specific 
incorporation of viral genomic RNA is mediated by the zinc finger domains of NC 
(Schwartz et al, 1997), while p6 is responsible for the recruitment of the cellular 
protein complexes critical for efficient particle release (Gottlinger et al, 1991; Ono, 
2010). 
Initial Gag-Gag interactions are believed to occur in the cytoplasm while the 
formation of higher ordered structures appears to take place at the plasma membrane 
(Ono et al, 2000). Gag localises to the membrane micro-domains from where 
budding of progeny virions takes place (Holm et al, 2003). The Gag/Gag interactions 
also stimulate the formation of complexes between Gag-Pol and Gag (Bukrinskaya, 
2004). The Gag/Gag-Pol complexes are directed to the plasma membrane by the 
membranotropic signal present on the MA region of Pr55GAG (Halwani et al, 2003). 
The Gag/Gag-Pol ratio is essential for RNA dimerisation, a process that is required 
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for efficient RNA packaging and the integrity of the newly formed virions (Sakuragi 
et al, 2003; Shehu-Xhilaga et al, 2001). 
The HIV accessory proteins Vpr, Vif and Nef are also packaged into HIV virions. 
Vpr is packaged into the virions through an interaction with the p6 domain of 
Pr55GAG in a ratio of 1:7 (Bachand et al, 1999; Muller et al, 2000). It has an 
important role in the post-entry stage of infection which has been discussed in 
section 1.11.3. Vif also gets incorporated into the progeny virions through an 
interaction with Pr55GAG (Bardy et al, 2001; Bouyac et al, 1997a). Vif is believed to 
be important in virion core stability and infectivity (Bukrinskaya, 2004). Virions 
produced in its absence have reduced infectivity. Nef is packaged into progeny 
virions non-specifically and is believed to play a role during the virion uncoating 
process discussed in detail in section 1.10.3.1 (Aiken & Trono, 1995; Li et al, 2005). 
In addition to viral proteins, some cellular entities are also packaged into virions. 
One of them, Cyp A is packaged through an interaction with the CA domain of 
Pr55GAG and promotes viral infectivity (discussed in section 1.10.1.1) (Thali et al, 
1994). In addition the cellular RNAse L inhibitor HP68 is associated with pre-
assembled viral complexes of Gag, Gag-Pol and Vif and is believed to play a role in 
the formation of immature virus particles (Zimmerman et al, 2002). Numerous 
cellular RNAs also get incorporated into progeny virions, one of them being 
tRNALys3, which is the primer that initiates reverse transcription in the target cell 
post-entry. It gets incorporated through an interaction with specific RT sequences 
within Gag-Pol (Mak et al, 1994). 
Budding of progeny virions is initiated following the association of genomic 
RNA/polyprotein complexes with the Env glycoproteins at the plasma membrane 
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(Fig. 1.5) (Emini, 2002). Two domains have been identified in the p6 sequence, 
PTAP and LYPXnL, which mediate the efficient release of virions (Demirov et al, 
2002; Strack et al, 2003). Similar conserved domains like PPPY and YPDL have also 
been identified in other viruses and are collectively referred to as ‘late’ domains 
essential for the late budding stage of the virus (Bieniasz, 2006). The current view in 
the literature is that the late domains of HIV hijack the cellular machinery 
responsible for the inward vesiculation in late endosomes which generates 
multivesicular bodies (MVBs) and use this machinery for viral release from the cell 
surface (Fujii et al, 2007).  
The class E Vacuolar protein sorting (Vps) proteins in mammals are required for the 
formation of three high molecular weight endosomal sorting complexes required for 
transport (ESCRT-1, 2 and 3) of cargo like activated receptors to the MVBs before 
their degradation in lysosomes (Fujii et al, 2007). The cycling of ESCRT from the 
limiting membrane of MVB to the cytoplasm is catalysed by the ATPase Vps4. 
Several studies have shown an interaction of the PTAP domain of p6 with Tsg101 
(tumor susceptibility gene101), a component of the ESCRT-1 complex and 
demonstrated the importance of this p6-Tsg101 interaction in HIV budding and 
release (Demirov et al, 2002; Garrus et al, 2001; VerPlank et al, 2001). The 
recruitment of charged multivesicular body proteins (CHMPs), a component of the 
ESCRT-3 complex (Martin-Serrano et al, 2003; von Schwedler et al, 2003) and the 
activity of ATPase Vps4 are also required for this process (Kieffer et al, 2008). On 
the other hand, the LYPXnL motif of p6 has been demonstrated to bind with Alix, a 
protein playing a role in endosomal metabolism (Zhai et al, 2008). The p6-
Tsg101interaction is thought to play a primary role while the LYPXnL-Alix 
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interaction has been shown to have a supporting role in virus release and budding 
from the cell surface (Dussupt et al, 2009). 
Prior to the process of budding, the Gag-Gag and Gag-Pol complexes are selectively 
associated with membrane micro-domains predominantly made up of cholesterol, 
glycosphingolipids and sphingomyelin called lipid rafts (Aloia et al, 1993; Holm et 
al, 2003). It is believed that these lipid rafts act as scaffolds for the assembly and 
subsequent budding of the immature virions from the cellular surface. 
1.11.6 Maturation 
The virions released from cells are immature and made up of precursors of structural 
proteins arranged in a spherical configuration in close association with the envelope. 
These spherical immature virions are processed and matured in a process called 
maturation (Fig. 1.5). Maturation is not essential for assembly or release but is 
critical for the infectivity of the newly released virions (Peng et al, 1989). During the 
process, large-scale reorganisation takes place in the structure of the virus particle by 
ordered cleavage of poly-protein precursors by viral enzyme protease (PR) (Kohl et 
al, 1988; Wiegers et al, 1998).  
This cleavage of the Gag and Gag-Pol precursors takes place either at the plasma 
membrane immediately prior to budding or shortly after release of the virus particles 
(Kaplan et al, 1994). The first cleavages to occur are carried out by immature PR 
which is associated within the Gag-Pol precursor (Bukrinskaya, 2004). Two Gag-Pol 
precursors dimerise and are later cleaved to form the mature PR which is a dimer and 
is responsible for all subsequent cleavages (Tessmer & Krausslich, 1998). Ordered 
and accurate cleavage of the precursors is of prime importance for the infectivity of 
the mature virions. After activation of the mature PR, the first point of cleavage is  
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Figure 1.5 Schematic representation of the HIV-1 replication cycle: The major 
events occurring during the early and late stages of HIV-1 life cycle have been 
depicted above. (Figure adapted from: Freed EO, 2001)  
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between p2 and NC, the second between MA and CA and the last between CA and 
p2. The p2-NC cleavage in Gag is important for NC condensation to form the 
ribonucleoprotein (RNP) core (Wiegers et al, 1998). The last cleavage between CA 
and p2 triggers the formation of the conical CA shell over the NC/RNA core. This 
core condensation process is important for the conical, electron dense core 
morphology and hence infectivity (Wiegers et al, 1998).  
The reorganisation and morphological changes in Gag also results in a change in the 
conformation of the packaged viral genomic RNA. The genomic RNA dimer is 
initially encapsidated in an extended conformation while later it adopts a condensed 
structure (Fu & Rein, 1993; Vogt, 1996). PR based cleavage is believed to be 
essential in this step as it is the mature NC that mediates this reorganisation of the 
genomic RNA (Darlix et al, 1995). It is this condensed RNA together with the 
associated NC which provides a scaffold for the ordered maturation of the virus 
particles making them infectious (Sheng et al, 1997). 
 
1.12 Host cellular restriction factors affecting HIV infection 
 
To date, there are three major known types of host cellular restriction factors that are 
known to counteract HIV infection at three different stages of the HIV life cycle 
mentioned above. Although it is believed that there is still a vast amount of 
information to be accessed and there could be many more restriction factors 
inherently present in humans that are yet to be elucidated. While these factors are 
constitutively expressed in some cell types, they can be activated in other cells by 
type I interferon treatment. 
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1.12.1 APOBEC3 family of cytidine deaminases 
The APOBEC3 family of cytidine deaminases, their antiviral activities and the role 
of viral accessory protein Vif in overcoming the inhibition exerted by them is 
discussed in detail in sections 1.14 and 1.15. 
1.12.2 Trim5α  
The role played by Trim5α proteins in retroviral restriction was first evident when it 
was found out that these proteins were responsible for the inability of HIV-1 to 
establish a successful infection in old world monkeys (Stremlau et al, 2004). 
Similarly human and primate cells were found to be refractory to infection by certain 
strains of Murine Leukemia Virus (MLV) or Equine Infectious Anemia Virus 
(EIAV) (Hatziioannou et al, 2004; Keckesova et al, 2004; Perron et al, 2004; Yap et 
al, 2004). 
The molecular details of the blockade to viral replication exerted by Trim5α is not 
yet completely clear however a broad understanding is available. The C-terminal 
domain of Trim5α directly recognises the incoming viral capsid causing an 
irreversible, lethal lesion within the capsids leading to their premature disassembly 
and proteasome-mediated degradation (Stremlau et al, 2006). This domain also 
governs the specificity of Trim proteins towards capsid proteins from certain viruses 
(Perez-Caballero et al, 2005). The Trim proteins also consist of a central coiled-coil 
domain responsible for multimerisation which is known to be essential for Trim 
activity (Neil & Bieniasz, 2009). In addition, they also contain an N-terminal 
‘effector’ domain which increases the potency of inhibition mediated by Trim5α 
(Perez-Caballero et al, 2005). 
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HIV has evolved to escape this restriction exerted by human Trim5α by atleast two 
different mechanisms. Certain mutations in the HIV capsid sequence prevent its 
recognition by human Trim proteins and thus prevent the subsequent premature 
capsid disassembly and degradation (Ylinen et al, 2005). The HIV capsid proteins 
are also known to bind Cyclophilin A, a host cellular protein, which coats the capsid 
and prevents its degradation by Trim5α (Towers et al, 2003). 
However, still a lot remains to be known about the exact mechanism of Trim5α 
mediated post-entry inhibition of HIV replication, but it is one of the promising 
targets for future antiretroviral drug development. 
1.12.3 Tetherin 
Tetherin is a recently discovered antiretroviral restriction factor that acts at the virion 
release stage of the HIV life cycle (Neil et al, 2008; Van Damme et al, 2008). 
Tetherin crosslinks the mature virus particles to the cell membrane and thus prevents 
their release (Neil et al, 2006). The tethered virus particles are then reinternalised and 
directed to the late endosomes where they are either retained or destroyed by the 
lysosomal enzymes (Neil et al, 2006). 
However HIV has also evolved an escape mechanism from this tetherin-mediated 
restriction. HIV encodes the viral accessory protein Vpu which specifically 
sequesters tetherin from the sites of viral assembly thereby preventing the adverse 
effects of tetherin on viral particle release (Neil et al, 2008). Vpu reduces the level of 
tetherin at the cell surface and forwards it to the 26s proteasome for degradation 
allowing productive viral replication to continue within the PBMCs (Goffinet et al, 
2009; Van Damme et al, 2008). 
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Thus HIV-1 Vpu is critical for counteracting the host cell restriction factor tetherin 
and the proper release of the viral particles formed at the cellular membrane.  
1.13 The Virus Infectivity Factor of HIV 
 
1.13.1 Introduction 
The vif gene of HIV-1 was initially recognised as a short open reading (sor) in the 
centre of the HIV-1 genome, overlapping pol at its 5’end and vpr at its 3’end, which 
encodes a 192 amino acid protein (~23 Kdaltons) designated Vif (Kan et al, 1986; 
Lee et al, 1986; Ratner et al, 1985; Sanchez-Pescador et al, 1985; Wain-Hobson et al, 
1985). 
1.13.2 Cell type dependent requirement of HIV-1 Vif  
Vif, which has homologues in all lentiviruses with the exception of equine infectious 
anaemia virus (EAIV), is an abbreviation of virus infectivity factor and this stems 
from the fact that viral genomes with deletions of vif yield significantly lower levels 
(>3log10) of infectious virus when grown in a either a range of so-called ‘non-
permissive’ T-cell lines (eg: CEM,HUT78 and H9) (Fisher et al, 1987; Sodroski et 
al, 1986; Strebel et al, 1987) or crucially in peripheral blood mono-nuclear cells 
(PBMCs) (Gabuzda et al, 1994), the natural host cells for HIV-1 (Fig. 1.6). By 
contrast when such vif deleted virus is grown in other T-cell lines (eg: C8166, SupT1 
and Jurkat) termed ‘permissive’ cells, the yield of virus is similar to that seen with 
wild type virus (Fan & Peden, 1992; Gabuzda et al, 1992) (Fig. 1.6). This dichotomy 
of behaviour in different host cells could be explained either by the synthesis of a Vif 
substitute in ‘permissive’ cells or alternatively the synthesis of an inhibitor of virus 
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replication by ‘non-permissive’ cells that Vif is required to overcome. Using 
heterokaryons formed between permissive and non-permissive cells the latter 
phenotype was found to be dominant and consequently that Vif is required by HIV-1 
to overcome an inhibitor of viral replication expressed in PBMCs and non-
permissive T-cell lines (Madani & Kabat, 1998; Simon et al, 1998). In an elegant 
study using subtraction cloning, Malim’s group identified the cellular inhibitor as 
CEM15 (Sheehy et al, 2002) (subsequently called APOBEC3G abbreviated to A3G) 
which was rapidly shown to be a member of the APOBEC3 family of cytidine 
deaminases and is discussed in greater detail in the later sections of this thesis. 
1.13.3 General characteristics of the HIV-1 Vif protein 
Vif is a basic phosphorylated protein expressed in the late stages of the virus 
replication cycle (Yang & Gabuzda, 1999; Zhang et al, 2000). The majority of Vif 
protein appears to localise to the cytoplasm and cellular membrane mainly co-
localising with Pr55GAG (Goncalves et al, 1994; Karczewski & Strebel, 1996; Simon 
et al, 1997).  
Because of its highly insoluble nature and its tendency to aggregate, purification of 
the Vif protein has not been successful to-date and hence little structural data is 
available for this protein (Barraud et al, 2008). It shows no significant sequence 
similarity or regions of homology to any other known protein. It has therefore been 
very difficult to predict the various functional domains of Vif (Lake et al, 2003). 
However, biochemical analyses have revealed residues throughout the protein which 
are essential for a variety of Vif functions and interactions (Simon et al, 1999). 
 
 
48 
 
 
Figure 1.6 Cell type dependent requirement of HIV-1 Vif: When vif-deleted HIV-
1 infects certain T-cell lines e.g. C8166, its growth, replication and infectivity is 
similar to wild type HIV-1, consequently these cells are referred to as ‘Permissive’ 
cells for the virus. By contrast, when vif-deleted HIV-1 is allowed to infect other T-
cell lines eg H9 or more significantly, peripheral blood lymphocytes, the natural host 
cells for HIV-1 in humans, the first cycle of replication in these cells is normal. 
However, the resultant progeny virions are non-infectious; consequently these cells 
are called ‘Non-permissive’ cells for the virus. This difference in infectivity is due to 
the presence of an inhibitor of virus replication in the Non-permissive cells identified 
as belonging to the APOBEC3 family of proteins  (Figure adapted from: Rose et al, 
2004). 
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1.13.4 Conserved domains within the HIV-1 Vif protein 
The Vif proteins of closely related HIV-1 strains are highly conserved while those 
from distantly related lentiviruses have diverged significantly (Barraud et al, 2008; 
Oberste & Gonda, 1992). Sequence alignment of HIV-1, HIV-2 and SIV shows 
certain conserved domains such as the N-terminal tryptophan-rich stretch, a HCCH 
motif and a SOCS-box motif (Barraud et al, 2008).  
1.13.4.1 The N-terminal Tryptophan-rich region  
The N-terminal tryptophan-rich region (residues 1 to 21) in the Vif sequence has 
been shown to play a role in Vif recognition and subsequent suppression of the host 
cell restriction factors APOBEC3G (A3G) and APOBEC3F (A3F) (Fig. 1.7) (Tian et 
al, 2006).  
1.13.4.2 The HCCH motif 
The HCCH motif (residues 108–139) consists of two conserved His/Cys pairs, the 
sequence and spacing of which is critical for Vif function (Fig. 1.7). Each of the 
residues within these two pairs was found to be important for the binding of Cullin 5 
to Vif and the subsequent proteasomally mediated degradation of A3 proteins by the 
E3-ubiquitin ligase complex (Luo et al, 2005; Mehle et al, 2004a; Yu et al, 2004).  
1.13.4.3 The SOCS-box motif 
The highly conserved 144SLQYLA149 motif also called the SOCS-box is responsible 
for the binding of Vif to ElonginC, which further targets A3 antiviral factors to the 
proteasome for degradation (Fig. 1.7) (Mehle et al, 2004a; Mehle et al, 2004b; Yu et 
al, 2003; Yu et al, 2004).  
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1.13.5 Vif multimerisation 
HIV-1 Vif protein has a tendency towards multimerisation which is reported to be 
crucial for viral infectivity (Yang et al, 2001). It has also been found that blocking 
Vif dimerisation prevents the Vif-mediated degradation of A3 proteins and in turn 
leads to the incorporation of these proteins in progeny HIV virions (Miller et al, 
2007; Yang et al, 2003). Thus multimerisation of Vif is essential for the productive 
replication of HIV-1 inside host cells. The C-terminal domain of Vif, specifically the 
conserved 161PPLP164 amino acid sequence is involved in this function (Fig. 1.7) 
(Yang et al, 2003). As of yet, the exact role of multimerisation in Vif function and its 
active form within cells is still to be known. 
1.13.6 Vif phosphorylation 
HIV-1 Vif is phosphorylated in vivo and in vitro by cellular kinases. The 
phosphorylation of Vif was first identified by Yang et al through [32P] 
orthophosphate labelling of the in vivo transfected and expressed Vif protein in HeLa 
cells. Subsequently they performed kinase assays by incubating CEM cell lysates 
with purified Vif protein in presence of [γ-32P] ATP to show that Vif is also 
phosphorylated in vitro.  Analysis of the [32P]-labelled phosphoamino acids within 
the phosphorylated Vif protein pointed towards the involvement of serine/threonine 
residues in Vif phosphorylation (Yang et al, 1996).  
To identify the Vif phosphorylation sites, the purified protein was phosphorylated in 
vitro with [γ-32P] ATP in the presence of CEM cell lysate and subjected to protease 
digestion followed by radioactive peptide sequencing. Four major phosphorylation 
sites: T96, S144, T155 and T188, have been identified within the Vif sequence  (Fig. 
1.7) (Yang et al, 1996; Yang & Gabuzda, 1998). 
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Importantly, S144 is a part of the highly conserved 144SLQYLA149 motif (Section 
1.12.4.3) and phosphorylation of Vif at this site is critical for its activity as 
demonstrated by the fact that replacement of this residue with alanine results in loss 
of Vif activity and also inhibits HIV-1 replication (Yang et al, 1996). Vif binding to 
Elongin C is also negatively regulated by the phosphorylation of S144 within the 
SOCS-Box motif (Mehle et al, 2004a). Elongin C is an important part of the E3 
ubiquitin ligase complex required for the Vif-mediated degradation of A3G. Thus 
phosphorylation is important for productive HIV-1 infection but not A3G 
degradation. Thus the phosphorylated form of Vif may have some other as yet 
unknown functions independent from the degradation of A3G. Similarly, mutations 
of the T96 phosphorylation site result in inhibition of HIV-1 replication and 
significant loss of Vif activity (Yang & Gabuzda, 1998).  
The cellular kinases responsible for the phosphorylation and regulation of Vif protein 
were found to be p44/42 Mitogen-activated protein kinases (MAPK) (also known as 
ERK-1 and ERK-2). ERK1 and ERK 2 are present in all cell types and play a role in 
cellular proliferation and differentiation in response to various mitogens, growth 
factors and cytokines. Thus there exists a direct link between MAPK and HIV-1 
replication & infectivity and activation of MAPK by various mitogens and 
extracellular stimuli may conbtribute to activation of HIV-1 replication (Yang & 
Gabuzda, 1999). 
Thus phosphorylation plays an important part in Vif function. However its complete 
role in the replication cycle of HIV-1 is yet to be fully understood. 
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1.13.7 The Vif-Pr55GAG interaction 
Vif has been shown to interact with the precursor of the virion structural proteins, 
Pr55GAG. However, there are conflicting reports regarding the region of Vif involved 
in this interaction. Previous in vitro interaction studies suggested the carboxy-
terminal 22 amino acids as being important for this interaction (Bouyac et al, 1997a) 
however recent in vivo studies point towards the N-terminal Arginine-rich region and 
the central area (residues 70-100) of the Vif sequence as being indispensible for the 
Vif-Pr55GAG interaction (Syed & McCrae, 2009). 
1.13.8 The Vif-genomic RNA interaction 
Vif binds to HIV-1 genomic RNA in vivo (Dettenhofer et al, 2000; Khan et al, 2001) 
and in vitro (Dettenhofer et al, 2000; Henriet et al, 2005) and any mutation in the Vif 
sequence affecting its RNA function also reduces viral replication in non-permissive 
cells suggesting that RNA binding is crucial for Vif function (Khan et al, 2001; 
Zhang et al, 2000).  
It has been reported that Vif binds to the genomic RNA in the cytoplasm of virus 
infected cells to form a 40S messenger ribonucleoprotein (mRNP) complex (Zhang 
et al, 2000). The same report also mentioned that Vif-RNA binding affinity decreases 
in the presence of Pr55GAG while Vif does not exert any such effect on Gag-RNA 
binding. Recently it was shown that Vif preferentially and cooperatively binds to the 
5’ end of viral genomic RNA and is a part of a complex containing genomic RNA, 
Gag, Gag-Pol and HP68 (Henriet et al, 2005; Zimmerman et al, 2002). There is still 
considerable debate in the literature about whether Vif requires genomic RNA to 
mediate its encapsidation into the newly formed virus particles (Khan et al, 2001) or 
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whether the direct interaction between Vif and the NC domain of Pr55GAG is 
sufficient for the incorporation of Vif into progeny virions (Bardy et al, 2001). 
Vif has also been reported to promote the annealing of primer tRNALys3 to the primer 
binding site, favour genomic RNA dimerisation, decrease pausing of the RT and 
enhance first strand transfer during reverse transcription suggesting that Vif can 
operate as an RNA chaperone (Henriet et al, 2007). 
1.13.9 Intravirion processing of Vif by HIV-1 Protease 
Vif is packaged into the budding progeny virus particles where it is processed by the 
viral enzyme PR (Khan et al, 2002). The site of this processing has been mapped to 
position A150 within the Vif sequence (Fig. 1.7). Mutations in Vif which affect its 
PR processing also modulate viral infectivity indicating that processing of Vif is 
essential for its function (Khan et al, 2002). 
1.13.10 Role of Vif in HIV core stability  
Virions lacking Vif exhibit structural abnormalities in their nucleocapsid cores. The 
broad end of the cone shaped core in packed tightly with electron dense material but 
the opposite narrow end appears transparent (Borman et al, 1995; Bouyac et al, 
1997b; Höglund et al, 1994; Ohagen & Gabuzda, 2000). In addition, viruses 
produced in the absence of Vif form nucleoprotein complexes that disassemble 
prematurely leading to the nucleolytic destruction of the nucleic acids within them 
(Simon & Malim, 1996). When virion cores derived from both Vif- and wild type 
HIV-1 are subjected to harsh conditions to mimic the environment at the time of 
uncoating of the core within a target cell during infection, viral cores derived in the 
absence of Vif are much less stable and release the core-associated proteins like p24, 
RT and p7 more readily compared to cores produced in the presence of Vif   
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Figure 1.7 Schematic diagram of the Vif protein depicting its various functional 
domains: The N-terminal tryptophan rich region (green) spanning 1-21 amino acids 
is involved in the suppression of A3G and A3F proteins (Tian et al, 2006). Amino 
acids 1-114 (pink) confer RNA binding activity to HIV-1 Vif (Khan et al, 2001; 
Zhang et al, 2000). The highly conserved HCCH motif (brown) spanning amino 
acids 108-139 consists of two His/Cys pairs and is involved in binding of Elongin C 
to Vif and the subsequent proteasomal degradation of A3 proteins (Luo et al, 2005; 
Yu et al, 2004). The SOCS-box motif from amino acids 144 to 149 (red) is also 
highly conserved and mediates the binding of Cullin 5 to Vif and thus playing an 
important role in A3 degradation (Yu et al, 2004). Residues 161-164 (blue) are 
involved in the multimerisation of Vif which is essential for Vif function (Yang et al, 
2003). The four major phosphorylation sites for Vif have been depicted by the 
symbol      . These are T96, S144, T155 and T188 and play an important part in Vif 
function. Vif is processed by the viral enzyme protease and the site of PR processing 
has been mapped to A150  (Khan et al, 2002) and has been depicted by the symbol         
   . 
 
 
 
55 
 
 
(Ohagen & Gabuzda, 2000). All these findings point towards a role for Vif in the 
stabilisation of the virion core thereby influencing the subsequent uncoating process 
to give mature viral nucleoprotein complexes and functional preintegration 
complexes capable of establishing a productive infection. 
 
1.14 The APOBEC family of Cytidine Deaminases 
1.14.1 Background 
The APOBEC family of genes consists of Activation induced deaminase (AID) and 
APOBEC1 located on chromosome 12, APOBEC2 present on chromosome 6 and a 
series of 7 APOBEC3 genes found in a single gene cluster located on chromosome 
22 (Goila-Gaur & Strebel, 2008; Jarmuz et al, 2002). APOBEC proteins are present 
only in vertebrates and exert their effects by cytidine deamination through 
conversion of cytidine residues to uracil inducing hypermutation in either DNA or 
RNA. While APOBEC1 acts on mRNA, APOBEC3 and AID act on single stranded 
DNA (Wedekind, 2003; Yoshikawa et al, 2002).  
The earliest recognised family member is AID which is selectively expressed in 
activated B cell germinal centres.  It plays an important role in the innate immune 
response by promoting antigen derived antibody diversification through deamination 
of the cytidine residues in immunoglobulin genes (Conticello, 2008). This leads to 
immunoglobulin gene diversification, somatic hypermutation and class-switch 
recombination events (Franca et al, 2006; Neuberger et al, 2003). Like AID, 
APOBEC2 also has a cytidine deaminase motif and is expressed mainly in cardiac 
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and smooth muscles. However the role it plays in these cells is yet to be understood 
(Franca et al, 2006).  
APOBEC1 and APOBEC3 have developed later in evolutionary terms and are 
specific to mammals. APOBEC1 is expressed in the human small intestine and is 
responsible for ApoB pre-mRNA editing. It deaminates the cytidine at position 6666 
within the ApoB mRNA to uracil thereby changing a glutamine codon within its 
sequence into a stop codon. This results in the formation of ApoB48, a truncated 
functional form of ApoB instead of ApoB100 which is the original form. ApoB48 is 
an important constituent of the chylomicrons, the very low density lipoproteins 
(VLDL) responsible for the transport of triglycerides from the intestine to various 
body tissues (Anant et al, 1995; Conticello, 2008; Yang et al, 2000).  
The A3 family of proteins consists of 7 genes in humans and is discussed in more 
detail in section 1.14.2.   It is interesting to note that while rodents express just one 
APOBEC3 gene in addition of APOBEC1, 2 and AID, humans and other non-human 
primates have 7 APOBEC3 genes. The mechanism of this expansion in humans and 
other primates remains unclear. It is believed that APOBEC genes first evolved to 
counteract the activity of endogenous retrotransposons and so prevent genetic 
instability and later expanded their repertoire to exogenous invading genetic 
elements as well. This could be one of the reasons why there was an expansion in the 
number of APOBEC3 genes in humans and other non-human primates (Franca et al, 
2006). 
1.14.2 APOBEC3 proteins  
As indicated in section 1.13.2, the cellular anti-HIV factor counteracted by Vif was 
identified as belonging to the APOBEC3 (A3) family of proteins. The APOBEC3 
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family consists of APOBEC3A, APOBEC3B (A3B), APOBEC3C, APOBEC3DE 
(A3DE), APOBEC3F (A3F), APOBEC3G (A3G) and APOBEC3H. All these 
molecules act as cytidine deaminases and convert dC residue in DNA or RNA into 
dU thereby inducing hypermutation. Each member of the APOBEC3 family contains 
a characteristic domain structure. A short α-helical domain (H) is followed by a 
catalytic domain (CD). The CD is connected to a pseudocatalytic domain (PCD) by a 
linker (L) peptide (Fig. 1.8) (Jarmuz et al, 2002). In A3B, A3DE, A3G and A3F 
these domains are duplicated. Thus the domain organisation in these enzymes is H1-
CD1-L1-PCD1-H2-CD2-L2-PCD2. Each CD contains a conserved motif H-X-E-(X)
 
23-28-P-C-(X) 2-4-C in which the Histidine and Cysteine residues coordinate Zn2+ ions 
and the Glutamic acid is involved in the proton shuttling process that occurs during 
the deamination reaction (Betts et al, 1994; Goila-Gaur & Strebel, 2008; Jarmuz et 
al, 2002).  
1.14.3 Antiviral activities of various A3 proteins 
While A3G is by far the most studied member of the APOBEC3 family, there are six 
other members of the A3 family, A3A, A3B, A3C, A3DE, A3F and A3H, which are 
also involved in the mutation and restriction of HIV-1 under different conditions. 
However the most important antiretroviral A3 protein in terms of natural HIV-1 
infection in humans other than A3G is A3F (Malim, 2009). It has almost 50% 
sequence similarity to A3G and also has a Vif-sensitive restriction phenotype  
(Liddament et al, 2004; Wiegand et al, 2004). It is interesting to note that the 
sequence elements in Vif required to overcome the inhibition of A3G and A3F are 
distinct from each other (Russell & Pathak, 2007; Simon et al, 2005). A3G and A3F 
are both expressed in CD4+ T cells, the natural host cells for HIV in humans, and the  
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Figure 1.8 Domain organisation of APOBEC3 proteins:  This figure depicts the 
domain structure of the members of the APOBEC3 family. All molecules of the 
family have a conserved cytidine deaminase domain in their structure. While 3B, 
3DE, 3F and 3G have 2 copies of the domain within their coding sequence, 3A, 3C 
and 3H only have one copy. The two-domain enzymes have a catalytically active 
domain (Green) and a catalytically inactive domain (Red) (Figure modified from: 
Goila-Gaur et al, 2008). 
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Vif protein of HIV-1 has evolved to evade the antiretroviral effects of both these 
proteins allowing normal viral replication within these cells. 
Among the remaining candidates, A3B has been shown to inhibit HIV-1 replication 
even in the presence of Vif but the experiments have been carried out in 
overexpression single cycle infectivity assays and not in a spreading infection system 
(Bishop et al, 2004; Doehle et al, 2005). Moreover, the level of expression of A3B in 
CD4+ T cells is very low and hence it is unlikely that it would have a major effect on 
the natural course of HIV-1 infection (Malim, 2009).  
A3A, A3C, A3DE and A3H have all been shown to restrict HIV-1 infection 
modestly in a Vif-sensitive manner under various experimental conditions however 
the role played by these moieties in the natural course of HIV-1 infection is still 
under investigation (Bourara et al, 2007; Dang et al, 2006; Peng et al, 2007; Tan et 
al, 2009).  
1.14.4 APOBEC3G and its effects on viral infectivity 
1.14.4.1 Intracellular A3G complexes and antiviral activity 
A3G also has the ability to bind RNA in addition to its well documented effects on 
single-stranded DNA (Chelico et al, 2006; Iwatani et al, 2006). In fact, the RNA 
binding function may be important for regulating its catalytic and antiviral activity as 
demonstrated from the finding that RNAse treated A3G samples are catalytically 
more active (Chiu et al, 2005). Thus RNA may have a role to play in the formation of 
the cytoplasmic A3G High molecular mass (HMM) ribonucleoprotein (RNP) 
complexes observed in T-cells lines and activated CD4+ T-cells (Goila-Gaur et al, 
2008; Kozak et al, 2006; Wang et al, 2007b). Activated CD4+ T-cells are more 
permissive to HIV-1 than resting PBMCs in which there is a post-entry block to viral 
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replication (Chiu et al, 2005). In activated CD4+ T-lymphocytes A3G is 
predominantly found in the HMM form while in resting CD4+ T-cells it is found in a 
low molecular mass or LMM form (Chiu et al, 2005). Thus there appears to be a 
correlation between antiviral activity and the cellular configuration of A3G (Goila-
Gaur & Strebel, 2008). Analysis of the deaminase activity of A3G in transiently 
transfected 293T cells has revealed that HMM A3G was catalytically less active than 
LMM A3G but the activity of HMM A3G could be restored by RNAse treatment 
(Chiu et al, 2005). Thus the current view is that HMM A3G is catalytically inactive 
while LMM A3G raises a post entry block to viral replication. It is important to note 
here that this post entry block to viral replication is in no way related to the Vif-
sensitive restriction of HIV-1 which depends on the incorporation of A3G into 
budding virus particles and subsequent effect of A3G on viral DNA synthesis in the 
next cycle of viral replication. 
1.14.4.2 Vif-sensitive restriction of HIV-1 by A3G 
A broadly-accepted hypothesis to explain A3G inhibition of HIV-1 replication can be 
summarised as follows. In the absence of Vif, A3G from ‘non-permissive’ cells such 
as PBMCs, becomes incorporated into the assembling HIV virion through an 
interaction with the nucleocapsid (NC) region of Pr55GAG. An early event in HIV 
replication is the reverse transcription of the RNA genome into DNA. A3G is 
proposed to target the cytidine residues present in the single-stranded DNA 
intermediate. By deamination, it converts them to uracil, resulting in large numbers 
of guanine to adenine transitions in the proviral DNA synthesised. This 
hypermutation of the viral genome leads to its inactivation and the resultant 
phenotype of greatly reduced yield of infectious virus (Mangeat et al, 2003). 
However, the presence of functional Vif is proposed to promote the prior degredation 
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of A3G by recruitment into an E3 ubiquitin ligase complex, resulting in the 
polyubiquitinisation of A3G and its rapid proteasome-dependent degradation (Yu et 
al, 2003). This Vif-induced degradation of A3G means that it is not available for 
incorporation into the maturing virus particles and so a normal yield of infectious 
virus is produced.  
1.14.4.3 Deaminase-independent mechanisms of HIV-1 inhibition by A3G 
It became widely accepted that the antiviral activity of A3G correlated broadly with 
its cytidine deaminase function. However recently there have been a number of 
reports dissociating antiviral activity from cytidine deaminase function. A3G was 
found to inhibit the process of HIV-1 reverse transcription (Iwatani et al, 2007). A 
different group has reported that A3G inhibited the annealing of tRNALys3 with viral 
RNA thereby interfering with the initiation of reverse transcription (Guo et al, 2006). 
A3G was also reported to inhibit the DNA strand transfer reaction during the reverse 
transcription process (Li et al, 2007). Another report suggested the involvement of 
A3G with the HIV-1 Integrase and its inhibition of integration and proviral DNA 
formation (Luo et al, 2007). However there is still considerable disagreement in the 
literature about whether or not the deaminase-independent effects of A3G are 
sufficient to explain its antiviral activity. 
 
1.15 The role of Vif in A3G antagonism 
 
Expression of Vif in cells containing A3G leads to a gradual reduction in the steady 
state levels of A3G while the A3G mRNA levels remain relatively constant. A3G is 
an inherently stable protein with a half life of >8 hr (Goila-Gaur & Strebel, 2008). In 
pulse/chase analyses, in the presence of Vif the half-life of A3G was found to be 
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between 5 min and 4 hrs depending on the experimental protocol used (Goila-Gaur & 
Strebel, 2008; Marin et al, 2003; Mehle et al, 2004b; Stopak et al, 2003).  
As indicated in section 1.14.4.2, this reduction in A3G stability was found to be due 
to the Vif-induced degradation of A3G by the cellular ubiquitin-dependent 
proteasome system. Several domains in Vif are critical for this function. The highly 
conserved SLQ(Y/F)LA motif (referred to as SOCS box section 1.13.4) near the C-
terminus is involved in its binding with Elongin C, a component of the E3 ubiquitin 
ligase complex (Mehle et al, 2004a; Mehle et al, 2004b; Yu et al, 2003; Yu et al, 
2004). The HCCH domain (section 1.13.4) upstream of the SOCS motif is involved 
in the interaction with Cullin 5 (Luo et al, 2005; Mehle et al, 2004a; Yu et al, 2004). 
Thus the HCCH domain together with the SOCS box motif enable Vif to recruit the 
E3 ubiquitin ligase complex containing Cullin5, Elongin B, Elongin C and Rbx1 (Yu 
et al, 2003). Rbx1 complexes with A3G and speeds its polyubiquitination and 
subsequent degradation by the 26s proteasome (Yu et al, 2003). 
Unfortunately, as further studies have been reported, this straightforward model of 
A3G inhibition and its Vif-mediated alleviation has become undermined by 
observations that cannot easily be accommodated by the simple model. These 
include: 
(i) A mutation in A3G that renders it resistant to Vif induced proteasomal 
degradation but whose inhibition of HIV can still be alleviated by Vif (Opi et 
al, 2007). 
(ii) Mutants of Vif that have lost the ability to induce A3G degradation but have 
retained the ability to block the inhibition of HIV replication by A3G 
(Yamashita et al). 
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(iii) Mutants of A3G that appear to have lost their cytidine deaminase activity but 
nevertheless retain the ability to block replication of Vif deleted virus (Bishop 
et al, 2006; Iwatani et al, 2007). 
(iv) The severe impairment of virion nucleocapsid morphology and reverse 
transcriptase activity of Vif deleted (∆Vif) virus produced from the first cycle 
of growth in non-permissive cells (Goncalves et al, 1996; Hoglund et al, 
1994). 
(v) Fusion of A3G to a Vpr fragment allows it to escape the Vif blockade even 
though it continues to be degraded by Vif (Ao et al, 2008). 
These studies are discussed in greater detail in Chapter 3. They have lead to a view 
emerging that whilst there has been rapid progress in trying to dissect Vif’s role in 
overcoming the A3G based facet of the innate immune response against HIV-1, clear 
lacunae remain in detailed understanding of the mechanics of this process.  
 
1.16 Hypothesis 
 
The increasing number of reports showing that the mechanism of Vif-induced 
proteasomal degradation of A3G may not wholly explain its action in overcoming 
the A3G blockade to infectious virus production, suggest that some other mechanism 
may come into play in the Vif mediated exclusion of A3G from the HIV virion. It is 
known that both Vif and A3G proteins interact with Pr55GAG of HIV allowing them 
to be specifically incorporated into the core of the budding progeny virions (Alce & 
Popik, 2004; Bouyac et al, 1997a). Hence the possibility exists that Vif actually 
competes with A3G for Pr55GAG binding and excludes it from the budding virion 
core. 
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Therefore the central hypothesis that this study sets out to investigate is that a 
competition exists between Vif and A3G proteins for Pr55GAG binding whereby Vif 
outcompetes A3G resulting in the exclusion of the inhibitor from the budding 
progeny virions and prevention of its harmful effects in the next cycle of virus 
infection, as an alternative mechanism of Vif in overcoming the A3G block to HIV 
replication. 
 
1.17 Aims 
 
To understand the dynamics between Vif and A3G in greater detail and obtain 
evidence to support the hypothesis outlined above the following were the 
experimental objectives of this study: 
(i) To determine whether Vif and A3G interact at the same site on Pr55GAG. The 
simplest model of competition between these two proteins would involve 
both of them interacting at the same site and competing with each other for 
Pr55GAG binding. 
(ii) After showing that both Vif and A3G interact at the same site on Pr55GAG, the 
second objective was to demonstrate the competition between Vif and A3G 
for Pr55GAG binding resulting in the displacement and exclusion of A3G by 
Vif. 
(iii) To study the sub-cellular localisation of Vif, A3G and Pr55GAG and to find 
out if co-expression of Pr55GAG with Vif/A3G results in a change in the 
localisation pattern of Vif and/or A3G. 
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CHAPTER 2 
 
Materials and Methods 
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2.1 Suppliers 
 
General chemicals were obtained from BDH Laboratory Supplies, Fisher Scientific 
(Loughborough, Leicestershire), Merck Ltd. (Poole, Dorset) and Sigma-Aldrich 
Company Ltd. (Gillingham, Dorset) and were of molecular biology, analytical or 
blotting grade. 
Equipment and other reagents (unless otherwise stated) were obtained from the 
following suppliers: 
Bio-Rad Laboratories (Hemel Hempstead, Hertfordshire) 
Ammonium persulphate, TEMED, sodium dodecyl sulphate (SDS). 
Bio sera (East Sussex, U.K) 
Foetal Calf Serum (FCS). 
Fermentas UAB (Vilnius, Lithuania) 
Prestained Protein Ladder 10-180 kDa.  Restriction and modification enzymes. 
GE Healthcare, Amersham Biosciences (Amersham, Buckinghamshire) 
HybondTM Nitrocellulose membranes, ECLTM Advance Western Blotting Detection 
Kit 
Invitrogen Corporation, R & D Systems Ltd., (Abingdon, Oxfordshire) 
TA CloningTM System, restriction and modification enzymes, Taq DNA polymerase, 
1 Kbp DNA ladder, LipofectamineTM 2000 Reagent. 
New England Biolabs (UK) Ltd., (Hitchin, Hertfordshire) 
Restriction and Modification enzymes. 
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Qiagen Ltd., (Crawley, West Sussex) 
QIA quick Gel extraction kit. 
Roche Diagnostics Ltd., (Lewis, East Sussex) 
CAT ELISA kit. 
Sigma-Aldrich Company Ltd., (Gillingham, Dorset) 
Butanol (molecular biology grade),  kanamycin, ampicillin, SigmaSpinTM Maxiprep 
kit 
Whatman International Ltd., (Maidstone, Kent) 
Filter paper Grade 5 (70mm) 
National Diagnostics Ltd., (Hessle, North Humberside) 
ProtoGel 30% 
Department of Biological Sciences, University of Warwick – Media Preparation 
LB broth, LB agar, DMEM, Versene, trypsin, phosphate buffered saline (PBS), 10X 
Tris-Boric acid-EDTA (TBE), 10X SDS PAGE running buffer, 10X protein transfer 
buffer. 
 
2.2 Materials 
 
2.2.1 Standard buffers and solutions 
Luria-Bertani Broth (LB): 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) 
yeast extract. 
LB agar: LB Broth containing 1.5% (w/v) bacto-agar. 
Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM Na2HPO4, 1.4 mM 
KH2PO4 
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2X Sample buffer: 0.2% (w/v) SDS, 1% (v/v) glycerol, 50 mM Tris-HCl buffer 
(pH6.8), bromophenol blue. 
1X SDS PAGE loading buffer: 50% (v/v) 2 x sample buffer, 100 mM dithiothreitol 
(DTT) 
SDS PAGE running buffer: 0.05M Trisma base, 0.384M glycine, 0.1% (w/v) SDS 
Tris-HCl buffered saline (TBS): 50 mM Tris.HCl, 150 mM NaCl, pH 8.0 
TBE: 90mM Tris base, 90mM boric acid, 1mM EDTA, pH8.0. 
10X Agarose gel loading buffer: 50% (v/v) glycerol, 0.01% (w/v) bromophenol 
blue, 0.01% (w/v) xylene cyanol, 2% TBE (v/v). 
10X Protein transfer buffer: 1 L: 30.3 g Trizma base (= 0.25 M) ,144 g Glycine (= 
1.92), pH should be 8.3; do not adjust.  
TfbI: 10 mM RbCl2, 10 mM CaCl2, 30 mM potassium acetate, 50 mM MnCl2, 15% 
(v/v) glycerol, pH 5.8. 
TfbII: 10 mM RbCl2, 75 mM CaCl2, 10 mM 3[N-morpholino] propanesulphonic 
acid (MOPS), 15% (v/v) glycerol, pH 6.5. 
1X HBS:  1L : 5g HEPES (Acid), 8g NaCl, 1g Dextrose, 3.7g KCl, 10ml 
Na2HPO4(7H2O)  
TSE: 20 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA 
Stripping Buffer: 2% (w/v) SDS, 62.5mM Tris-HCl pH 6.8, 100mM β-
mercaptoethanol 
2.2.2 Bacterial Strain  
INVαF´ (Invitrogen)   
Genotype: F´ endA1 recA1 hsdR17 (rk-, mk+) supE44 thi-1 gyrA96 relA1 
φ80lacZ∆M15 
∆(lacZYA-argF)U169 λ- 
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2.2.3 Cell lines  
a) COS-1  
Description: SV40 transformed African Green Monkey Kidney cells (supplied by 
Prof. M. McCrae, University of Warwick) 
Culture Medium: DMEM + 10% FCS (v/v) 
b) 293T 
Description: SV40 transformed Human Embryonic Kidney cells (supplied by Prof. 
M. McCrae, University of Warwick) 
Culture Medium: DMEM + 10% FCS (v/v) 
2.2.4 Monoclonal antibodies 
a) Anti-HA antibody, produced in mouse (Sigma-Aldrich Cat. No. H9658) used at 
1:10,000 dilution for western blots and 1:250 dilution for immunofluorescence 
procedures. 
b) Mouse anti-Vif monoclonal antibody (Cat. No. 2745) obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH: from Transgene used at 1:250 dilution. 
c) mAb to p24 (ARP 454) obtained from the Programme EVA Centre for AIDS 
Reagents, NIBSC, UK and was donated by Drs. Ferns and Tedder, and DAKO 
Ltd UK used at 1:3000 dilution. 
d) Anti-Mouse IgG (γ-chain specific)−Alkaline Phosphatase antibody produced 
in goat (Sigma-Aldrich Cat. No. A3438) used at 1:25,000 dilution. 
e) Anti-mouse IgG (whole molecule)-Peroxidase antibody, produced in Goat 
(Sigma-Aldrich Cat. No. A4416) used at 1:5000 dilution. 
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f) Anti-Rabbit IgG (whole molecule)–Peroxidase antibody produced in goat 
(Sigma-Aldrich Cat. No. A6154) used at 1:100,000 dilution. 
g)  Alexa Fluor® 594 goat anti-rabbit IgG (H+L) antibody  (Invitrogen Cat. No.    
       A-11012) used at 1:3000 dilution. 
h)  Alexa Fluor® 594 goat anti-rabbit IgG (H+L) antibody  (Invitrogen Cat. No.    
       A-11005) used at 1:500 dilution. 
 
2.2.5 Antisera  
Rabbit HIV-1HXB2 Vif Antiserum obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: from Dr. Dana 
Gabuzda used at 1:1000 dilution for western blots and 1:200 dilution for 
immunofluorescence detection. 
2.2.6 Primers 
The oligonucleotide primers utilised in this study are shown in Table 2.2.1. All the 
primers were synthesised and supplied by Invitrogen Corporation unless stated 
otherwise. 
Table 2.2.1 Oligonucleotide primers used in this study 
Primer 
Name 
Primer Sequence Used for 
     NCDel                      5’GGC AAT TTT AGG AAC 
CAA AGA AAG3’ 
NC Region of Pr55GAG from 
amino acid 4 to 11; Position: 
1476 of the HIV Genome                                                              
NCReverse 5’TTG TCT ATC GGC TCC Amplification of NC Region of 
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TGC TTC TGA3’ Pr55GAG;  Position: 1777 of the 
HIV Genome 
NUCSeq 5’AGC ATT GGG ACC AGC 
GGC TAC ACT3’ 
 
Sequencing Primer for NC 
Region of Pr55GAG;   Position: 
1340 of the HIV Genome 
GagHpaF 5’CCA AAG AAA GAT TGT 
TAA CTG TTT CAA TTG 
TGG C3’ 
Creation of HpaI site at amino 
acid 13 on NC Region of 
Pr55GAG; Position: 1490 of the 
HIV Genome 
GagHpaR 5’GCC ACA ATT GAA ACA 
GTT AAC AAT CTT TCT 
TTG G3’ 
Creation of HpaI site at amino 
acid 13 on NC Region of 
Pr55GAG; Position: 1523 of the 
HIV Genome 
EcoGagF 5’CTT GGT GAA TTC ATG 
GGT GCG AGA GCG 3’  
 
Amplification of Gag from its 
origin along the establishment 
of an EcoRI site at its N 
terminal end; Position: 336 of 
the HIV Genome 
HpaIGagR   5’GCG CGT GTT AAC TCT 
CTG CAT CAT TAT GG3’ 
 
Pr55GAG amplification from 
amino acid  3 of the NC in 
reverse direction along with 
establishment of a HpaI site at 
the end; Position: 1475 of the 
HIV Genome 
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1551GagMu
tF 
5’ CA GCC AGA AAT TGC 
AGA GCT CCT GAG GAA 
AAG GGC TGT TGG AAA 
TG 3’ 
Forward primer for site 
directed mutagenesis of 
Pr55GAG to replace two basic 
amino acids with two acidic 
ones in the Basic Linker region 
of the NC 
1551GagMu
tR 
5’ CA TTT CCA ACA GCC 
CTT TTC CTC AGG AGC 
TCT GCA ATT TCT GGC TG 
3’ 
Reverse primer for site directed 
mutagenesis of Pr55GAG to 
replace two basic amino acids 
with two acidic ones in the 
Basic Linker region of the NC 
GagRSeq 5’GTC TGA AGG GAT GGT 
TGT AG3’ 
 
Reverse sequencing primer for 
the N-Terminal region of 
Pr55GAG along with the start 
codon; Position: 544 of the 
HIV Genome 
 
A3GRSeq 5’GCT GAA CCA GTG GAA 
GAA TC3’ 
 
Reverse sequencing primer for 
Apobec3G N-Terminal 
terminal region along with the 
start codon; Position:  456 of 
the APOBEC3G sequence 
pMSeq 5’AAG TGC GAC ATC ATC 
ATC GG3’ 
 
Sequencing primer for pM 
vector for checking if  the 
inserted gene sequence is in 
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frame with the GAL4-BD; 
Position:  793 of the pM vector 
sequence 
pVPSeq 5’ GAT GTT TAC CGA TGC 
CCT TG3’ 
 
Sequencing primer for pVP 
vector for checking if  the 
inserted gene sequence is in 
frame with the VP16-AD; 
Position: 612 of the pVP16 
vector sequence 
pcDNASeq 5’CCA CTG CTT ACT GGC 
TTA TC3’ 
 
Sequencing primer for pcDNA 
3.1 vector for checking the 
sequence and alignment of the 
inserted gene; Position: 838 of 
the pcDNA3.1 vector sequence 
DrC97AF 
 
5’ATA TCC TGG AGC CCC 
GCT ACA AAG TGT ACA 
AGG 3’         
Forward primer for site-
directed mutagenesis of A3G-
HA replacing Cysteine at 
position 97 with Alanine 
DrC97AR 5’CCT TGT ACA CTT TGT 
AGC GGG GCT CCA GGA 
TAT 3’ 
Reverse primer for site-directed 
mutagenesis of A3G-HA 
replacing Cysteine at position 
97 with Alanine 
EcoRIHAF 5’GAA TTC GCC ACC ATG 
TAC CCA TAC GAT 3’ 
 
Forward primer for the 
amplification of the 3xHA to 
tag it to the N-terminal end of 
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Vif  
EcoRIHAR 5’ GAA TTC AGC GTA ATC 
TGG AAC GTC ATA 3’ 
Reverse primer for the 
amplification of the 3xHA to 
tag it to the N-terminal end of 
Vif 
 
2.3 Molecular biology techniques 
 
2.3.1 Agarose gel electrophoresis 
DNA or cDNA samples were electrophoresed on 0.8 to 1.3 % Agarose gels 
containing 1µg/ml of Ethidium Bromide in 1X TBE buffer. 1/10 volume of 10X TBE 
agarose gel loading buffer was added to the samples and the 1kB DNA ladder before 
loading into preformed wells in the agarose gel. The samples were electrophoresed at 
70-100 mA for 60-90 minutes. The bands were visualised using the Bio-Rad Gel Doc 
XR system and analysed using the Quantity One 1D gel analysis software. 
2.3.2 Quantification of DNA 
Concentration of DNA solutions was determined by comparing an unknown DNA 
sample band on an agarose gel with a known quantity of 1Kb DNA ladder. The 1636 
bp band on the Invitrogen 1Kb DNA ladder was used as the reference. When 1µg of 
ladder was loaded per lane the 1636 bp band contains approximately 100ng of DNA.   
DNA concentrations were also measured using a NanoDrop ND-1000 V3.2.1 
(Thermo Scientific) at A260 where an absorbance of 1.0 corresponded to 50 µg/ml of 
DNA. The quality of DNA was estimated by using the A260/A280 ratio where a value 
≥ 1.8 indicated a pure sample. 
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2.3.3 Ethanol precipitation of nucleic acids 
DNA was precipitated from aqueous solutions containing 0.2M LiCl and at least 2.5 
volumes of ice cold 100% ethanol. The solution was kept at -70oC for 1 hour or at -
20oC overnight. The precipitated DNA was pelleted by centrifugation at 12000 rpm 
for 20 minutes. The supernatant was decanted and the pellet washed with 80% ice 
cold ethanol and centrifuged at 12000 rpm for a further 10 minutes. The supernatant 
was again discarded post-centrifugation and the pellet dried in vacuum for 30 
minutes. The dried pellet was resuspended in sterile water.  
2.3.4 Phenol extraction of nucleic acids 
Nucleic acid solutions were mixed with 2 volumes of Phenol/50mM Tris.HCl 
thoroughly for 1 minute. The samples were centrifuged briefly to separate the phenol 
and aqueous phases. After discarding the separated phenol, the aqueous solution was 
mixed with 2-3 volumes of diethyl-ether for 1 minute. Ether extraction was carried 
out 3 times until the aqueous solution became clear. The excess ether was removed in 
a stream of nitrogen gas for 1 minute. 
2.3.5 Polymerase Chain Reactions  
Taq DNA Polymerase was used for most routine PCR applications. However more 
demanding applications such as site-directed mutagenesis were performed using 
Platinum Pfx DNA Polymerase which has a higher fidelity, specificity and yield than 
Taq polymerase.  
Standard PCR reactions were carried out in a final volume of 25-50 µl. For a 25 µl 
PCR reaction the following were mixed in a 500 µl eppendorf tube. For larger 
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reaction volumes, constituents were added in the same proportions as indicated 
below: 
For PCR using Taq DNA Polymerase: 
1µl of 50mM MgCl2 
2.5µl of 10X PCR Buffer {200 mM Tris-HCl (pH 8.4), 500 mM KCl} 
0.5µl of Invitrogen Taq DNA Polymerase (5U/µl) 
1 µl of 5mM dNTP mixture  
1.5 µl of each Primer (100ng/ µl) 
1 µl of DNA template (100ng/ µl) 
The mixture was made up to a final reaction volume of 25 µl by adding sterile water. 
Reaction conditions: 25 cycles of 94 oC for 1 min; 60 oC for 1 min; 72 oC for 2-4 min 
(extension time dependent on the size of the template to be amplified-1min/Kb) 
using a PeqLab Primus 25 advanced Thermocycler. 
For PCR using Platinum Pfx DNA Polymerase: 
0.5 µl of 50 mM MgSO4 
2.5 µl of 10X Pfx Amplification Buffer 
1.25 µl of 10X PCR Enhancer Solution 
0.2 µl of Platinum Pfx DNA Polymerase (2.5U/ µl) 
1 µl of 5mM dNTP mixture  
1.5 µl of each Primer (100ng/ µl) 
1 µl of DNA template (100ng/ µl) 
The mixture was made up to a final reaction volume of 25 µl by adding sterile water. 
Reaction conditions: 94 oC for 2 min; followed by 25 Cycles of 94 oC for 30 Sec; 55 
oC for 30 Sec; 72 oC for 5-8 min (extension time dependent on the size of the 
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template to be amplified-1min/Kb) using a PeqLab Primus 25 advanced 
Thermocycler. 
2.3.6 Restriction enzyme digests 
Restriction enzyme digests were performed according to the manufacturers’ 
recommendations for the specific restriction enzymes. The incubation period used for 
most enzymes was 37 oC for 1 hour (unless otherwise mentioned). Digested DNA 
was electrophoresed on an agarose gel to confirm if the enzyme digest had worked. 
2.3.7 DNA extraction from an agarose gel 
Restriction enzyme digested DNA was electrophoresed on 0.9 to 1.3% agarose gel. 
The desired DNA band was cut from the gel slice and eluted using a QIA quick Gel 
extraction kit (Qiagen Ltd.) according to the manufacturer’s instructions. 
2.3.8 Dephosphorylation of plasmid DNA 
Linearised plasmid DNA was subjected to dephosphorylation at its 5’ ends by using 
Shrimp Alkaline Phosphatase (SAP) (Fermentas) to prevent self-ligation of the 
vector and increase the efficiency of its ligation with the insert being used. 4 µl of 
SAP (1U/ µl) was employed together with 3 µl of 10X SAP Reaction Buffer in a 
total volume of 30 µl. The samples were incubated overnight at 37 oC. The SAP 
enzyme in the samples was heat inactivated at 65 oC for 20 minutes prior to using the 
DNA in ligation reactions. 
2.3.9  Ligation of DNA 
For all ligation reactions, T4 DNA Ligase (Invitrogen) was used together with 5X 
Ligase Buffer. For ligations of insert into a linearised plasmid, the digested vector 
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was dephosphorylated with Shrimp Alkaline Phosphatase (Fermentas) prior to setting 
up the ligation. 
Most ligation reactions were performed in a total volume of 20 µl. 4 µl of T4 DNA 
Ligase was used and 4 µl of 5X Ligase Buffer was added. Insert and vector were 
used in a molar ratio of 3:1. The amount of insert DNA used for ligation was 
calculated as follows: 
Insert (ng) = Vector (ng) × {Insert (Kb)/ Vector (Kb)} ×3 
The samples set-up for ligation were incubated at 16 oC for at least 16 hours. Post-
incubation, chemically competent INVαF´ E. coli were transformed with the ligated 
samples by the heat shock method of chemical transformation (section 2.4.3). 
2.3.10 Sequencing 
All ligated/mutated plasmid constructs were sequenced to check for in frame 
junctions/ orientation and to check the sequence for the introduction of any 
adventitious errors by the DNA polymerase. The DNA sequencing was carried out at 
the Molecular Biology Sequencing Service, Department of Biological Sciences, 
University of Warwick, using Big Dye Terminator Version 3.1 Chemistry and run on 
a 3100 Genetic Analyser (Applied Biosystems). The sequencing data was analysed 
using Chromas Lite 2.0 or Clone Manager, SciEd Central, v7.04. 
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2.4 Bacteriology techniques 
 
2.4.1 Bacterial culture 
E. coli cells were cultured in LB Broth overnight in an incubator-shaker at 37 oC 
shaking vigorously at 200-250 rpm. Chemically transformed bacterial cultures were 
either plated onto LB Agar plates or allowed to grow in LB Broth with appropriate 
antibiotics and incubated overnight at 37 oC. The transformed cells were stored for 
future use as 50% Glycerol (v/v) stocks. 
2.4.2 Preparation of competent cells for chemical transformation 
2ml of a fresh overnight culture of the INVαF´ strain of E. coli was added to 100ml 
of LB broth prewarmed to 37 oC. The culture was allowed to grow to an OD600 of 
0.39. After the culture had reached the desired optical density, it was placed on ice 
for 5 minutes and pelleted by centrifugation at 6000rpm for 10 minutes at 4 oC. The 
pellet was resuspended in 40ml of TfbI, and re-centrifuged at 6000 rpm for 10 
minutes at 4 oC. The resultant supernatant was discarded and the pellet was dissolved 
in 4 ml of Tfb II and incubated on ice for 2 hours. The resuspended competent cells 
were then separated into aliquots of 200 µl and stored at -80 oC for up to 8 weeks 
before use. 
2.4.3 Chemical transformation of competent cells 
Competent cells stored at -80 oC were thawed on ice and mixed with the ligation 
products (section 2.3.9). The resultant mixture was allowed to incubate for 30 
minutes on ice, before the cells were heat shocked at 42 oC for 50 seconds and 
quickly placed back on ice. 500 µl of warm LB broth was added to the cells and they 
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were grown in an incubator-shaker at 37 oC and 200-250rpm for 2 hours. After 2 
hours, the culture was plated onto LB agar plates with appropriate antibiotics and 
grown overnight at 37 oC. 
2.4.4 Small-scale preparation of plasmid DNA from bacteria 
Bacterial colonies from section 2.4.3 were picked from antibiotic-agar plates and 
inoculated into 5ml of LB broth with the appropriate antibiotic. The inoculated broth 
was cultured overnight at 37 oC in an incubator-shaker at 200 to 250 rpm. For 
extraction of plasmid DNA, 1.5 ml of the overnight culture was used. The DNA was 
extracted using a QIAprep Spin Miniprep Kit (Qiagen) following the manufacturer’s 
protocol. 
2.4.5 Large-scale preparation of plasmid DNA from bacteria  
5ml of a fresh overnight culture of transformed bacteria carrying the desired plasmid 
from section 2.4.4 was added to 200 ml of LB broth and allowed to incubate 
overnight at 37 oC in an incubator-shaker at 200-250 rpm. For large scale extraction 
of plasmid DNA, the GenEluteTM Maxiprep kit (Sigma-Aldrich) was used according 
to the manufacturer’s instructions. 
 
2.5 Basic techniques in mammalian tissue culture 
 
2.5.1 Maintaining cells in culture 
COS-1 and 293T cells were cultured in sterile tissue culture flasks at 37oC in a 5% 
CO2 atmosphere. DMEM containing 10% Fetal Calf Serum (FCS) (v/v) was used as 
the culture medium for passage of both cell lines. Prior to passage, the cells were first 
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washed twice with Versene (0.02% EDTA in PBS). After these washes, cells were 
incubated in the presence of Trypsin solution (0.02% EDTA containing 0.25mg/ml 
Trypsin) for 2-3 minutes to detach adherent cells from the flask surface. The cell 
suspension was centrifuged at 1300rpm for 3 minutes to pellet the cells. The pelleted 
cells were resuspended in DMEM with FCS and plated at the required density. 
2.5.2 Storage of Cell lines 
Cells were grown to confluency, washed with versene and trypsinised as detailed in 
section 2.5.1. Post-trysinisation, the cells were pelleted at 1300 rpm for 3 minutes. 
The resulting pellet was resuspended in culture medium. The concentration of 
cells/ml recovered was determined using a neubauer’s haemocytometer. If N was the 
total number of cells observed under the light microscope in the 4 peripheral squares, 
then, 
No. of cells/ ml of culture medium = N/4 × 104 
After calculating the concentration, the cells were re-centrifuged at 1300 rpm for 3 
minutes and resuspended in 90% FCS and 10% DMSO at a concentration of 
107cells/ml. Aliquots of 1 ml were transferred to cryogenic vials and stored at -20oC 
for 1 day, -70oC for the 2nd day and then transferred to liquid nitrogen for long term 
storage. 
2.5.3 Lipofectamine transfection protocol for cells 
COS-1/293T cells were transfected using Lipofectamine 2000 (Invitrogen) as the 
transfection reagent. One day prior to the transfection 106 cells per well were seeded 
in 12-well tissue culture dishes. The cells were allowed to grow overnight until they 
became ~85% confluent (COS-1 cells) or ~75% confluent (293T cells) at 37oC in a 
5% CO2 atmosphere and then transfected. The DNA to be transfected was diluted in 
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250 µl of serum-free DMEM in a 1.5 ml eppendorf tube. Lipofectamine 2000 was 
gently mixed before use and diluted separately in 250 µl of serum-free DMEM. A 
Lipofectamine (µl) / DNA (µg) ratio of 1:1.5 was used. After 5 minute incubation, 
the diluted DNA and diluted Lipofectamine were combined and mixed gently. The 
DNA-Lipofectamine mixture was allowed to incubate for 30 minutes. Culture 
medium was removed from cells and replaced with the DNA-Lipofectamine mixture. 
The cells were allowed to incubate with the serum-free mixture for 4 hours at 37oC. 
After 4 hours, the DNA-Lipofectamine mixture was replaced with 2 ml of fresh 
DMEM with 10% FCS + pen/strep. The transfected cells were incubated for 48-72 
hours before being subjected to analysis. 
2.5.4 Calcium phosphate transfection protocol for 293T cells 
293T cells were transfected using Calcium phosphate as the transfection reagent. A 
day before transfection, a confluent 175 cm2 flask of cells was split using a 1:15 ratio 
and seeded in 10 cm tissue culture dishes with 10ml of DMEM+ 10%FCS. After 
overnight incubation when the monolayer had reached 70-80% confluency, the 
media in each plate were replaced with fresh DMEM with 10% FCS & pen/strep and 
then transfected. The transfections were set up using 30 µg of total DNA. For each 
transfection 0.5ml of 1X HBS was added to a 1.5ml eppendorf tube. Appropriate 
DNAs were added to each tube and the contents were mixed thoroughly. 30µl of 
2.5M CaCl2 was added to each tube and mixed immediately. The mixture was 
allowed to sit for 30 minutes. The transfection mix was then added to the cells in a 
drop-wise fashion simultaneously rocking the tissue culture dishes back and forth. 
The transfected cells were allowed to be incubated at 37oC in a 5% CO2 atmosphere. 
The following day the media in all dishes was replaced with 10ml of fresh DMEM 
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with 10% FCS. The cells were typically incubated for 48-72 hours before being 
subjected to further analysis. 
 
2.6 Protein biochemistry techniques 
2.6.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The Bio-Rad Mini-PROTEAN 3 system was used for all routine SDS-PAGE 
applications. The composition of the stacking gel and the resolving gel used in this 
study is shown in table 2.6.1 below:  
Table 2.6.1 Composition of the stacking and resolving gel used in SDS-PAGE 
(A)  12.5 % Resolving Gel 
Components 
 
Volume used 
30% Acrylamide; 0.8%N’N’-bis-methylene-acrylamide 4.167 
1.5M Tris-HCl pH 8.3 2.5 
10% SDS 0.1 
H2O 3.178 
Ammonium persulphate 0.05 
TEMED 0.005 
                                                                         Total Volume =               10 ml 
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(B)  3% Stacking Gel 
Components 
 
Volume used 
30% Acrylamide; 0.8%N’N’-bis-methylene-acrylamide 1.0 
1.5M Tris-HCl pH 6.8 0.8 
10% SDS 0.1 
H2O 8.0 
Ammonium persulphate 0.1 
TEMED 0.01 
                                                                         Total Volume =               10 ml 
Protein samples suspended in 1X SDS-PAGE loading buffer were incubated in a 
boiling water bath for 5 minutes and then centrifuged at 13,200 rpm for 30 seconds. 
The samples were then loaded onto the gel and electrophoresed at 150V for 80 
minutes. A prestained protein ladder (10-180 kDa; Fermentas) was used to determine 
the size of the proteins being analysed. 
2.6.2 Western Blotting 
After fractionation on SDS-PAGE gels, proteins were transferred onto ECL Hybond 
nitrocellulose membranes (GE Amersham) using a transblot apparatus (Bio-Rad) 
with 1X transfer buffer containing 20% methanol (v/v) either at 0.08 A for 16 hours 
or at 0.35 A  for 1.5 hours at 4oC. Blotted proteins were detected either 
colorimetrically or by chemiluminescence. 
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2.6.3 Colorimetric detection of proteins on a Western Blot 
Anti-mouse alkaline phosphatase conjugated antibody (Sigma-Aldrich A3438) was 
used as a secondary antibody to detect proteins colorimetrically by employing 
BCIP/NBT Phosphatase substrate tablets (Sigma-Aldrich B5655) according to the 
manufacturer’s instructions. 
2.6.4 Chemiluminescence detection of proteins on a Western Blot 
Anti-mouse IgG (whole molecule)-Peroxidase antibody, produced in Goat (Sigma-
Aldrich A4416) was used as the secondary antibody for chemiluminescence 
detection of proteins by employing the ECL-Chemiluminescence Detection Kit (GE 
Healthcare Life Sciences) and the blot analysed using the Bio-Rad ChemiDoc XRS 
imaging system according to the manufacturer’s instructions. 
2.6.5 Reprobing the same blot with different antibodies  
After detection of one protein in a blot, if the same blot needed to be probed for a 
different protein, stripping buffer (section 2.2.1) was used. After the first detection, 
the blot was incubated in a 500 C water bath for 15 minutes in presence of stripping 
buffer. Post-incubation, the blot was given 3×15 minute washes with TBS. 
Subsequently the blot was then probed again with antibody for the second protein. 
 
2.7 Mammalian two-hybrid assay 
 
COS-1 cells were transfected with pM and pVP16 plasmid constructs together with 
either CAT or GFP reporter plasmid using the standard Lipofectamine transfection 
protocol (section 2.5.3). The transfected cells were allowed to incubate at 37oC in a 
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5% CO2 atmosphere for 48-72 hours. GFP reporter expression was monitored in live 
cells 48 hours post-transfection using a UV light microscope. Subsequently the GFP 
expression within transfected cells was analysed using the ImageJ image analysis 
software (described in detail in section 2.10). The GFP reporter expression data was 
further confirmed by quantitatively assaying the CAT reporter expression using a 
CAT ELISA kit (Roche) and transfected cell extracts made 72 hours post-
transfection by following the manufacturer’s instructions. 
 
2.8 Sucrose gradient analysis of GAG virus-like particles (VLPs) 
 
293T cells were transfected with a Pr55GAG expression plasmid (pGAG-EGFP) using 
the standard Calcium phosphate transfection protocol (section 2.5.4). GAG-EGFP 
chimeric protein expression was observed in live cells using the UV light microscope 
48 hours post-transfection. Subsequently, cell culture supernatants containing VLPs 
from transfected 293T cells were harvested at 72 hours post-transfection, clarified by 
centrifugation at 1300 rpm for 3 minutes and filtered through a 0.45µm pore-sized 
filter. The filtered supernatant was centrifuged through a 20% sucrose cushion in a 
Beckman SW-28 rotor at 100,000 g for 2 hrs at 4°C to pellet the VLPs. The pellets 
were resuspended in Phosphate Buffered Saline (PBS). GAG VLPs resuspended in 
PBS were overlaid onto linear 20-60% sucrose gradients and centrifuged in a 
Beckman SW40Ti rotor for 16 hrs at 4°C. After ultracentrifugation, equal fractions 
were collected from the bottom of the gradient, fraction 1 being the lowermost and 
fraction 14 being the uppermost with ‘p’ being the resuspended pellet. Proteins were 
later precipitated from the collected fractions by treating with 10% Trichloroacetic 
acid (TCA). The TCA precipitates were collected by centrifugation at 13,200 rpm for 
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15 min. The supernatant from the centrifuged samples was discarded and pellets 
were resuspended in SDS-sample buffer, 8M Urea and 2M Sodium hydroxide 
(NaOH) for analysis by SDS-PAGE as detailed in section 2.6. The VLP proteins 
incorporated into the nitrocellulose membrane were probed as described in section 
2.2.4 and analysed using chemiluminescence (section 2.6.4). 
 
2.9 Immunofluorescence imaging of transfected cells by confocal 
microscope 
 
293T cells were used for transfection and subsequent immunofluorescence 
procedures. Cover slips were placed at the bottom of the 12 well tissue culture plates 
used for transfection. Subsequently the cells were plated onto the wells containing 
cover slips in such a way that the monolayer growth occured on the cover slip 
surface. The cells were allowed to grow overnight until they became ~75% 
confluent. Later, they were transfected using the standard Lipofectamine transfection 
protocol mentioned in section 2.5.3.  
2.9.1 Fixing of cells on coverslips 
48 hours post-transfection, the cells were washed twice with 0.5 ml PBS and 
incubated with 0.5 ml of 10% (w/v) formaldehyde in PBS for 10 minutes. Post-
incubation, the formaldehyde was discarded and the cells were washed again with 
PBS. Subsequently the cells were incubated with 0.5 ml 0.5% NP40 in PBS for 10 
minutes to permeabilise them. The cells were again washed with PBS after this 
incubation. If the proteins to be detected were tagged with GFP, then the coverslips 
were directly washed in the presence of nuclear stain DAPI and imaged under the 
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confocal microscope. However, if the proteins were not GFP tagged, they were 
probed with primary and secondary antibody as described below before analysis. 
2.9.2 Staining 
After the last PBS wash, the cells were blocked for 1 hour in 0.5ml of 10mg/ml BSA 
in PBS. Later the cover slips were washed thrice with PBS. 0.25ml of primary 
antibody diluted in 1% BSA in PBS was then added to the wells containing cover 
slips using the optimised concentration and left to incubate for 1 hour. After 1 hour, 
the cells were again washed thrice with PBS. 0.25 ml secondary antibody diluted in 
1% BSA in PBS was later added in dark to the wells and the cells were allowed to 
incubate for 1 hour. The cover slips were later washed in dark for 3 times with PBS. 
The final PBS wash was performed in the presence of nuclear stain DAPI at 1µg/ml 
(in PBS) and allowed to incubate for 5 minutes in dark. The cover slips were later 
removed from wells after the DAPI wash and dried on filter paper in dark. The dried 
cover slips were inverted onto a small amount of mounting medium (Vectorshield) 
on a slide and the edges of the cover slips were sealed with nail varnish. Finally the 
cover slips mounted on the slides were used for imaging using Leica TCS SP5 
confocal microscope. 
2.10 Image analysis using ImageJ software 
The fluorescence in transfected cells was measured by analysing the images captured 
using the software ImageJ. For all applications, the images were first background 
subtracted using the ‘subtract background’ application which employs a rolling ball 
radius algorithm and considers intensity values outside the radius to be background.  
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For the GFP fluorescence quantification in chapter 3, the images were converted to 
grey scale and the mean grey value of each image was measured. The mean grey 
value is the mean of brightness value of all individual pixels within an image. Hence 
the mean grey value of an image is directly proportional to the GFP fluorescence 
intensity for that image. 
 
2.11 Other computer software applications 
Sequencing data was analysed using Chromas Lite 2.0 or Clone Manager, SciEd 
Central, v7.04. Plasmid maps detailing the position of the genes, the restriction 
enzyme sites and promoters were constructed by using Clone Manager, SciEd 
Central, v7.04 and PlasMapper version 2.0 software. Band densitometry of the 
proteins within western blots was carried out using Scion Image software. The bar 
charts presented in this study were prepared using GraphPad Prism 5. The statistical 
analyses of the numerical data in this study were carried out using GraphPad InStat  
3.  
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CHAPTER 3 
 
Mapping the site of interaction of Vif and 
APOBEC3G with Pr55GAG 
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3.1 Background: 
 
The vif gene of HIV-1 is essential for HIV infectivity in Peripheral Blood 
Mononuclear Cells (PBMCs), the natural host cells for HIV. One of the functions of 
Vif is to antagonise the inhibition of virus replication imposed by APOBEC3G 
(A3G) which is constitutively expressed in PBMCs and a component of the human 
innate immune response. 
Following the recognition that Vif is indispensible to HIV in overcoming the 
inhibition exerted by A3G, considerable attention has been focussed on the 
mechanism by which Vif executes this function and allows viral replication and 
infectious virus production in its normal host cells. 
Initially a relatively simple picture emerged, whereby Vif expressed in the cytoplasm 
of HIV infected cells was found to form a Vif-Cul5-SCF complex that recruited A3G 
leading to its polyubiquitination and forwarding to the 26S Proteasome for 
degradation (Yu et al, 2003). However more recently there have been a number of 
conflicting reports emerging in the literature which have undermined this 
straightforward model. 
One of the first studies to challenge the initial model of Vif action demonstrated that 
even though a low level of A3G was detected in Vif+ HIV-1 infected cells, the 
progeny virions still remained infectious suggesting that Vif was exerting some other 
as yet uncharacterised mechanism to exclude A3G from the budding progeny virions  
(Kao et al, 2004). Further evidence came in form of the report in which the block to 
virus replication of a degradation resistant mutant of A3G could still be alleviated by 
Vif  (Opi et al, 2007). A second independent line of evidence established that the 
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fusion of A3G to a fragment of the viral Vpr protein allows it to overcome Vif’s 
relief of the block even though it is still degraded by Vif (Ao et al, 2008). 
Consequently a view is emerging that whilst there has been rapid progress in trying 
to dissect Vif’s role in overcoming the A3G based facet of the inherent immune 
response against HIV-1, a detailed knowledge about the mechanism involved in not 
yet clear. 
 
3.2 New hypothesis for the primary role of Vif in overcoming A3G 
based inhibition of HIV replication: 
 
Vif and A3G have both been shown to interact specifically with Pr55GAG and become 
incorporated into the core of budding HIV virions (Bouyac et al, 1997a; Cen et al, 
2004; Huvent et al, 1998; Schafer et al, 2004; Syed & McCrae, 2009). The 
hypothesis for Vif’s primary role in alleviating the A3G block that this study 
seeks to test is that Vif outcompetes A3G for Pr55GAG binding, thereby 
preventing its incorporation into budding progeny virions and subsequent 
inhibitory effects on HIV replication.  
This explanation of Vif’s primary role in circumventing this facet of the innate 
immune response would in its simplest form require both Vif and A3G to interact 
with the same site on Pr55GAG. Consequently the first experimental objective was to 
establish if this was the case or not and the experiments described in this chapter try 
to address this question. 
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3.3 Experimental strategy 
It was decided to insert mutations in the regions of interest within the Pr55GAG 
sequence and study the effect of these mutations on the Vif-Pr55GAG and A3G-
Pr55GAG interactions. The regions of interest within the Pr55GAG sequence were 
defined on the basis of previous reports addressing these interactions (Burnett & 
Spearman, 2007; Luo et al, 2004). Most of those studies pointed towards the 
involvement of the Nucleocapsid (NC) domain of Pr55GAG in interactions with both 
Vif and A3G (Burnett & Spearman, 2007; Luo et al, 2004).  
To shed light on the interactions of both Vif and A3G with the NC domain, it is 
essential to first understand the sequence and the structure of the NC portion of 
Pr55GAG. Fig. 3.1 (A), (B) & (C) depict the domain organisation of Pr55GAG, the 
amino acid sequence of its NC domain and the 3-D structure of NC bound to the 
RNA stem-loop structure SL3 of the genomic Psi RNA packaging signal 
respectively. Residues K3-R10 at the N-terminal of the NC protein form a helix that 
binds to the RNA major groove of SL3 genomic Psi RNA {Fig. 3.1 (C)}. In addition 
there are two zinc finger knuckles (V13-A30 & G35-E51) which are separated by the 
basic linker segment (P31-K34) {Fig. 3.1(B)}. The zinc finger domains along with 
the basic linker are involved in the interactions with the exposed bases of the RNA 
tetraloop of the SL3 Psi genomic RNA packaging signal {Fig. 3.1 (C)}. Thus the N-
terminal region of NC along with the two zinc fingers and basic linker are involved 
in the interaction and subsequent encapsidation of the viral genomic RNA into newly 
formed virus particles. The NC sequence ends with a C-terminal tail spanning amino 
acids R52 to N55 {Fig. 3.1 (C)}  (De Guzman et al, 1998).  
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Little was known about the position at which Vif might interact within the NC 
domain of Pr55GAG (Huvent et al, 1998). On the other hand, the A3G-Pr55GAG 
interaction was slightly better characterised. A previous study had reported that the 
‘I’ domain spanning residues M1-K11 at the N-terminal of the NC portion of 
Pr55GAG was indispensable for the A3G-Pr55GAG interaction {Fig. 3.1 (B)} (Luo et 
al, 2004). Hence the mutant NCDel was created by the deletion of amino acids G4 – 
T12 from the N-terminal of NC leaving the first three amino acids which are a part of 
the viral protease cleavage site intact {Fig 3.1 (B) & (C)}. A more recent report 
however suggested that it was not the ‘I’ domain but the basic linker segment present 
between the two zinc finger motifs of the NC which was involved in the interaction 
of A3G with the polyprotein GAG precursor {Fig. 3.1 (B)} (Burnett & Spearman, 
2007). Consequently a substitution mutant NCSub was also constructed by 
substituting amino acids 32RKK34 within the basic linker with 32EEK34 thereby 
inserting two acidic amino acids (E-Glutamic acids) in place of two basic ones (32R-
Arginine and 33K-Lysine) {Fig 3.1 (B) & (C)}.  
Both of these mutants NCDel and NCSub were tested for interactions with Vif and 
A3G to find out whether these two proteins interacted at the same site on Pr55GAG. 
 
3.4 Assay system: 
The primary assay used to study interactions between Vif/A3G and Pr55GAG was the 
mammalian two-hybrid assay.  
3.4.1  Introduction to the two-hybrid assay: 
The two-hybrid assay system is an assay protocol used to study protein-protein 
interactions in vivo. It was first developed using the GAL4 transcription factor of the 
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Figure 3.1 Diagrammatic representation of the position of the mutations within 
Pr55GAG. {A} Domain organisation of Pr55GAG with the Nucleocapsid (NC) region 
highlighted (grey). {B} NC region of  Pr55GAG :  (i) NCDel: Deletion of amino acid 
4-12 region within the NC sequence (ii) NCSub: Substitution of two basic amino 
acids, R (Arginine) and K (Lysine) with two acidic amino acids, E (Glutamic acid). 
{C} Ribbon diagram of the HIV-1 NC and SL3 Ψ RNA complex with the position of 
NCDel and NCSub mutations highlighted. Colour code: N-terminal helix (dark blue), 
1st Zinc finger F1 (sky blue), basic linker (yellow), 2nd Zinc finger F2 (green) and 
RNA (grey, except for the bases in contact with the zinc fingers and basic linker 
which are coloured). The white beads represent the zinc atoms bound to the two zinc 
fingers. The positions of the mutants NCDel and NCSub are highlighted with white 
rectangles. Figure modified from De Guzman et al, 1998. 
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yeast Saccharomyces cerevisiae (Fields & Song, 1989). 
It is based on the principle that many eukaryotic transcription factors have two 
distinct physically separable functional domains. In the case of the GAL4 
transcription factor these are a GAL4 DNA binding domain which binds to the 
Upstream Activation Sequence (UAS) and an activation domain which initiates gene 
transcription. Normally these two domains form an integral part of the GAL4 protein 
and function as a single unit. However, in the two-hybrid assay, the two domains are 
physically separated and fused in frame with two genes of interest thought to interact 
with each other. If the two proteins do indeed form a protein-protein complex and 
hence bring the two GAL4 domains near each other, then their proximity is sufficient 
to reconstitute a functional GAL4 transcription factor and initiate transcription of any 
gene lying downstream of the GAL4 responsive UAS (Fig. 3.2). 
The yeast two-hybrid assay has a number of advantages over other assay protocols 
for investigating protein-protein interactions. First, it does not require purification of 
the candidate proteins to be studied, nor does it require any antibodies to these 
proteins to be available. Secondly, because the proteins being analysed are expressed 
in vivo, they are more likely to retain their native conformation. The assay has also 
been found to have a good dynamic range and hence useful for the detection of 
interactions occurring transiently/weakly within cells. All these merits make it a very 
useful technique for the study of protein-protein interactions in vivo. 
A further advantage of the two-hybrid assay is, having established that an interaction 
between two proteins exists, then it is an extremely potent tool for mapping the 
regions of the interaction through the use of deletion/site-directed mutagenesis of the 
entities involved. 
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Figure 3.2 Working Principle of the mammalian two-hybrid assay: {A} Regular 
transcription of the reporter gene under the control of a GAL4 responsive promoter 
when the Activation domain (AD) and DNA binding domain (BD) are intact. {B} In 
the two-hybrid system, the two domains are physically separated and fused to the 
two genes of interest (here, Pr55GAG and Vif). As Vif and Pr55GAG interact with each 
other, the two domains come into proximity to each other initiating reporter gene 
transcription. {C} In the case of two non-interacting proteins, the two domains 
remain separated and there is no reporter gene transcription  
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Finally an important application of the two-hyrid assay system has been its use in 
screening cDNA libraries for cellular interacting partners of a protein of interest 
(Chien et al, 1991). This application has been used widely to detect and decipher 
cellular interaction networks. The ease with which the cloned cDNAs can be isolated 
to yield positive interaction partners makes it one of the methods of choice for 
screening cDNA libraries. 
3.4.2  The mammalian two-hybrid system: 
The mammalian two-hybrid assay is a modification of the yeast two-hybrid protocol.  
It incorporates all the advantages of the yeast two-hybrid system and has the 
additional benefit of the proteins being expressed in mammalian cells, rather than 
yeast cells. This allows the method to be used to detect protein interactions which are 
dependent on mammalian type post-translational modification of the proteins 
involved, which is not possible with the yeast two-hybrid assay. 
 
3.4.3 Two-hybrid assay applications in HIV research 
The yeast two-hybrid assay has already been used to detect protein-protein 
interactions between different Human Immunodeficiency Virus proteins. One of the 
earliest application dates back to 1992, when Luban et al used the two-hybrid assay 
to demonstrate multimerization of retroviral Gag polyproteins (Luban et al, 1992). 
Later, it was employed to show a direct interaction between the viral accessory 
protein Vpr and the Matrix protein of HIV-1 (Sato et al, 1996). It has also been 
exploited to screen cDNA libraries for elucidating virus-host cell protein interactions 
(Lama & Trono, 1998).  
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3.5 Vectors used in the Mammalian two-hybrid assay: 
 
3.5.1 Two-hybrid assay vectors 
Two expression plasmids are employed in the mammalian two-hybrid assay; pM 
(DNA binding domain, BD) cloning vector is used to construct a fusion gene 
encoding the chimeric protein of interest linked to the GAL4 DNA binding domain. 
Similarly, pVP16 (Activation domain, AD) cloning vector is used to construct a 
fusion gene encoding second chimeric fusion protein containing the transcriptional 
activation domain derived from the VP16 protein of the Herpes Simplex Virus (Fig. 
3.3). These two plasmids are available commercially as part of Clontech’s 
Matchmaker ™ assay system and were used to generate additional constructs to 
those available from previous work done at Warwick. These plasmids AD-Vif, AD-
A3G and BD-Pr55GAG encoding the respective proteins fused in frame with either the 
Activation Domain (AD) or the DNA Binding Domain (BD) under the control of the 
SV40 promoter have been described previously (Syed & McCrae, 2009). The 
plasmid BD-A3G has previously been shown to be self-activating within the two-
hybrid system and hence was not used in the experiments described in this study 
(Syed, 2008). 
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Figure 3.3 Mammalian two-hybrid assay vectors: {A} pM Vector: The pM vector 
is used to generate a fusion protein of the GAL 4 DNA Binding domain (BD) with 
the protein of interest. There is a nuclear localisation signal within the GAL4 
sequence which directs the chimeric protein to the nucleus. {B} pVP16 Vector: The 
pVP16 vector is used to generate a fusion protein of the VP16 Activation domain 
(AD) with the protein of interest.  There is the SV40 nuclear localisation signal 
within the VP16 AD sequence which targets the fusion protein to the nucleus. 
Transcription is initiated from the SV40 promoter in both the vectors. Genes of 
interest are cloned using the multiple cloning sites such that the genes are in frame 
with the BD and AD respectively in both the vectors.  
101 
 
3.5.2 Generation of Pr55GAG mutants 
Two Pr55GAG mutants were used in the assay. BD-NCDel was constructed by first 
inserting a HpaI restriction enzyme site into the coding sequence of Pr55GAG by site-
directed mutagenesis of the BD- Pr55GAG plasmid using a PCR based mutagenesis 
protocol with the forward primer GagHpaF and the reverse primer GagHpaR (Table 
2.2.1) to generate BD-Pr55GAG-HpaI (Fig. 3.4B). A further PCR based mutagenesis 
of the BD-Pr55GAG-HpaI using the forward primer EcoGagF and the reverse primer 
HpaIGagR was then carried out to delete amino acids 4-12 from the amino terminus 
of the NC region of Pr55GAG (Table 2.2.1)(Fig. 3.4C). The PCR product and BD-
Pr55GAG-HpaI vector were digested with EcoRI and HpaI so that the insert could be 
ligated into the parent vector resulting in a deletion of 4-12 amino acids from the N-
terminal of NC domain of Pr55GAG (BD-NCDel) (Fig. 3.1 , 3.4 D & Fig. 
1.1Appendix). A second Pr55GAG mutant, BD-NCSub was constructed by site-
directed mutagenesis of BD-Pr55GAG again using PCR based mutagenesis using the 
forward primer 1551GagMutF and the reverse primer 1551GagMutR (Table 2.2.1). 
This produced a mutated Pr55GAG in which there had been the substitution of two 
basic amino acids (Arginine and Lysine) with two acidic ones (Glutamic acid) in the 
basic linker of the NC region of the protein (BD-NCSub) {Fig. 3.1 and Fig. 1.2 
Appendix}. 
3.5.3 Reporter vectors: 
Two reporter plasmids pUAST-hrGFP-neo and pG5CAT (Clontech) were employed 
in the two-hybrid assay containing respectively the Green Fluorescent protein (GFP) 
gene and Chloramphenicol Acetyl Transferase (CAT) gene downstream of the GAL4 
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Figure 3.4 Schematic of construction of the Pr55
GAG
 mutant BD-NCDel. {A} 
BD-Pr55
GAG
: Schematic diagram showing Pr55
GAG
 flanked by restriction enzymes 
EcoRI and BamHI and inserted in frame downstream of the DNA binding domain of 
pM vector.  {B} Construction of BD-Pr55GAG-HpaI: Insertion of an HpaI restriction 
enzyme site immediately downstream of the first 11 amino acids at the N-terminus of 
the Nucleocapsid (NC) domain of Pr55GAG by PCR based site-directed mutagenesis 
of BD-Pr55
GAG
.
 
 {C} PCR based mutagenesis of BD-Pr55GAG-HpaI to delete amino 
acids 4-12 near the amino terminus of the NC region of Pr55
GAG
.  
A.
B.
C.
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Figure 3.4 Schematic of construction of the Pr55
GAG
 mutant BD-NCDel (Contd.) {D} Restriction digest of both BD-Pr55GAG-HpaI and the 
PCR amplified insert shown in C with enzymes EcoRI and HpaI. Digested vector and insert were ligated to form BD-NCDel, a mutant version of 
Pr55
GAG 
where amino acids 4-12 from the amino terminus of the Nucleocapsid are deleted from the Pr55
GAG
 coding sequence.   
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responsive element and the minimal promoter of the Adenovirus E1b gene (Fig. 3.5). 
GFP was chosen for use as an initial qualitative reporter (pUAST-hrGFP-neo)         
because its expression could be easily and rapidly screened in live cells. The GFP 
expression level within cells was later analysed with ImageJ image analysis software.  
The GFP expression data was then confirmed using the quantitative CAT reporter 
(pG5CAT) by employing the CAT ELISA to gauge the change observed in strength 
of any interactions seen. 
3.5.4 Assay controls:  
The positive controls used throughout this study exploited the previously reported 
interaction between murine p53 and SV40 Large-T antigen (Ali & DeCaprio, 2001). 
The plasmid pM-p53 which encodes a chimeric murine protein p53 fused in frame 
with the DNA Binding Domain of the pM vector was used together with the pVP16-
T plasmid which encodes the chimeric SV-40 Large-T antigen fused to the 
Activation Domain of the pVP16 vector. When pM-p53 and pVP16-T were co-
transfected with either reporter plasmid, positive reporter gene expression was seen.  
The negative controls used for the two-hybrid assays were individual plasmids 
expressing the AD or BD fusion protein constructs of interest together with either 
empty BD or empty AD vector respectively. The following combinations were 
employed: (a) AD-A3G + empty BD vector (b) AD-Vif + empty BD vector (c) BD-
Pr55GAG + Empty AD vector (d) BD-NCDel + Empty AD vector and (e) BD-NCSub 
+ Empty AD vector. Cells were transfected separately with all these various 
combinations of plasmids together with either GFP or CAT reporter vector to 
monitor the background levels of reporter gene expression and rule out the non-
specific self-activation of the reporter vectors with single plasmids. 
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Figure 3.5 Reporter vectors used in the mammalian two-hybrid assay. {A} 
pUAST-hrGFP-Neo: Contains the Green Fluorescent Protein (GFP) gene positioned 
downstream of the GAL4 responsive element and a minimal promoter from the 
Adenovirus E1b gene. It is used as a qualitative reporter in the two-hybrid assay as 
the GFP expression can be easily observed under the UV microscope in live cells. 
{B} pG5CAT:  Contains the Chloramphenicol Acetyl Transferase (CAT) gene 
positioned downstream of the GAL4 responsive element and a minimal promoter 
from the Adenovirus E1b gene.  It is used as a quantitative reporter to both confirm 
the qualitative reporter data whilst at the same time allowing an estimation to be 
made about the relative strength of the interactions.  
B.
A.
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3.6 Assay protocol 
The mammalian two-hybrid assay protocol has been described in detail in section 2.7 
of the Materials and Methods. Each well was transfected with 1.5 µg of each of the 
plasmids used. The cells were analysed as described in section 2.7. 
 
3.7 Mapping the regions of interaction on Pr55GAG where Vif and 
A3G interact: 
Some studies aimed at mapping the region of Pr55GAG that interacts with A3G have 
already been reported before in this chapter (Burnett & Spearman, 2007; Luo et al, 
2004). The initial work mapped site of interaction between these two proteins to the 
so called I domain located at the amino terminus of the Nucleocapsid (NC) portion of 
Pr55GAG (Fig. 3.1 B) (Luo et al, 2004). However a subsequent report localised the 
interaction site to the basic linker region of NC which lies further into the protein 
between two zinc finger domains (Fig. 3.1 B) (Burnett & Spearman, 2007). To 
investigate the importance of both these regions on the interaction of A3G and/or Vif 
with Pr55GAG, the mutants NCDel and NCSub described in sections 3.3 and 3.5.2 
were used (Fig. 3.1 B and C).     
The interactions were first studied by using the GFP reporter vector and monitoring 
the level of GFP expression to estimate the presence of an interaction where a high 
level of GFP expression indicated that the interaction was present while background 
level GFP expression indicated no interaction (Fig. 3.6, 3.8 and 3.11). When COS-1 
cells transfected with BD-p53 and AD-LargeT along with GFP reporter vector were 
observed under UV light microscope, many cells were positive for GFP expression 
indicating that the two proteins interacted with each other in this system. This protein 
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pair was the positive control for the assay (Fig. 3.6 A). The negative controls for the 
assay were single plasmids expressing chimeric proteins of interest fused to either 
the BD/AD domains transfected in cells along with empty AD/BD vectors 
respectively and GFP reporter vector. Thus cells transfected with AD-Vif and empty 
BD vector along with GFP reporter gave background level GFP expression 
indicating that AD-Vif does not self-activate the GFP reporter (Fig. 3.6 B). Similarly 
cells transfected with AD-A3G and empty BD, BD-Pr55GAG and empty AD, BD-
NCDel and empty AD & BD-NCSub and empty AD also gave very low GFP 
reporter expression pointing that these plasmids on their own did not activate 
reporter expression (Fig. 3.6 C, D, E and F).   
Transfection of the same positive and negative controls was then carried out by 
employing the CAT reporter vector instead of GFP. CAT enzyme values were then 
measured by following the standard CAT ELISA protocol on extracts of transfected 
cells as mentioned in section 2.7.  As expected, in case of the CAT reporter vector, 
the positive control yielded high CAT enzyme values while the negative controls 
mentioned above resulted in background level CAT enzyme expression (Fig. 3.9 A 
and 3.12 A). 
After ascertaining that the positive and negative controls for the assay were 
functioning optimally with both the GFP and CAT reporter vectors, the next step was 
to study the interactions of both Vif and A3G with Pr55GAG and the two GAG 
mutants NCDel & NCSub.  
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Figure 3.6 GFP reporter expression levels of the positive and negative controls 
for the mammalian two-hybrid assay: COS-1 cells were transfected with the 
respective plasmids using a standard Lipofectamine transfection protocol detailed in 
section 2.5.3. Live cells were observed for GFP expression 48 hours post transfection 
under UV light microscope (section 2.7). The positive control for the assay exploited 
the previously reported interaction between murine p53 and SV40 large T antigen. 
The negative controls for the assay were individual plasmids expressing AD/BD 
domain fused chimeric proteins of interest together with either empty BD or empty 
AD vector respectively. In addition to the plasmid combinations mentioned below, 
cells were also co-transfected with the GFP reporter vector whose expression was 
under the control of a GAL4 responsive element. Monitoring the levels of GFP 
reporter gene expression enabled the readout of whether an interaction was present 
between two proteins of interest or not. Panels on the right hand side show visible 
light image of the transfected cells and panels on the left display fluorescence of GFP 
under UV light. 
The following plasmid combinations were employed: 
{A} Positive control: BD-p53 + AD-LargeT along with GFP reporter vector 
{B} Negative control 1: AD-Vif + Empty BD vector along with GFP reporter vector 
{C} Negative conrol 2: AD-A3G + Empty BD vector along with GFP reporter vector
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Figure 3.6 (contd.) GFP reporter expression levels of the positive and negative 
controls for the mammalian two-hybrid assay 
{D} Negative control 3: BD-Pr55GAG + Empty AD vector with GFP reporter vector 
{E} Negative control 4: BD-NCDel + Empty AD vector with GFP reporter vector 
{F} Negative control 5: BD-NCSub + Empty AD vector with GFP reporter vector 
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3.7.1 A3G-Pr55GAG interaction  
When cells were transfected with AD-A3G and BD-Pr55GAG along with GFP 
reporter vector, positive GFP expression was observed indicating that A3G and 
Pr55GAG specifically interact with each other (Fig. 3.7 A). Similarly co-transfection 
with AD-A3G and BD-NCDel along with GFP reporter resulted in positive GFP 
expression (Fig. 3.7B). This result was unexpected as the deleted region in NCDel 
had been shown in a previous report to mediate the interaction between A3G and 
Pr55GAG (Luo et al, 2004). Thus this result did not support Luo et al.’s conclusions 
that the N-terminal ‘I’ domain of NC was important in mediating the A3G-Pr55GAG 
interaction. By contrast, when cells were co-transfected with AD-A3G and BD-
NCSub along with GFP reporter, a huge drop in GFP expression was observed and 
the GFP expression almost became comparable to negative control levels (Fig. 3.7C). 
This result was in support of Burnett and Spearman’s conclusions that the basic 
linker region in the NC domain of Pr55GAG was important in mediating the 
interaction of A3G with Pr55GAG.  
Later, the images were analysed using ImageJ software for the intensity of GFP 
expression by converting the RGB images to gray scale and measuring the mean gray 
value for each image as described in section 2.10 (Fig. 3.8 A). The mean gray value 
of the image was directly proportional to the intensity of GFP expression.  
When a bar chart was plotted to show the relative GFP intensity using the mean gray 
values in Fig 3.8 A, the GFP intensity for AD-A3G and BD-Pr55GAG was almost 2.5 
times more than that of the positive control (Fig. 3.8 B). The reason for the relatively 
lower values of reporter gene expression observed with the positive control could be 
due to the cell line employed for these studies. COS-1 cells used in this assay carry 
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an integrated copy of the SV40 genome and constitutively express biochemically 
active SV-40 encoded LargeT antigen. The positive control for this experiment was 
the interaction between BD-p53 and AD-LargeT. Hence the endogenously expressed 
LargeT protein in COS-1 cells could be competing with the chimeric AD-fused 
LargeT protein used in the two-hybrid assay for binding with BD-p53. This 
sequestration of BD-p53 by the endogenously expressed LargeT was possibly being 
reflected in form of reduced levels of reporter gene expression.  
The GFP intensity with AD-A3G and BD-NCDel was even more when compared 
with AD-A3G and BD-Pr55GAG but this increase was statistically not significant 
(p>0.05) (Fig. 3.8 B). In contrast, the GFP intensity of AD-A3G and BD-NCSub was 
significantly reduced (p<0.001) when compared with AD-A3G and BD-Pr55GAG and 
was almost comparable to negative control levels (Fig. 3.8 B). This significant drop 
in GFP intensity observed with NCSub indicated that the substitution mutations in 
the basic linker of NC had a deleterious effect on the A3G-Pr55GAG interaction. 
Thus from the GFP expression data it was clear that the mutations in the NCSub 
mutant of Pr55GAG were responsible for disrupting the A3G-Pr55GAG interaction. 
Contrary to a previous report, the mutations in NCDel mutant of Pr55GAG had no 
effects on the A3G-Pr55GAG interaction. 
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Figure 3.7 GFP reporter expression levels of the interactions between wild type 
Pr55GAG and the two GAG mutants with A3G: COS-1 cells were transfected with 
the respective plasmids using a standard Lipofectamine transfection protocol detailed 
in section 2.5.3. Live cells were observed for GFP expression 48 hours post 
transfection under UV light microscope (section 2.7).  
{A} BD-Pr55GAG + AD-A3G: Wild type Pr55GAG and A3G together with GFP 
reporter  
{B} BD-NCDel + AD-A3G:  NCDel mutant of Pr55GAG and A3G together with GFP 
reporter  
{C} BD-NCSub + AD-A3G: NCSub mutant of Pr55GAG and A3G together with GFP 
reporter  
The levels of GFP reporter expression were monitored to determine whether an 
interaction was present between the two proteins of interest or not whereby positive 
GFP expression indicated the presence of an interaction while no or background 
level GFP expression indicated no interaction.  
Panels on the right hand side show visible light image of the transfected cells and 
panels on the left display fluorescence of GFP under UV light. 
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Figure 3.8 Quantifying the level of GFP expression using the image analysis 
software ImageJ to provide some indication of the strength of the interactions of 
A3G with wild type Pr55GAG and the two GAG mutants: COS-1 cells were 
transfected with the indicated plasmid combinations in addition to the GFP reporter 
vector. 48 hours post-transfection, the cells were observed under UV light 
microscope and images were analysed for GFP expression using the image analysis 
software ImageJ. The RGB images were converted to gray scale to allow 
measurement of the gray values of each pixel within an image. The mean gray value 
of all pixels was thus directly proportional to the intensity of GFP. 
{A} Table depicting the mean gray values of images analysed using ImageJ against 
the plasmid combinations used in a transfection. The positive control for the assay 
exploited the interaction between murine p53 and SV40 Large T antigen. The 
negative controls for the assay were individual plasmids expressing AD/BD domain 
fused chimeric proteins of interest together with either empty BD or empty AD 
vector respectively. 
 {B} Bar chart depicting the GFP intensity within an image relative to the positive 
and negative controls (the positive control being 100% and the lowest negative 
control being 0%) drawn using the mean gray values in the table 3.8 {A}. Error bars 
indicate Mean ± SEM (n=2 experiments). ns= difference not significant (p>0.05); 
***= significant difference (p<0.001). The p values were calculated using one way 
ANOVA with post test. 
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To confirm the results obtained with the GFP reporter vector, the same experiments 
were repeated with CAT reporter vector and the results analysed by CAT ELISA on 
transfected cell extracts. Fig 3.9 A tabulates the absolute CAT values obtained against 
the various plasmid combinations employed for studying the A3G-Pr55GAG 
interaction. BD-p53 and AD-LargeT along with CAT reporter vector gave positive 
CAT enzyme expression (positive control) (Fig. 3.9 A). Similar to what was observed 
with the GFP reporter vector, the CAT enzyme expression values obtained from cells 
transfected with AD-A3G and BD-Pr55GAG along with CAT reporter vector were 
almost 1.75 times compared to those obtained from the positive control (Fig. 3.9 B).  
Similarly when cells were transfected with AD-A3G and BD-NCDel, the CAT 
enzyme expression was even more than that observed with AD-A3G and BD-
Pr55GAG (Fig. 3.9 B). This increase in CAT expression observed with NCDel when 
compared to Pr55GAG was statistically significant (p<0.01) (Fig. 3.9 B). In case of the 
GFP reporter data, there was an increase in GFP intensity observed with the NCDel 
mutant but this increase was found to be not significant (p>0.05) (Fig. 3.8 B). Thus, 
in this case, there was an apparent discrepancy in the results obtained from the GFP 
reporter and CAT reporter data, the reasons for which have been discussed in the next 
section. 
In contrast, when cells were transfected with AD-A3G and BD-NCSub along with 
CAT reporter vector, there was a statistically significant decrease in the CAT enzyme 
expression when compared to that observed with AD-A3G and BD-Pr55GAG (p<0.01) 
(Fig. 3.9 B). This result was in agreement with the GFP reporter data mentioned 
earlier. Thus the basic residues (Arginine and Lysine) in the basic linker of the NC 
region of Pr55GAG play an important role in mediating the A3G-Pr55GAG interaction. 
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 Figure 3.9 CAT reporter expression levels of the interactions between wild type 
Pr55GAG and the two GAG Mutants with A3G: COS-1 cells were transfected with 
the respective plasmids using the standard Lipofectamine transfection protocol 
described in section 2.5.3. Cell extracts were analysed for CAT enzyme expression 
72 hours post-transfection using a CAT ELISA kit (Roche) according to the 
manufacturer’s instructions (section 2.7).   
{A} Table showing the absolute CAT values obtained by CAT ELISA against the 
various combinations of plasmids used in a transfection. The positive control for the 
assay exploited the interaction between murine p53 and SV40 large T antigen. The 
negative controls for the assay were individual plasmids expressing AD/BD domain 
fused chimeric proteins of interest together with either empty BD or empty AD 
vector respectively. 
{B} Bar chart depicting the CAT reporter expression levels relative to the positive 
and negative controls (the positive control being 100% and the lowest negative 
control being 0%) calculated using the absolute CAT values in Table 3.9 {A}. Error 
bars indicate Mean ± SEM (n=2 experiments). **= significant difference (p<0.01). 
The p values were calculated using one way ANOVA with post test. 
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3.7.2 Vif-Pr55GAG interaction 
When COS-1 cells were transfected with AD-Vif and BD-Pr55GAG along with GFP 
reporter vector, positive GFP expression was observed similar to that with BD-p53 
and AD-LargeT (positive control) (Fig. 3.10 A). Thus AD-Vif and BD-Pr55GAG 
interact specifically with each other. Similarly when AD-Vif was transfected with 
BD-NCDel, positive GFP expression was observed indicating that the deleted region 
in NCDel did not play any part in the interaction of Vif with Pr55GAG (Fig. 3.10 B). 
In contrast, when cells were transfected with AD-Vif and BD-NCSub, there was a 
huge decrease in reporter GFP expression signifying that the substitution mutations 
in NCSub were responsible for disrupting the interaction of Vif with Pr55GAG (3.10 
C). 
Later, images were analysed using the software ImageJ for quantifying the change in 
GFP intensity observed. Figure 3.11 A tabulates the mean gray values of images 
against the various plasmid combinations employed. When a bar chart was plotted to 
demonstrate the relative GFP intensity by using the mean gray values in figure 3.11 
A, the GFP intensity of AD-Vif and BD-Pr55GAG was almost 2 times more to that 
observed with the positive control (Fig. 3.11 B). The GFP intensity of AD-Vif with 
BD-NCDel was even more than that observed with AD-Vif and BD-Pr55GAG 
however this increase was not significant (p>0.05) (Fig. 3.11 B). In contrast there 
was a huge drop in GFP intensity observed with AD-Vif and BD-NCSub when 
compared to that of AD-Vif and BD-Pr55GAG. This decrease in GFP intensity 
observed in comparison with AD-Vif and BD-Pr55GAG was statistically significant 
(p<0.001). Thus mutations in the basic linker region significantly impair the Vif - 
Pr55GAG interaction. 
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Figure 3.10 GFP reporter expression levels of the interactions between wild type 
Pr55GAG and the two GAG mutants with Vif: COS-1 cells were transfected with 
the respective plasmids using a standard Lipofectamine transfection protocol detailed 
in section 2.5.3. Live cells were observed for GFP expression 48 hours post 
transfection under UV light microscope (section 2.7).  
{A} BD-Pr55GAG + AD-Vif: Wild type Pr55GAG and Vif together with GFP reporter  
{B} BD-NCDel + AD-Vif:  NCDel mutant of Pr55GAG and Vif together with GFP 
reporter  
{C} BD-NCSub + AD-Vif: NCSub mutant of Pr55GAG and Vif together with GFP 
reporter  
The levels of GFP reporter expression were monitored to determine whether an 
interaction was present between the two proteins of interest or not whereby positive 
GFP expression indicated the presence of an interaction while no or background 
level GFP expression indicated no interaction.  
Panels on the right hand side show visible light image of the transfected cells and 
panels on the left display fluorescence of GFP under UV light. 
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Figure 3.11 Quantifying the level of GFP expression using the image analysis 
software ImageJ to provide some indication of the strength of the interactions of 
Vif with wild type Pr55GAG and the two GAG mutants: COS-1 cells were 
transfected with the indicated plasmid combinations in addition to the GFP reporter 
vector. 48 hours post-transfection, the cells were observed under UV light 
microscope and images were analysed for GFP expression using the image analysis 
software ImageJ. The RGB images were converted to gray scale to allow 
measurement of the gray values of each pixel within an image. The mean gray value 
of all pixels was thus directly proportional to the intensity of GFP. 
{A} Table depicting the mean gray values of images analysed using ImageJ against 
the plasmid combinations used in a transfection. The positive control for the assay 
exploited the interaction between murine p53 and SV40 large T antigen. The 
negative controls for the assay were individual plasmids expressing AD/BD domain 
fused chimeric proteins of interest together with either empty BD or empty AD 
vector respectively. 
 {B} Bar chart depicting the GFP intensity within an image relative to the positive 
and negative controls  (the positive control being 100% and the lowest negative 
control being 0%) drawn using the mean gray values in the table 3.11 {A}. Error 
bars indicate Mean ± SEM (n=2 experiments). ns= difference not significant 
(p>0.05); ***= significant difference (p<0.001). The p values were calculated using 
one way ANOVA with post test. 
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GFP reporter data was later corroborated by employing the CAT reporter vector 
instead of the GFP vector and repeating the same experiments again. Figure 3.12 A 
tabulates the absolute CAT values obtained by performing the CAT ELISA on 
transfected cell extracts against the various combinations of plasmids employed to 
study the Vif-Pr55GAG interaction. Figure 3.12 B depicts a bar chart drawn from the 
values in figure 3.12 A showing the CAT enzyme expression of various plasmid 
combinations employed relative to the positive and negative controls.  BD-p53 and 
AD-LargeT give positive CAT expression (positive control) (Fig. 3.12 B). When 
cells were transfected with AD-Vif and BD-Pr55GAG along with CAT reporter vector 
the CAT enzyme expression observed was almost 2.5 times more compared to that 
with the positive control (Fig 3.12 B). Similarly the CAT expression observed with 
AD-Vif and BD-NCDel was even more compared to that seen with AD-Vif and BD-
Pr55GAG. However this increase was statistically not significant when compared with 
AD-Vif and BD-Pr55GAG (p>0.05) (Fig. 3.12 B). In contrast there was a statistically 
significant drop in CAT expression observed with AD-Vif and BD-NCSub when 
compared with AD-Vif and BD-Pr55GAG (p<0.001) (Fig. 3.12 B). This significant 
decrease in CAT expression of AD-Vif with NCSub signifies the importance of the 
basic linker region of the NC of Pr55GAG and its critical role in the Vif-Pr55GAG 
interaction. 
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Figure 3.12 CAT reporter expression levels of the interactions between wild 
type Pr55GAG and the two GAG Mutants with Vif: COS-1 cells were transfected 
with the respective plasmids using the standard Lipofectamine transfection protocol 
described in section 2.5.3. Cell extracts were analysed for CAT enzyme expression 
72 hours post-transfection using a CAT ELISA kit (Roche) according to the 
manufacturer’s instructions (section 2.7).   
{A} Table showing the absolute CAT values obtained by CAT ELISA against the 
various combinations of plasmids used in a transfection. The positive control for the 
assay exploited the interaction between murine p53 and SV40 large T antigen. The 
negative controls for the assay were individual plasmids expressing AD/BD domain 
fused chimeric proteins of interest together with either empty BD or empty AD 
vector respectively. 
{B} Bar chart depicting the CAT reporter expression levels relative to the positive 
and negative controls (the positive control being 100% and the lowest negative 
control being 0%) calculated using the absolute CAT values in Table 3.12 {A}. Error 
bars indicate Mean ± SEM (n=2 experiments). ns= difference not significant 
(p>0.05); ***= significant difference (p<0.001). The p values were calculated using 
one way ANOVA with post test. 
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Thus according to the GFP as well as CAT reporter data, there was a significant drop 
in reporter gene expression observed with both, AD-A3G and BD-NCSub & AD-Vif 
and BD-NCSub, suggesting that the mutated region within the basic linker of NC 
domain of Pr55GAG is involved in the interaction of both Vif as well as A3G with 
Pr55GAG. 
3.8 Summary: 
The mammalian two-hybrid assay studies previously performed in our lab have 
already confirmed the Pr55GAG–A3G and Pr55GAG-Vif interactions in vivo (Syed, 
2008; Syed & McCrae, 2009). The BD-A3G plasmid was tested in the two-hybrid 
system in our lab before and was found to be self-activating reporter gene 
expression. Hence all the experiments were carried out using AD-A3G plasmid and 
hence could be carried out only in one way and not the other way round. 
When the NCDel mutant of Pr55GAG was tested for interaction with Vif/A3G using 
this assay, the results showed that deletion of amino acids 4-12 at the amino terminus 
of NC had no effect on the interaction with either Vif or A3G. On the contrary, an 
increase was observed in both GFP as well as CAT reporter expression when cells 
were transfected with either AD-A3G and BD-NCDel or AD-Vif and BD-NCDel 
when compared to AD-A3G and BD-Pr55GAG or AD-Vif and BD-Pr55GAG 
respectively. Important to note here is that the increase was not significant with AD-
Vif and BD-NCDel in case of both GFP as well as CAT reporter data (p>0.05) (Fig. 
3.11 B and 3.12 B). 
However in case of AD-A3G and BD-NCDel, there was a discrepancy observed 
between GFP and CAT reporter data. While in both cases there was an increase in 
reporter expression when compared with AD-A3G and BD-Pr55GAG, the increase 
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observed with CAT reporter was significant (p<0.01) (Fig. 3.9 B) while the increase 
seen with the GFP reporter data was not (p>0.05) (Fig. 3.8 B). One possible reason 
for this discrepancy could be a difference in sensitivity of both these methods of 
analysis. While measurement for CAT enzyme requires an ELISA on the transfected 
cell extracts, the analysis of GFP expression is carried out by image analysis 
software on images of live cells expressing GFP.  
If the CAT ELISA was a more sensitive method, then one possibility could be that 
the deletion of amino acids 4-12 from the N-terminal of the NC domain of Pr55GAG 
changes the Pr55GAG conformation in such a way that its affinity for A3G increases. 
On the other hand, if the GFP analysis data was correct and the increase was not 
significant, then the inference would be that the deletion has no effect on the A3G-
Pr55GAG interaction. However this is a very interesting finding and warrants further 
analysis. 
By contrast, when the NCSub mutant of Pr55GAG was used, significant reductions in 
reporter expression levels with both Vif and A3G were observed suggesting that the 
basic linker region between the two zinc finger motifs of the NC portion of Pr55GAG 
is important for the interaction with both Vif and A3G. In case of A3G, this supports 
the conclusions reached by Burnett and Spearman (Burnett & Spearman, 2007).  
Other possible interpretation of this result could be that the BD-NCSub mutant itself 
is non-functional and scrambled due to which it interacts neither with Vif nor with 
A3G. This possibility has been addressed in greater detail in the next chapter. 
To summarise, both Vif and A3G interact at the same site on Pr55GAG of HIV. This 
site is located in the basic linker region of its Nucleocapsid domain. These 
observations make possible a scenario where one of the actions of Vif in overcoming 
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the A3G block to virus replication is to compete with it for Pr55GAG binding thereby 
preventing its encapsidation into the newly formed HIV virions (Fig. 3.8). 
 
 
 
 
 
 
Figure 3.13 Diagrammatic summary of the results and the direction ahead 
Vif  and A3G both interact at the Basic Linker region of the Nucleocapsid domain of 
Pr55GAG . As they interact at the same site on Pr55GAG, a competition between them 
becomes possible. Thus Vif may successfully compete with A3G and prevent it from 
interacting with Pr55GAG thereby excluding it from being incoporated into newly 
formed HIV virions. 
 
131 
 
 
 
 
 
CHAPTER 4 
 
Assessment of the functionality of the 
NCSub mutant of Pr55GAG 
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In the previous chapter, Vif and A3G were both shown to interact at the same site on 
Pr55GAG.  However it remained possible that the negative interaction results for Vif 
and A3G binding to NCSub were due to misfolding of the mutated Pr55GAG. To 
address this issue, a functionality test for the NCSub mutant of Pr55GAG was 
required.  This has been addressed in detail in this chapter. 
 
4.1 Background 
 
During the HIV-1 replication cycle, the interaction of the viral regulatory protein Rev 
with the Rev Response Element (RRE), its RNA target, is essential for the expression 
of the viral structural proteins (Cullen & Greene, 1989).  Rev is known to facilitate 
nuclear export of RRE containing mRNAs and improve their stability. 
It has however been found that in the absence of Rev, there is poor expression of 
viral proteins suggesting that there are some inhibitory sequences upstream of  the 
structural protein coding sequence in the HIV genome (Schwartz et al, 1992b). Using 
site-specific mutagenesis, the inhibitory sequences have been successfully removed 
without requiring a change to the amino acid sequence of Pr55GAG. This has resulted 
in the generation of a Pr55GAG expression vector in which Pr55GAG synthesis is 
independent of Rev (Schwartz et al, 1992a). This rev-independent Pr55GAG 
expression construct directs formation of GAG virus-like particles (VLPs) and their 
release into the supernatant. 
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4.2 Plasmid used in the assay 
 
The rev-independent GAG expression plasmid (pGAG-EGFP) directs the expression 
of GAG-EGFP fusion protein and allows the formation of GAG VLPs and their 
release into the supernatant (Fig. 4.1). This plasmid was obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH 
(Cat#11468) to which it was supplied by Dr. Marilyn Resh. 
 
4.3 Incorporation of the same mutations in the pGAG-EGFP 
plasmid sequence as in NCSub mutant 
 
Using a similar strategy to that described in section 3.5.2, MutGAG (GM) was 
constructed by site-directed mutagenesis of pGAG-EGFP (G) using PCR based 
mutagenesis with the forward primer 1551GagMutF and the reverse primer 
1551GagMutR (Table 2.2.1). This produced a mutated Pr55GAG in which two basic 
amino acids (Arginine and Lysine) had been substituted with two acidic ones 
(Glutamic acid) in the basic linker of the NC region of the protein similar to NCSub 
(Fig. 1.3 Appendix). 
 
4.4 Hypotheses 
 
4.4.1 Membrane localisation 
One of the functional properties of Pr55GAG expressed inside cells is to localise to the 
plasma membrane for initiating particle assembly (Bryant & Ratner, 1990).  When  
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Figure 4.1 Vector used for the GAG assembly assay. pGAG-EGFP (G): This 
plasmid directs the expression of a Pr55GAG-EGFP fusion protein from the CMV 
promoter and was originally constructed to allow imaging of the intracellular 
trafficking of the GAG protein. The expressed fusion protein also forms fluorescent 
GAG virus-like particles with equal efficiency to wild-type GAG. 
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the wild-type GAG plasmid (G) is transfected into 293T human embryonic kidney 
cells, the Pr55GAG-GFP fusion protein localises to the cytoplasmic membrane. For the 
mutant Pr55GAG (GM) to be functional, the expressed GM-GFP fusion protein should 
also localise to the plasma membrane similar to wild type GAG.  
4.4.2 Particle assembly 
The Gag expressed when wild-type GAG plasmid (G) is transfected into 293T cells, 
forms virus-like particles. If the mutant GAG protein (GM) folds correctly and is 
functional, it will also form virus-like particles similar to those produced by the wild 
type protein. 
 
4.5 Assays employed:  
 
4.5.1 Membrane localisation 
To study the membrane localisation of the Pr55GAG-GFP fusion protein, 293T cells 
were plated into 12 well dishes as detailed in section 2.9. The cells were separately 
transfected with 1.5µg of either G or GM plasmid using the standard Lipofectamine 
transfection protocol (section 2.5.3). The GFP-tagged wild type and mutant GAG 
fluorescent proteins were detected inside cells by using a confocal microscope as 
described in section 2.9. 
4.5.2 Sucrose gradient analysis of GAG VLPs 
The assay protocol for the sucrose gradient analysis of GAG VLPs has been 
described in detail in section 2.8 of Materials and Methods. Cells were transfected 
with 15µg of either G or GM plasmid using the calcium phosphate transfection 
136 
 
protocol described in section 2.5.4. (Campanero & Flemington, 1997). The VLPs 
were analysed as described in section 2.8.   
 
4.6 Results 
 
4.6.1 Confocal imaging of the expressed GAG-GFP fusion protein inside cells 
To study the localisation of GAG proteins inside cells, 293T cells were transfected 
with either G or GM plasmid and prepared for imaging as described in sections 4.5.1 
and 2.9. The GFP fluorescence inside cells was observed under the confocal 
microscope. 
Wild-type GAG-GFP fusion protein localised to the cytoplasmic membrane when 
293T cells were transfected with the G plasmid (Fig.4.2). Similarly when cells were 
transfected with the GM plasmid, the mutant Pr55GAG-GFP fusion protein also 
localised to the plasma membrane indicating that the mutant had the same functional 
property as wild-type Pr55GAG (Fig. 4.2). 
4.6.2 VLP assembly assay 
To further test the functionality of the GM mutant of Pr55GAG, 293T cells were 
separately transfected with either G plasmid expressing wild-type Pr55GAG fused to 
GFP or the GM plasmid which expressed a mutated version of Pr55GAG fused to GFP 
where the two basic amino acids (Arginine and Lysine) in the basic linker of the 
nucleocapsid were replaced with two acidic amino acids (Glutamic acids). 72 hours 
post-transfection the supernatant atop the transfected cells was collected and 
processed as detailed in section 2.8 (Fig. 4.3). 
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Figure 4.2 GFP localisation of wild type (G) and mutant (GM) GAG-GFP fusion 
proteins inside 293T cells studied using confocal microscope. 293T cells were 
separately transfected with either G or GM plasmid using the standard Lipofectamine 
transfection protocol described in section 2.5.3. 48 hours post-transfection, the cells 
were prepared for imaging under the confocal microscope as described in section 2.9. 
Green fluorescence indicates the position of the GAG-GFP fusion protein, with the 
nuclei of cells being stained blue due to the nuclear stain DAPI.  
{A} Wild type Pr55GAG-GFP fusion protein (scale bar is 25µm) 
{B} Mutant Pr55GAG-GFP fusion protein (scale bar is 10 µm) 
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Figure 4.3 GAG assembly assay to test the functionality of the NCSub mutant of 
Pr55GAG. The rationale of this assay is that if the mutant GM is able to form VLPs 
with similar efficiency and density to those produced by wild type G, then it is 
functional indicating that its folding has not been disrupted by the substitutions in the 
basic linker region of NC. 293T cells were transfected with either G/ GM plasmid 
using the calcium phosphate transfection protocol described in detail in section 2.5.4. 
Supernatant containing VLPs generated from the respective plasmids is concentrated 
and centrifuged through 20-60% sucrose gradients. Equal aliquots were collected 
from the bottom of the gradient, fractionated on SDS-PAGE gel and analysed by 
immunoblotting for the presence of GAG protein. 
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Alternate fractions of the gradient from aliquot number 2 to 14 together with the 
pellet fraction ‘p’ as described in section 2.8 were first analysed for the presence of 
GAG virus like particles. The expressed wild-type Pr55GAG and the mutant Pr55GAG 
both generated VLPs following transfection into 293T cells (Fig. 4.4).  The VLPs 
were detected in aliquot number 4 of the gradient in both the wild type and the 
mutant plasmid transfections together with some diffusely stained smears in aliquots 
6 to 10  with the smear being more prominent in aliquot number 10 (Fig. 4.4). 
Consequently it was decided to use only aliquots 4, 6, 8 and 10 for further studies on 
the GAG VLPs. 
Figure 4.5 shows gradient fractions 4, 6, 8 and 10 re-analysed for the presence of 
GAG VLPs with both wild type and mutant GAG proteins. The VLPs were again 
found to be present in aliquot number 4 of the gradient fraction with wild type 
Pr55GAG. The density of aliquot number 4 was later measured using a refractometer 
and found to be 1.16 g/ml. Pr55GAG carrying the substitution mutations of NC seen in 
NCSub was also able to generate VLPs in the GAG assembly assay, with VLPs 
being found in the same gradient fraction (aliquot number 4) as that seen for wild 
type GAG (Fig. 4.5). The density of fraction 4 containing mutant GAG VLPs was 
also measured and was found to be the same as that seen for wild type GAG VLPs 
(1.16 g/ml). There was also a smear of GAG protein detected on the blot 
corresponding to gradient fraction 8 (Fig. 4.5) which is discussed in detail in the next 
section. 
The overall conclusion of this assay is therefore that the mutant GAG was able to 
generate VLPs which were found in the same gradient fraction as wild type GAG 
VLPs and had the same density as wild type Pr55GAG VLPs. Thus the basic linker  
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Figure 4.4 Sucrose gradient analysis of GAG VLPs. 293T cells were transfected 
with either G or GM plasmid separately using the standard calcium phosphate 
transfection protocol mentioned in section 2.5.4. Supernatant containing VLPs 
generated from the respective plasmids was concentrated and centrifuged through 
20-60% sucrose gradients. Equal aliquots from 1 to 14 along with pellet fraction ‘p’ 
were collected from the bottom of the gradient. Alternate aliquots (p, 2, 4, 6 etc.) 
were fractionated on an SDS-PAGE gel and analysed by immunoblotting for the 
presence of GAG protein. Pr55GAG was probed with a mouse anti-p24 antibody 
(1:3000) as described in section 2.2.4. Phosphatase conjugated goat anti-mouse was 
used as a secondary antibody(1:25,000). The blot was detected colorimetrically using 
BCIP/NBT alkaline phosphatase substrate tablets (Sigma-Aldrich B5655) dissolved 
in deionised water (section 2.6.3). The track labelling indicates the fraction number 
analysed with ‘L’ being the protein ladder. The numbering down the right side shows 
the migration position of the molecular weight size markers in KDaltons. The 
migration positions of wild type Gag (blot A) and the GAG mutant (blot B) in 
fraction number 4 (G4 and GM4 respectively) are indicated on the left hand side of 
the blot. 
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Figure 4.5 VLP assembly assay of the NCSub mutant of Pr55GAG. Wild type(G) 
and mutant (GM) GAG VLPs were fractionated on 20-60% sucrose gradients and 
gradient fractions analysed by polyacrylamide gel electrophoresis and western 
blotting using anti-p24 as the primary antibody as described in section 2.2.4. 
Peroxidase conjugated goat anti-mouse (1:5000) was used as the secondary antibody. 
Proteins were detected using an ECL Chemiluminescence Detection Kit (GE 
Healthcare Life Sciences) and analysed using the Bio-Rad ChemiDoc XRS Imaging 
System. The numbering of the gel tracks denotes the specific sucrose gradient 
fraction analysed with L being the protein ladder and the numbering down the right 
side shows the migration position of molecular weight size markers in KDaltons. The 
position of wild type and mutant Pr55GAG in gradient fraction G4 and GM4 
respectively is arrowed. 
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Pr55GAG mutant was assembling correctly indicating that the mutations in the basic 
linker of its nucleocapsid domain did not have any effect on the Pr55GAG folding. 
4.7 Summary 
 
It has been well established that Pr55GAG can direct the synthesis of virus-like 
particles (VLPs) both in vivo and in vitro without any requirement for other 
accessory viral or cellular factors (Campbell & Rein, 1999; Campbell & Vogt, 1995). 
However, these VLPs are non-infectious due to the absence of viral RNA. 
Each VLP is composed of ~5000 GAG molecules forming a compact structure as a 
result of the ordered multimerisation of individual GAG proteins (Briggs et al, 2004). 
A small change at the amino acid level in Pr55GAG could potentially result in 
improper protein folding and ultimately prevent the multimerization of GAG 
molecules.  
The fact that mutant GAG was found localised to the cytoplasmic membrane similar 
to wild type GAG and formed VLPs with similar efficiency and density to those of 
the wild type protein is a clear demonstration that the amino acid substitutions made 
to produce the NCSub mutant had not lead to a large change in folding, allowing the 
protein to retain its functionality. 
However the plasmid used in this assay was a rev-independent codon optimised 
version of Pr55GAG fused to GFP (pGAG-EGFP) whereas the plasmid used in the 
mammalian two-hybrid studies detailed in the previous chapter was Pr55GAG fused to 
the DNA binding domain (BD-Pr55GAG).   Although the two versions of Pr55GAG 
used in the experiments described in chapters 3 and 4 were therefore different, it 
could still be argued that the mutations in the basic linker region did not compromise 
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the ability of the Pr55GAG protein to self-assemble into virus like particles thus 
retaining its functionality. A more direct approach would have been to subclone the 
Pr55GAG-DNA binding domain sequence into a CMV promoter vector and express 
the Pr55GAG fusion protein in the presence of the viral Rev protein (Rev dependent 
Pr55GAG expression). However this was technically more demanding and hence it 
was decided to insert the mutations into the codon optimised version of Pr55GAGand 
analyse the VLPs obtained from this construct. 
In addition to the GAG band detected in aliquot number 4 with both the wild type 
and mutant GAG proteins, there was also a smear of GAG protein detected in aliquot 
number 10 (Fig. 4.4) and aliquot number 8 (Fig. 4.5). The smear was darker 
especially in the ~25kDa region of the blot. This smear was most probably due to 
mechanical fragmentation of GAG VLPs occurring during the various steps involved 
in analysis. This fragmentation presumably affected the density of the VLPs resulting 
in the fragmented proteins being detected in the upper aliquots of the gradient 
corresponding to the less dense sucrose fractions. The reason for the smear being 
more prominent in two different aliquot fractions (fraction 10 and fraction 8 in Fig. 
4.4 and 4.5 respectively) in two separate experiments could be due to the 
instrumental error introduced while preparing the sucrose gradient. However the 
changes observed were the same for both G as well as GM proteins obviating the 
error and hence allowing for a rational comparison of the results obtained. 
Another attractive approach which could have been applied to tackle the 
functionality issue of GAG VLPs was to compare the in vitro proteolytic digestion 
profiles of wild type and mutant GAG VLPs. The purified mutant and wild type 
GAG VLPs could be treated with HIV-1 Protease and subjected to SDS-PAGE 
followed by immunoblotting with mAb to p24 (AG 3.0) which enables the detection 
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of polyprotein p55, processing intermediates as well as mature p24. If their digestion 
profiles were found to be similar, it could be reasonably argued that their assembly 
was also not very different from each other. However, at that time, the sucrose 
gradient analysis of virus-like particles seemed a relatively simpler approach to adopt 
because of the ready availability of all the reagents needed for the experiment. 
To summarise, inserting the same basic linker region mutations as those seen in 
NCSub into the Rev-independent Pr55GAG expression construct did not have any 
effect on its self-assembly suggesting that the mutations did not affect GAG 
multimerisation. Hence it can be reasonably argued that insertion of these mutations 
does not affect Pr55GAG functionality. 
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CHAPTER 5 
 
In vivo competition studies between Vif and 
A3G for Pr55GAG binding 
 
 
 
 
 
 
 
146 
 
5.1 Introduction 
Having successfully demonstrated that both Vif and A3G interact at the same site on 
Pr55GAG and also that mutations in the basic linker of NC did not impact Pr55GAG 
functionality, the logical next step was to investigate whether Vif and A3G compete 
with each other for this interaction site on Pr55GAG. To do this a novel modification 
of the mammalian two-hybrid assay was developed. 
 
5.2 Modification of the mammalian two-hybrid assay to study 
competition 
In the classical mammalian two-hybrid assay, the two proteins between which the 
interactions are to be studied are fused in-frame to the DNA-binding domain (BD) 
and Activation domain (AD) of the two-hybrid assay vectors respectively. A positive 
interaction between these proteins brings the BD and AD domains into close 
proximity to each other thereby reconstituting the transcription factor and initiating 
reporter gene transcription. This assay has been explained in detail in section 3.4. 
The novel modification to this assay introduced in this study was to express a third 
protein in addition to the pair of chimeric proteins mentioned above. This third 
protein had the capability to interact with one of the proteins within the pair; the only 
significant difference being that its interaction with its partner did not stimulate 
reporter gene transcription. Two hypothetical scenarios are possible in this case. If 
the interaction of the third protein with one of the proteins within the pair is mutually 
exclusive of the interaction between the pair, then expression of the third protein 
would have no effect on reporter gene transcription levels in the mammalian two-
hybrid assay. On the other hand, if the third protein competes for interaction and has 
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a higher relative affinity for this interaction compared to the other component of the 
pair, this should result in a drop in reporter gene transcription levels as the interaction 
between the chimeric protein-pair is disrupted due to the competition. 
AD-A3G interacts with BD-Pr55GAG to give positive reporter gene expression in the 
two-hybrid assay. If interaction between Vif and Pr55GAG has a higher affinity than 
that between A3G and Pr55GAG then expressing additional BD-Vif in the two-hybrid 
assay, that is able to interact with the BD-Pr55GAG fusion but not trigger reporter 
expression, should displace AD-A3G from the two-hybrid interaction and thereby 
lower reporter gene expression (Fig.5.1). It is important to note here is that AD-A3G 
and BD-Vif have already been shown not to interact with each other in a two-hybrid 
assay and therefore do not stimulate any reporter gene expression (Syed, 2008). 
Thus expressing BD-Vif in an assay being driven by the AD-A3G - BD-Pr55GAG 
interaction should allow a comparison to be made of the relative affinity of both 
these proteins for Pr55GAG binding. 
 
5.3 Assay protocol 
The mammalian two-hybrid assay transfection protocol has been explained in section 
2.7 of Materials and Methods. Increasing amounts of the BD-Vif plasmid (0ng to 
1500ng) were co-transfected, together with 1500ng each of AD-A3G, BD-Pr55GAG 
and the CAT reporter plasmids. As a negative control, the same experiment was 
performed in the reverse direction i.e. increasing amounts (0ng to 1500ng) of AD-
A3G plasmid were co-transfected, together with BD-Vif, AD-Pr55GAG and the CAT 
reporter plasmids. The overall amount of plasmid DNA in each transfection was 
balanced using an empty Activation Domain (AD) vector to eliminate any effects of 
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Figure 5.1 Simplified diagrammatic representation of the modified mammalian 
two-hybrid assay to study the competition between Vif and A3G for Pr55GAG 
binding. (A) Interaction between AD-A3G and BD-Pr55GAG gives positive CAT 
reporter expression levels (B) Addition of the plasmid BD-Vif to the system in (A) 
results in displacement of AD-A3G from BD-Pr55GAG pushing the Activation 
Domain (AD) and Binding Domain (BD) away from each other resulting in loss of 
CAT expression. It has already been shown that BD-Vif does not interact with AD-
APOBEC3G in this system and hence does not stimulate reporter gene expression 
(Syed, 2008). 
(BD-Vif does not interact with AD-APOBEC3G) 
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varying the total amount of DNA used on reporter expression. Empty AD vector was 
used instead of the empty BD vector because BD vector is sometimes known to non-
specifically activate reporter gene expression on its own which results in higher 
background reporter expression levels. CAT reporter expression was assayed as 
described in section 2.7. As BD-A3G was known to self-activate reporter gene 
expression (section 3.5.1), the experiments described in this study were designed 
only with AD-A3G and correspondingly the other plasmids used had to be modified. 
Hence for an assay driven by AD-A3G and BD-Pr55GAG, increasing amounts of BD-
Vif had to be added and when increasing amounts of AD-A3G were used in the 
control assay, the assay had to be driven by using the BD-Vif and AD-Pr55GAG 
interaction. 
 
5.4 Results 
5.4.1 Effect of increasing BD-Vif levels in two-hybrid assays driven by an AD-
A3G - BD-Pr55GAG interaction 
Figure 5.2 (A) tabulates the absolute CAT reporter expression values obtained 
against the various combinations of plasmids transfected. When COS-1 cells were 
transfected with AD-A3G and BD-Pr55GAG together with CAT reporter vector in the 
absence of added Vif (BDVif-0ng), high CAT enzyme levels were observed (Fig. 5.2 
A). This A3G-Pr55GAG interaction acted as the positive control for the assay.  
When BD-Vif and BD- Pr55GAG were transfected into COS-1 cells together with 
empty AD vector, background levels of reporter gene expression were observed (Fig. 
5.2 A). Similarly there was a background level of CAT expression detected when 
BD-Vif and AD-A3G were transfected together with empty AD vector indicating 
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that BD-Vif does not interact with AD-A3G (Fig. 5.2 A). It can therefore be inferred 
that these plasmid combinations or any individual plasmid within this combination 
did not activate reporter gene expression. These samples constituted the negative 
controls employed in this assay.  
When the levels of BD-Vif were increased gradually from 0ng to 1500ng in an assay 
driven by the A3G-Pr55GAG interaction, a corresponding stepwise reduction in CAT 
reporter levels was observed (Fig. 5.2 A). 
The bar chart plotted to tabulate this change observed in the CAT reporter levels 
relative to the positive and negative controls showed that there was a significant 
reduction (p< 0.01) in CAT reporter expression when 750ng of BD-Vif was added to 
the assay driven by AD-A3G and BD-Pr55GAG (Fig. 5.2 B). The CAT levels 
decreased even further in response to increased levels of BD-Vif with a very 
significant reduction (p<0.001) observed compared to the positive control when 
1500ng of BD-Vif was added to the assay driven by AD-A3G and BD-Pr55GAG (Fig. 
5.2 B). 
5.4.2 Effect of increasing the levels of AD-A3G in two-hybrid assays driven by a 
BD-Vif - AD-Pr55GAG interaction 
To rule out the possibility that the results described in the previous section were due 
to non-specific effects, the same experiment was carried out in the reverse 
orientation. To do this, increasing levels of AD-A3G were added to a two-hybrid 
assay driven by BD-Vif and AD-Pr55GAG. Figure 5.3 A tabulates the absolute CAT 
values obtained for the various combinations of plasmids employed in the 
experiment. BD-Vif and AD-Pr55GAG resulted in positive CAT reporter expression in 
the absence of AD-A3G (AD-A3G- 0ng) (Fig. 5.3 A). As before, this represented the 
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Figure 5.2 CAT reporter expression levels for a two-hybrid assay driven by the 
AD-A3G & BD-Pr55GAG interaction when the levels of BD-Vif plasmid co-
transfected were increased from 0ng to 1500ng: COS-1 cells were transfected with 
plasmids using the standard Lipofectamine transfection protocol described in section 
2.5.3. Cell extracts were analysed for CAT enzyme expression 72 hours post-
transfection using a CAT ELISA kit (Roche) according to the manufacturer’s 
instructions (section 2.7).   
{A} Table showing the absolute CAT values obtained by CAT ELISA for the 
various combinations of plasmids used in a transfection. The concentration of BD-
Vif was sequentially increased from 0ng to 1500ng balancing the total amount of 
DNA in each transfection with empty AD vector. 
 Z= AD-A3G +BD-GAG +CAT Reporter + pcDNA3.1-A3G-HA (1500ng each) 
The positive control for the assay was  
• Z + BD-Vif0 + EmptyAD1500 (Transfection in which the CAT reporter 
expression was driven by AD-A3G and BD-GAG in the absence of BD-Vif) 
The negative controls for the assay were  
• BD-Vif, BD-GAG and Empty AD vector (1500ng each) & 
• BD-Vif, AD-A3G and Empty AD vector (1500ng each). 
{B} Bar chart depicting the CAT reporter expression levels relative to the positive 
and negative controls (the positive control being 100% and the lowest negative 
control being 0%) calculated using the absolute CAT values in Table 5.2 {A}. Error 
bars indicate Mean ± SEM (n=2 experiments). **= significant difference (p<0.01). 
***= very significant difference (p<0.001). The p values were calculated using one 
way ANOVA with post test. 
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positive control for the assay. The negative controls used (1) AD-A3G + AD-GAG + 
empty AD and (2) AD-A3G + BD-Vif + empty AD both resulted in a background 
level CAT expression (Fig. 5.3 A).  
In contrast to what was seen in the earlier competition experiment, in this case no 
stepwise reduction was observed when the levels of AD-A3G were increased from 
0ng to 1500ng in an assay driven by the Vif-Pr55GAG interaction (Fig. 5.3 A). When 
a bar chart showing the CAT values relative to the positive and negative controls was 
plotted, no significant change was observed (p>0.05) in the CAT reporter expression 
levels when the amount of A3G was increased gradually from 0 to 1500 ng (Fig. 5.3 
B).  
This result strongly supports the proposal that the step-wise decrease in CAT reporter 
expression observed with an increase in the levels of BD-Vif in an assay driven by 
the A3G-Pr55GAG interaction (Fig. 5.2) was indeed specific. 
5.5 Potential limitations of the competition assay 
In addition to the competition hypothesis for Vif action, two other possible 
explanations for the results obtained in Figure 5.2 should be discussed. These are as 
follows: 
5.5.1 Competition between BD-Vif and BD-Pr55GAG for binding to the Upstream 
Activation Sequence of CAT reporter vector 
The proposal here is that stepwise decrease in reporter gene expression observed 
with increasing BD-Vif levels in a two-hybrid assay driven by AD-A3G and BD-
Pr55GAG results from BD-Vif directly competing with BD-Pr55GAG for binding to the 
specific Upstream Activation Sequence (UAS) in the promoter of the reporter vector 
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Figure 5.3 CAT reporter expression levels for a two-hybrid assay driven by the 
BD-Vif & AD-Pr55GAG interaction when the levels of AD-A3G plasmid co-
transfected were increased from 0ng to 1500ng: COS-1 cells were transfected with 
the respective plasmids using the standard Lipofectamine transfection protocol 
described in section 2.5.3. Cell extracts were analysed for CAT enzyme expression 
72 hours post-transfection using a CAT ELISA kit (Roche) according to the 
manufacturer’s instructions (section 2.7).   
{A} Table showing the absolute CAT values obtained by CAT ELISA against the 
various combinations of plasmids used in a transfection. The concentration of AD-
A3G was sequentially increased from 0ng to 1500ng balancing the total amount of 
DNA in each transfection with empty AD vector. 
 Z= AD-GAG +BD-Vif +CAT Reporter (1500ng each) 
The positive control for the assay was  
• Z + AD-A3G0 + EmptyAD1500 (Transfection in which the CAT reporter 
expression was driven by AD-GAG and BD-Vif in the absence of AD-A3G) 
The negative controls for the assay were  
• AD-A3G, AD-GAG and Empty AD vector (1500ng each) & 
• BD-Vif, AD-A3G and Empty AD vector (1500ng each). 
{B} Bar chart depicting the CAT reporter expression levels relative to the positive 
and negative controls (positive control being 100% and the lowest negative control 
being 0%) calculated using the absolute CAT values in Table 5.3 {A}. Error bars 
indicate Mean ± SEM (n=2 experiments). ns= difference not significant (p>0.05). 
The p values were calculated using one way ANOVA with post test. 
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thereby displacing BD-Pr55GAG binding thus squelching reporter gene expression by 
preventing its transcription initiation.  
The assays described in sections 5.4.1 and 5.4.2 were all conducted by employing the 
empty AD vector to balance out the total DNA in all wells and eliminate any effects 
of varying total amount of DNA on transfection efficiency. The empty BD vector 
was not used because it is known to have a relatively higher rate of self-activation 
and gives a higher background signal as compared to empty AD vector. Nevertheless 
to address this possible explanation for the competition observed, the experiment 
described in section 5.4.1 was repeated balancing the total amount of DNA in each 
case with empty BD vector instead of empty AD vector. 
The hypothesis would be that if the BD component of BD-Vif was indeed competing 
with BD-Pr55GAG for the DNA-binding domain interaction site on the reporter 
vector, then the empty BD vector would also compete for the same site. The 
expectation would be that there should be a uniform decrease in CAT reporter 
expression across all samples as the total amount of DNA-binding domain vectors 
(empty BD + BD-Vif) in each sample would be the same (1500ng). However when 
this experiment was carried out a uniform decrease in CAT reporter expression was 
not observed but rather there was again a stepwise drop in CAT expression with 
increase in BD-Vif levels from 0ng to 1500ng (Fig. 5.4 A and B). This result shows 
that competition at the DNA-binding domain interaction site on the reporter vector 
was not the explanation for the observed competition of BD-Vif on the A3G-Pr55GAG 
interaction. 
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Figure 5.4 CAT reporter expression levels for a two-hybrid assay driven by the 
AD-A3G & BD-Pr55GAG interaction when the levels of BD-Vif plasmid co-
transfected were increased from 0ng to 1500ng while the amount of total DNA 
in each transfection was balanced with empty BD vector: COS-1 cells were 
transfected with plasmids using the standard Lipofectamine transfection protocol 
described in section 2.5.3. Cell extracts were analysed for CAT enzyme expression 
72 hours post-transfection using a CAT ELISA kit (Roche) according to the 
manufacturer’s instructions (section 2.7).   
{A} Table showing the absolute CAT values obtained by CAT ELISA against the 
various combinations of plasmids used in a transfection. The concentration of BD-
Vif was sequentially increased from 0ng to 1500ng balancing the total amount of 
DNA in each transfection with empty BD vector. 
 X= AD-A3G +BD-GAG +CAT Reporter (1500ng each) 
The positive control for the assay was  
• X + BD-Vif0 + EmptyBD1500 (Transfection in which the CAT reporter 
expression was driven by AD-A3G and BD-GAG in the absence of BD-Vif) 
The negative controls for the assay were  
• BD-Vif, BD-GAG and Empty BD vector (1500ng each) & 
• BD-Vif, AD-A3G and Empty BD vector (1500ng each). 
{B} Bar chart depicting the CAT reporter expression levels relative to the positive 
and negative controls (positive control being 100% and the lowest negative control 
being 0%) calculated using the absolute CAT values in Table 5.4 {A}.  
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5.5.2 Proteasomal degradation of AD-A3G by BD-Vif 
It has been clearly demonstrated that Vif expressed in the cytoplasm of HIV infected 
cells forms a Vif-Cul5-SCF complex which recruits A3G leading to its 
polyubiquitination and forwarding to the 26S Proteasome for degradation (Yu et al, 
2003). Although the proteins expressed in the two-hybrid assays are targeted to the 
nucleus it remained possible that the reduced levels of CAT reporter seen in Fig. 5.2 
resulted from increasing levels of BD-Vif promoting degradation of the AD-A3G 
synthesised in the assay. 
To exclude this possibility, an additional plasmid, pcDNA3.1-A3G-HA, was also 
transfected into the COS-1 cells used in the competition assay (Figure 5.2). This 
plasmid expresses an HA-tagged A3G protein (A3G-HA) under the control of the 
constitutive immediate early promoter of cytomegalovirus. If the expressed BD-Vif 
was indeed promoting the degradation of AD-A3G resulting in decreased CAT 
enzyme expression, then it would be expected that it would also promote degradation 
of the HA-tagged A3G. 
However Fig. 5.5 shows that when the level of BD-Vif expressing plasmid was 
increased from 0 to 1500ng, there was no change in the level of A3G-HA observed. 
As BD-Vif did not have any effect on the HA-tagged A3G, it can be reasonably 
argued that it would not have any effect on AD-A3G. These results therefore make it 
very unlikely that this explains the competition for binding seen in figure 5.2, serving 
to strengthen the main conclusion reached. 
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Figure 5.5 BD-Vif does not promote the degradation of A3G. Cell extracts were 
collected from the two-hybrid assays shown in Fig. 5.2 which were additionally 
transfected with a plasmid (pcDNA3.1-A3G-HA) that expresses an HA tagged A3G. 
Samples were electrophoresed on a 12.5% SDS-PAGE gel and transferred onto a 
nitrocellulose membrane as described in section 2.6. The western blot was probed 
with anti-HA antibody and signal detected by chemiluminescence as described in 
section 2.6.4. The track labelling indicates samples where increasing levels of BD-
Vif were co-transfected V0=0ng to V1500=1500ng. The positive control was 
produced from cells transfected solely with pcDNA3.1-A3G-HA and the negative 
control from cells where this plasmid was not added to the transfection. The 
migration positions of A3G-HA and a degradation fragment are indicated on the 
right hand side of the blot. 
 
 
 
161 
 
5.6 Conclusions 
Increasing levels of Vif in the A3G-Pr55GAG driven assay was found to squelch 
reporter gene expression in a concentration dependent fashion (Fig. 5.2 and section 
5.4.1). By contrast, in an experimental control, increasing amounts of A3G in a Vif-
Pr55GAG driven assay had no effect on reporter expression levels (Fig. 5.3 and section 
5.4.2). This demonstrated that the stepwise reduction of CAT expression with 
increasing levels of Vif was a specific phenonmenon. 
There are a number of alternative interpretations which could be made of these data. 
The first is that as the levels of BD-Vif are increased in the system, it competes with 
BD-Pr55GAG for the UAS on the CAT reporter vector and hence squelches reporter 
gene expression due to the displacement of BD-Pr55GAG away from the reporter 
vector (section 5.5.1). To counter this interpretation, empty BD vector was used to 
balance the total amount of DNA in each sample and the experiment shown in figure 
5.2 repeated. This showed that the empty BD vector had no effect on the level of 
CAT reporter expression demonstrating that competition at the promoter of the 
reporter vector was not the explanation for the competition observed (Fig. 5.4 and 
section 5.5.1). 
The second argument that can be raised against the proposed competition between 
Vif and A3G for Pr55GAG binding was that as the levels of BD-Vif were increased in 
the system, the expressed BD-Vif was promoting the degradation of AD-A3G and 
this decrease in AD-A3G levels was leading to a drop in CAT reporter expression 
(section 5.5.2). To circumvent this argument, an additional plasmid expressing HA-
tagged A3G was added to the transfections and the effect of increasing amounts of 
Vif on the levels of A3G-HA were detected. There was no change in the level of 
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A3G-HA in any of the samples indicating that BD-Vif did not promote the 
degradation of A3G-HA (Fig. 5.5). It is however the case that A3G-HA is expressed 
in the cytoplasm of transfected cells while the two-hybrid assay proteins localise to 
the nucleus. Nevertheless degradation of A3G by Vif is known to occur in the 
cytoplasm and nuclear degradation of A3G has not yet been reported. Hence it can be 
reasonably argued that BD-Vif does not degrade AD-A3G. Direct monitoring of the 
level of AD-A3G within a nuclear fraction would have been a more accurate way to 
get around this argument. However previous experience in the lab has shown that the 
expression levels of two-hybrid assay proteins are so low that they are very difficult 
to detect on western blots. It is this experience that prompted the use of a tagged 
version of A3G under the control of the CMV promoter. A more accurate 
experimental control would have been to incorporate a nuclear localisation signal 
into the A3G-HA used which would have enabled a correct estimation of the A3G 
dynamics within the nucleus. 
To conclude, the results obtained in this competition assay strongly support the 
proposal that Vif can outcompete A3G for Pr55GAG binding. The advantage of this 
two-hybrid based assay is that it is an in vivo assay and tries to mimic as closely as 
possible the environment within cells. Its inherent weakness lies in the expression 
levels of the two-hybrid assay proteins making difficult the direct monitoring forcing 
reliance solely on the read-out obtained from the reporter gene vector. 
Clearly additional experiments using an independent assay system are necessary to 
support the conclusions reached here. However this finding opens up a new avenue 
to account for the mechanism by which Vif is able to overcome the block to HIV 
replication exerted by the A3G component of the innate immune response. 
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Chapter 6 
 
Application of the GAG VLP assembly assay 
for competition studies between Vif and A3G 
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6.1 Introduction 
 
Further to the findings that Vif and A3G compete with each other for interaction with 
Pr55GAG, the next logical aim was to validate this competition using an independent 
experimental assay protocol. The sucrose gradient assay has already been discussed 
in Chapter 4 where it was employed to study the functionality of the NCSub mutant 
of Pr55GAG.  In this section, the assay protocol was slightly modified to give readout 
of the competition between Vif and A3G for Pr55GAG binding. 
 
6.2 Background 
 
The degradation resistant A3G variant has been described in previous reports (Opi et 
al, 2007). This mutant of A3G which cannot be degraded by HIV-1 Vif was 
employed to explore whether competition is an additional mechanism for Vif action 
in addition to the widely accepted mechanism of proteasomal degradation of A3G by 
Vif. 
When expressed in cells, Pr55GAG protein directs the formation of GAG VLPs in the 
supernatant. Both Vif and A3G are known to become incorporated into the newly 
formed virus particles through a specific interaction with Pr55GAG (Bouyac et al, 
1997a; Cen et al, 2004; Huvent et al, 1998; Schafer et al, 2004; Syed & McCrae, 
2009).  
In a scenario where both Vif and A3G are co-expressed in cells together with 
Pr55GAG, the expressed Vif would deplete the cellular levels of A3G by proteasome-
mediated degradation of the latter (Yu et al, 2003). Consequently there would be 
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very low amounts of A3G protein within the cells. If proteasomal degradation is 
considered as the primary mechanism of Vif action, then the small amount of A3G 
remaining would not be detectably incorporated into the GAG VLPs generated by 
the expressed Pr55GAG. Thus the resultant VLPs would only have Vif detectably 
incorporated into them. With Vif-mediated degradation of A3G masking all other 
functions, it becomes very difficult to study if any additional mechanisms are 
employed by Vif to bypass the A3G block to virus replication. 
To circumvent this difficulty, the degradation resistant A3G variant was used. The 
hypothesis underpinning its use was that if competition and not degradation was an 
important mechanism for Vif action, then despite of not being able to degrade this 
A3G mutant, Vif would still be able to compete with it and prevent its incorporation 
into the budding GAG VLPs (Fig. 6.1). 
 
6.3 Plasmids used in the assay 
 
6.3.1 pGAG-EGFP (G) 
The Rev independent Pr55GAG expression construct pGAG-EGFP (G) has already 
been described in chapter 4. This plasmid directs the formation of GAG VLPs in the 
supernatant when transfected in 293T cells. 
6.3.2 pcDNA3.1-A3G-HA (A) 
The 3xHA-tagged A3G expression plasmid pcDNA3.1-A3G-HA (A) was obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH (Cat#9952) from Dr. Warner C. Greene.  
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Figure 6.1 Competition hypothesis for the mechanism of Vif action: When both 
Vif (V) and A3G (A) are co-expressed in the cells along with Pr55GAG, the expressed 
Vif would deplete the cellular levels of A3G by proteasome-mediated degradation of 
the latter. Thus the resultant VLPs would only have detectable Vif incorporated into 
them as shown in (1). If competition was an important mechanism for Vif action, 
then despite of not being able to degrade the degradation resistant A3G variant 
(AM), Vif would still be able to compete with it and prevent its incorporation into 
the budding GAG VLPs as shown in (2). 
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6.3.3 Construction of the degradation resistant A3G variant 
As described in previous reports, replacement of amino acid cysteine at position 97 
on the A3G sequence with alanine confers it with resistance to Vif mediated 
degradation (Opi et al, 2007). The degradation resistant mutant C97A A3G (AM) 
was constructed by PCR based site-directed mutagenesis of pcDNA3.1-A3G-HA 
using the forward primer DrC97AF and reverse primer DrC97AR (Table 2.2.1). This 
produced a mutated A3G in which there had been a substitution of cysteine at 
position 97 with alanine (Fig. 1.4 Appendix).  
6.3.4 pcDNA-HVif (V) 
The pcDNA-HVif (V) plasmid was obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH from Dr. Stephan Bour 
and Dr. Klaus Strebel. This plasmid expresses a codon-optimized Vif protein of 
HIV-1 NL4-3 under the control of the CMV promoter. 
 
6.4 Assay 
 
293T cells were plated in 10cm tissue culture dishes and used at 70-80% 
confluencey. Cells were transfected with 10µg each of G and V plasmids together 
with 10µg of either A or AM plasmid using the standard calcium phosphate 
transfection protocol (section 2.5.4) (Campanero & Flemington, 1997). As positive 
controls for the assay, 10µg G plasmid was transfected with 10 µg of either A or AM 
plasmid in the absence of V.  The total amount of plasmid DNA in all dishes was 
balanced by empty pcDNA3.1 (+) vector. The VLPs obtained from transfected cell 
supernatants were analysed as described in section 2.8 (Fig. 4.2). Pr55GAG was 
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probed with mAb to p24, the HA-epitope tagged A3G was probed with monoclonal 
anti-HA antibody produced in mouse while Vif was detected using the mouse anti-
Vif monoclonal antibody (section 2.2.4). The blotted proteins were detected either 
colorimetrically (section 2.6.3) or by chemiluminescence (section 2.6.4). 
6.5 Optimisation of the antibody concentrations to be used 
Different concentrations of the above mentioned antibodies were tried to optimise the 
detection of Vif, A3G and Pr55GAG. In the end optimal concentrations for the 
detection of these proteins were obtained and these were 1:250 for mouse anti-Vif 
antibody, 1:10000 for mouse anti-HA antibody and 1:3000 for mAb to p24. A blot 
obtained from cell extracts expressing the above proteins developed using the 
optimised antibody concentrations is shown in Fig. 6.2. As the Vif signal with the 
mouse anti-Vif antibody was very weak, the rabbit HIV-1 HXB2 Vif antiserum was 
employed for Vif detection in all subsequent experiments.  
6.6 Results 
293T cells were transfected with either A or AM and G plasmids along with or in the 
absence of pcDNA-hVif. When extracts from these cells were analysed for the 
presence of wild type A3G-HA (A), A3G-HA variant (AM) and Pr55GAG (G), there 
was no visible change in the A3G variant (AM) concentration in cells expressing G, 
V and AM when compared with cells expressing just G and AM {Fig. 6.3 (1), (2) 
and (3)}. This was expected as the A3G variant cannot be degraded by Vif. Thus the 
A3G/GAG ratio in cells transfected with GAG, Vif and AM (GVAM) was similar to 
those from which Vif was excluded (GAM) {Fig. 6.3 (3)}. 
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Figure 6.2 Analysis of cell extracts by immunoblotting:  293T cells were 
transfected with the respective plasmids using the standard calcium phosphate 
transfection protocol (section 2.5.4). The cell extracts were collected 48 hrs post 
transfection, electrophoresed on 12.5% SDS-PAGE gel and transferred onto a 
nitrocellulose membrane (section 2.6). Vif was probed for using a mouse anti-Vif 
antibody (1:250), A3G-HA using a mouse anti-HA antibody (1: 10,000) and GAG 
with a mouse anti-p24 antibody (1:3000) described in section 2.2.4. Phosphatase 
conjugated goat anti-mouse was used as a secondary antibody (1:25,000). The blot 
was detected colorimetrically using BCIP/NBT alkaline phosphatase substrate tablets 
(Sigma-Aldrich B5655) dissolved in deionised water (section 2.6.3). The migration 
positions of Gag-EGFP, A3G-HA & its degradation fragment and Vif are indicated. 
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However there was a drop observed in the A3G levels in cells expressing G, V and A 
when compared with cells expressing just G and A {Fig. 6.3 (1), (2) and (3)}.  This 
result was also expected as Vif mediated proteasomal degradation of A3G leads to a 
decrease in cellular A3G levels. Thus the A3G/GAG ratio in GVA was almost one-
third to that observed in GA {Fig. 6.3 (3)}. Fig. 6.3 (4) shows the expression levels 
of the Vif (V) protein within these cells. 
When GAG VLPs obtained from the supernantant derived from transfected cells 
mentioned above were analysed for the presence of A3G and Pr55GAG, contrary to 
expectations, the experimental control consisting of VLPs obtained from cells 
expressing G, V and A showed no visible reduction in the A3G concentration when 
compared with VLPs obtained from cells expressing just G and A {Fig. 6.4 (1) and 
(2)}. Densitometric analysis revealed a small decrease in the A3G/GAG ratio of 
GVA when compared to GA but the magnitude of this reduction was not enough to 
be accountable for the Vif mediated exclusion of A3G from GAG VLPs {Fig. 6.4 
(3)}.  
This result was not consistent with previous well-established articles reporting on the 
mechanism of Vif action. Although a Vif-dependent decrease in A3G levels in cell 
extracts was observed, however a corresponding decrease in A3G levels from the 
VLPs derived from these cells was not seen. This meant that the positive control for 
the experiment was not functioning as expected, the reasons for which are discussed 
in the next section.  
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 Figure 6.3 Analysis of extracts derived from cells expressing either A3G or the 
A3G variant and Pr55GAG in the presence or absence of Vif: 293T cells were 
transfected with the indicated plasmids using the standard calcium phosphate 
transfection protocol (section 2.5.4). Cell extracts were collected 48 hrs post 
transfection, electrophoresed on 12.5% SDS-PAGE gel and transferred onto a 
nitrocellulose membrane and analysed by immunoblotting as described in Materials 
and Methods.  
(1) A3G-HA was detected by the mouse anti-HA antibody (1: 10000) and 
(2) GAG was detected by the mouse anti-p24 antibody (1:3000).  
Peroxidase conjugated goat anti-mouse (1:5000) was used as the secondary antibody. 
(3) Computer-aided densitometric analysis of A3G and GAG protein bands in (1) & 
(2). The bar chart depicts A3G/GAG ratio against the combination of plasmids 
transfected.  
(4) Analysis of the expression levels of Vif in cell extracts mentioned above using a 
rabbit Vif antiserum (1:1000) as the primary antibody. Peroxidase conjugated goat 
anti-rabbit (1:100,000) was used as the secondary antibody.  
All the proteins were detected by using an ECL Chemiluminescence detection kit 
(GE Healthcare Life Sciences) and analysed using the Bio-Rad ChemiDoc XRS 
imaging system. The track labelling indicates the respective plasmids transfected. 
The positions of Pr55GAG (G), A3G (A), the degradation resistant A3G Variant (AM) 
and Vif (V) are arrowed.  
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Figure 6.4 Analysing the amount of A3G protein incorporated in GAG VLPs in 
the presence or absence of Vif:  GAG VLPs harvested from supernatant of 293T 
cells expressing (i) Pr55GAG & A3G (GA) and (ii) Pr55GAG, Vif & A3G (GVA) were 
fractionated on 20-60% sucrose gradients and gradient fractions analysed by SDS-
PAGE and western blotting as described in Materials and Methods.  
(1) A3G-HA was detected by using mouse anti-HA antibody (1:10,000)   
(2) GAG was detected by using mouse anti-p24 antibody (1:3000) 
Peroxidase conjugated goat anti-mouse (1:5000) was used as the secondary antibody 
in all blots. Proteins were detected using an ECL-Chemiluminescence detection kit 
(GE Healthcare Life Sciences) and analysed using the Bio-Rad ChemiDoc XRS 
imaging system as described in Materials and Methods. The numbering of the gel 
tracks denotes the specific sucrose gradient fraction analysed while (L) denotes the 
position of the Ladder. The positions of Pr55GAG and A3G are arrowed. 
(3) Computer-aided densitometric analysis of A3G and GAG protein bands in (1) 
and (2). The bar chart depicts the A3G/GAG ratio in the GAG VLPs. 
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When VLPs derived from cells transfected with G and AM in the presence or 
absence of V were analysed for the levels of the A3G variant and Pr55GAG, no visible 
decrease in the amount of A3G variant was observed in VLPs derived from cells 
expressing G, V and AM when compared to VLPs obtained from cells expressing 
only G and AM {Fig. 6.5 (1) and (2)}. Thus the additional expression of Vif did not 
have any effect on the concentration of AM in virus-like particles. Densitometric 
analysis of the protein bands revealed a small decrease in the A3G/GAG ratio of 
GVAM when compared with GAM but the magnitude of this reduction was not 
comparable to what could be expected in the scenario of Vif mediated exclusion of 
A3G from GAG VLPs {Fig. 6.5 (3)}. 
 
6.7 Summary 
 
Although a 3-fold decrease in A3G concentration was detected in the cell extracts 
transfected with A3G, Pr55GAG and Vif plasmids when compared to the cells 
transfected with just A3G and Pr55GAG, a similar fall in the levels of A3G was not 
reflected in VLPs derived from those cells {Fig. 6.3 & Fig. 6.4 }. It was expected 
that due to the proteasome-mediated degradation of A3G by Vif, the levels of A3G in 
the cells would reduce leading to a corresponding decrease in A3G levels in the 
GAG VLPs obtained from those cells (Yu et al, 2003). But this was not found to be 
the case with the A3G/GAG ratio in VLPs with GVA being similar to that of GA 
{Fig. 6.4 (3)}. Thus the positive control for the experiment itself was not functioning 
optimally. 
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Figure 6.5 Comparison of the amounts of the degradation resistant A3G variant 
getting incorporated into GAG VLPs in the presence or absence of Vif:  GAG 
VLPs harvested from supernatant of 293T cells expressing (i) Pr55GAG & 
degradation-resistant A3G variant (GAM) and (ii) Pr55GAG, Vif and degradation-
resistant A3G (GVAM) were fractionated on 20-60% sucrose gradients and gradient 
fractions analysed by SDS-PAGE and western blotting as described in Materials and 
Methods.  
(1) A3G-HA variant (AM) was detected by using a mouse anti-HA antibody 
(1:10,000)   
(2) GAG was detected by using a mouse anti-p24 antibody (1:3000) 
Peroxidase conjugated goat anti-mouse (1:5000) was used as the secondary antibody 
in all blots. Proteins were detected using an ECL-Chemiluminescence detection kit 
(GE Healthcare Life Sciences) and analysed using the Bio-Rad ChemiDoc XRS 
imaging system as described in Materials and Methods. The numbering of the gel 
tracks denotes the specific sucrose gradient fraction analysed while (L) denotes the 
position of the ladder. The positions of Pr55GAG and the A3G variant are arrowed. 
(3) Computer-aided densitometric analysis of A3G and GAG protein bands in (1) 
and (2). The bar chart depicts the A3G/GAG ratio in the GAG VLPs.  
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One reason for this could be the non-specific incorporation of A3G in GAG VLPs. 
As during the experiment, all the proteins were over-expressed; this could lead to 
increased levels of A3G which could then non-specifically interact with Pr55GAG to 
get incorporated into the budding GAG VLPs.  
In light of the observations obtained from the positive control, it becomes very 
difficult to analyse the results of the experiment itself. Using the A3G variant (AM) 
in place of wild type A3G resulted in no change in the variant levels in GAG VLPs 
in the presence/absence of Vif {Fig. 6.5 (1), (2) and (3)}.  
In the cell extracts transfected with Pr55GAG, Vif and the A3G variant, there was no 
significant change in the variant levels either in the presence or in the absence of Vif. 
It is interesting to note here that the steady state levels of the degradation resistant 
mutant seen in cell extracts were almost 3-fold lower than those of wild-type A3G 
{Fig. 6.3 (1) and (3)}. This could either be due to the variant being constitutively 
unstable and thus having a lower half-life than wild type A3G or due to the 
expression levels of the variant from the plasmid being lower than the wild type 
A3G. The latter seems less likely as both the wild type as well as the degradation 
resistant mutant were being transcribed under the control of the same promoter 
(CMV). 
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Chapter 7 
 
Analysis of interactions of Vif and A3G 
with Pr55GAG in a VLP assembly assay 
 
 
 
 
 
 
180 
 
7.1 Background: 
 
By employing the mammalian two-hybrid assay, Vif and A3G were both shown to 
interact on the same site with Pr55GAG (Chapter 3). To obtain independent evidence 
in support of these interactions, it was decided to study them using the GAG VLP 
assembly assay. The sucrose gradient assay protocol has been described in section 
2.8. 
 
7.2 Plasmids used in the assay 
 
The pcDNA-HVif plasmid has been described in section 6.3.4. A 3×HA tagged 
version of pcDNA-HVif was constructed for use in this assay. The triple HA tags in 
pcDNA3.1-A3G-HA were amplified by PCR using forward primer EcoRIHAF and 
reverse primer EcoRIHAR {Table 2.2.1 and Fig. 7.1 (1)&(2)}. The amplified PCR 
product and vector pcDNA-HVif were both digested with restriction enzyme EcoRI 
so that the insert can be ligated in frame with the Vif gene sequence of the vector 
resulting in the formation of HA-pcDNA-HVif (*V) {Fig. 7.1 (3) & Fig. 1.5 
Appendix}. The correct orientation of the HA tag into the Vif expression plasmid 
was first verified by restriction digestion of the mutant with the enzyme NdeI and 
subsequent sequencing. 
In addition all the other plasmids used in this assay namely the Rev-independent 
GAG expression construct (G), the basic linker mutant of Pr55GAG (GM), and  
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Figure 7.1 Schematic of construction of the 3×HA tagged version of Vif (*V):  
(1) pcDNA3.1-A3G-HA: Schematic diagram showing the 3×HA tagged version of 
A3G in pcDNA3.1 vector (2) Amplification of the 3×HA tags by PCR: The triple 
HA tags at the C-terminal end of A3G sequence in pcDNA3.1-A3G-HA vector were 
amplified by PCR. The PCR primers were flanked by EcoRI restriction enzyme sites 
for subsequent restriction digestion of the PCR product (3) Construction of N-
terminal 3×HA tagged version of Vif: The amplified PCR product (insert) and 
pcDNA-HVif (vector) were treated with the restriction enzyme EcoRI. The digested 
insert and vector were ligated together to construct an N-terminally HA-tagged 
version of Vif such that the HA tags were in the same frame as the Vif sequence. The 
correct orientation of the HA tags was verified first by restriction digestion of the 
resultant plasmid with enzyme NdeI and subsequent sequencing (Fig. 1.5 Appendix).  
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pcDNA-3.1-A3G-HA (A)   have been already described in sections 4.2, 4.3 and 6.3.2 
respectively. 
7.3 Assay protocol 
 
The assay protocol for the sucrose gradient analysis of GAG VLPs has been detailed 
in section 2.8 of the Materials and Methods. 293T cells were transfected using the 
calcium phosphate transfection protocol (section 2.5.4) with 15µg of each plasmid in 
the following combinations: 
(i) *V and G                              (ii) *V and GM 
(iii)  A and G                              (iv) A and GM 
The GAG VLPs in the resultant cell culture supernatants were overlaid onto linear 
20-60% sucrose gradients and subjected to centrifugation in a Beckman SW40Ti 
rotor for 16 hrs at 4°C. After ultracentrifugation, equal fractions were collected from 
the bottom of the gradient, fractionated through 12.5% SDS-PAGE and analysed by 
immunoblotting (section 2.6). 
 
7.4 Hypothesis 
 
A significant reduction in the incorporation of both V and A in the mutant GAG 
VLPs in comparison to wild-type GAG VLPs would signify that neither Vif nor A3G 
interacts with the basic linker mutant of Pr55GAG. This would in turn be a proof that 
the basic linker region of the nucleocapsid domain is important for the interaction of 
both these proteins with Pr55GAG implying they interact at the same site on Pr55GAG. 
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7.5 Results 
 
When VLPs obtained from 293T cells transfected with *V and G were analysed for 
the presence of Vif and Pr55GAG, both Vif and GAG were found to be concentrated 
in the same fraction of the gradient (aliquot number 6). Similarly in VLPs obtained 
from cells where Vif was co-expressed with GM, no visible difference was detected 
in the amount of Vif getting incorporated into the mutant GAG VLPs when 
compared to wild type GAG VLPs. Densitometric analysis of Vif and the wild type 
& mutant Pr55GAG bands revealed a small reduction in the amount of HA-Vif in 
VLPs obtained from cells co-tranfected with *V and GM when compared with VLPs 
obtained from *V and G however this decrease was not comparable to the huge drop 
observed (~40 fold) in CAT reporter expression in the two-hybrid assay driven by 
AD-Vif and  BD-NCSub (Fig. 7.2 and Figs. 3.11 and 3.12 ). 
When 293T cells were transfected with either G or GM plasmids and pcDNA-3.1-
A3G-HA, the highest concentration of both A3G and Pr55GAG was detected in the 
same aliquot of the gradient (aliquot 4). No visible difference was observed in the 
levels of A3G in mutant GAG VLPs when compared to wild type GAG VLPs. On 
densitometric analysis of the protein bands obtained, a small reduction in the amount 
of A3G was observed in the VLPs obtained from cells co-transfected with A and GM 
when compared to the VLPs obtained from A and G however this reduction was not 
comparable to the significant drop (~40 fold) in CAT reporter expression seen in the 
two-hybrid assay driven by AD-A3G and BD-NCSub (Fig. 7.3 and Figs. 3.8 and 
3.9).  
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Figure 7.2 Application of the VLP assembly assay for studying the interactions of HA-Vif  with Pr55GAG:  GAG VLPs  harvested from the 
supernatant of 293T cells expressing (i) Pr55GAG & HA-Vif (*VG), and (ii) Basic linker GAG mutant & HA-Vif (*VGM) were fractionated on 
20-60% sucrose gradients and gradient fractions analysed by SDS-PAGE and western blotting as described in Materials and Methods.  
(1 & 2) HA-Vif was detected by using mouse anti-HA antibody (1:10,000).  
(3) GAG was detected by using mouse anti-p24 antibody (1:3000). 
Peroxidase conjugated goat anti-mouse (1:5000) was used as the secondary antibody in all blots. Proteins were detected using an ECL-
Chemiluminescence detection kit (GE Healthcare Life Sciences) and analysed using the Bio-Rad ChemiDoc XRS imaging system as described in 
Materials and Methods. The numbering of the gel tracks denotes the specific sucrose gradient fraction analysed while (L) denotes the position of 
the ladder. The positions of Pr55GAG, the GAG mutant and HA-Vif are arrowed. 
(4) Computer-aided densitometric analysis of HA-Vif and GAG protein bands in (1), (2) and (3). The bar chart depicts the Vif/GAG ratio in 
GAG VLPs. 
185 
 
186 
 
 
 
Figure 7.3 Application of the VLP assembly assay for studying the interactions of A3G  with Pr55GAG:  GAG VLPs  harvested from the 
supernatant of 293T cells expressing (i) Pr55GAG & A3G (AG), and (ii) Basic linker GAG mutant & A3G (AGM) were fractionated on 20-60% 
sucrose gradients and gradient fractions analysed by SDS-PAGE and western blotting as described in Materials and Methods.  
(1) A3G-HA was detected by using mouse anti-HA antibody (1:10,000). Peroxidase conjugated goat anti-mouse (1:5000) was used as the  
secondary antibody. A3G was detected using an ECL-Chemiluminescence detection kit (GE Healthcare Life Sciences) and analysed using the 
Bio-Rad ChemiDoc XRS Imaging System as described in Materials and Methods. 
(2) The antibodies in (1) were stripped off the blot by using Stripping Buffer (section 2.6.5) and the same blot was reprobed with anti-p24 
antibody (1:3000) for the detection of GAG. Alkaline Phosphatase conjugated goat anti-mouse (1:25000) was used as the secondary antibody. 
The blot was detected colorimetrically using BCIP/NBT alkaline phosphatase substrate tablets (Sigma-Aldrich B5655) dissolved in deionised 
water (section 2.6.3).   
The numbering of the gel tracks denotes the specific sucrose gradient fraction analysed while (L) denotes the position of the Ladder. The 
positions of Pr55GAG, the GAG mutant and A3G are arrowed. Positive control (+C) is cell extracts transfected with A3G and Pr55GAG (AG). 
(4) Computer-aided densitometric analysis of A3G and GAG protein bands in (1) and (2). The bar chart depicts the A3G/GAG ratio in GAG 
VLPs.  
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Densitometric analysis of the bands revealed that the reduction in the A3G levels 
observed in GM VLPs was two-fold more than the reduction in the Vif levels {Fig. 
7.2 (4) & 7.3 (3)}.  
 
7.6 Summary 
 
A significant drop in the levels of both Vif and A3G in the VLPs derived from the 
basic linker mutant of Pr55GAG was expected. In the mammalian two-hybrid studies 
described in Chapter 3, a 40-fold reduction in the CAT reporter expression levels 
was detected with the basic linker mutant when compared with wild type Pr55GAG 
suggesting that the mutation in this region had a very critical impact on the 
interactions of both these proteins with Pr55GAG. However, in the VLP assembly 
assay, a relatively small decrease was observed in the levels of both Vif and A3G in 
the VLPs obtained from cells transfected with the basic linker GAG mutant when 
compared with VLPs obtained from cells expressing wild-type Pr55GAG.  
This result is difficult to interpret when analysed in conjunction with previous 
observations detailed in Chapter 6. As discussed in section 6.7, non-specific 
incorporation of A3G was observed in the VLPs when A3G and Pr55GAG were 
allowed to co-express in cells. 
The experimental set-up for this assay was essentially the same as that used in 
Chapter 6. Thus it is possible that the assay is confounded by non-specific 
incorporation of these proteins, obviating any possibility of detecting changes in their 
specific incorporation into assembling virus-like particles.  
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Also of note here is the VLPs being concentrated in different aliquot number of the 
sucrose gradient in case of Vif and A3G. While Vif and Pr55GAG were found to be 
concentrated in aliquot number 6, A3G and Pr55GAG were detected in aliquot number 
4. This difference is possibly due to the method involved in preparing the sucrose 
gradient and the instrument error introduced while preparing it. As only a maximum 
of two gradients could be prepared at a time, to obviate this error, the samples to be 
compared (eg VG and VGM or AG and AGM) were prepared at the same time so 
that the gradients in their case were the same.  
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CHAPTER 8 
 
Co-localisation studies of Vif and A3G with 
Pr55GAG 
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8.1 Introduction 
Having shown that both Vif and A3G interact with Pr55GAG in the mammalian two-
hybrid assay set-up and subsequently having detected their presence in GAG VLPs, 
it was of great interest to study their localisation inside cells and the dynamics of 
their positions within cells relative to each other. It was also important to study 
whether the mutations in Pr55GAG which affected binding with Vif and A3G resulted 
in a change in their localisation profiles with respect to Pr55GAG or not. These 
questions were addressed by immunofluorescence imaging of cells expressing 
Vif/A3G and wild-type Pr55GAG/MutGAG using confocal microscope.   
 
8.2 Background 
A number of studies have been reported on the localisation of Vif inside cells. While 
some reports suggest that it localises to the cytoplasmic membrane as well as being 
diffusely distributed throughout the cytoplasm  (Goncalves et al, 1994; Simon et al, 
1997), others have suggested that Vif localises to the cytoskeleton and that this 
localisation is dependent upon intermediate filament vimentin (Karczewski & 
Strebel, 1996). Goncalves et al. and Karczewski et al. also reported observing a light 
nuclear staining for Vif in their studies in addition to the dominant cytosolic form 
with the precise amount varying from preparation to preparation.  Karczewski et al. 
also observed the nuclear localisation of Vif in cells lacking vimentin (Karczewski & 
Strebel, 1996). The difference seen in localisation patterns can be attributed to 
differences in experimental protocol and cell lines used. Goncalves et al. used 
antibody staining of transiently transfected COS cells (Goncalves et al, 1994), 
whereas Karczewski et al. performed their imaging studies in transfected HeLa cells 
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(Karczewski & Strebel, 1996) and Simon et al. used HIV-1 infected H9 cells 
(Goncalves et al, 1994; Simon et al, 1997).  
In contrast to Vif, the position of Pr55GAG in cells is much more constant. It has been 
reported to localise at the cytoplasmic membrane to initiate particle assembly  
(Hermida-Matsumoto & Resh, 2000). In fact Simon et al. have already reported that 
Vif and GAG co-localise at the plasma membrane in HIV-1 infected cells (Simon et 
al, 1997). 
In case of A3G, one group has shown A3G is distributed throughout the cytoplasm, 
with particular concentration occurring at punctuate cytoplasmic collections known 
as P bodies (Wichroski et al, 2005; Wichroski et al, 2006). However Burnett et al. 
were unable to observe the P body localisation of A3G, but rather reported co-
localisation of A3G with Pr55GAG at the plasma membrane and postulated that Gag 
was responsible for the membrane recruitment of A3G (Burnett & Spearman, 2007).   
8.3 Plasmids and antibodies used in the assay 
The rev-independent GFP tagged GAG expression plasmid pGAG-EGFP (G) and 
mutant plasmid MutGAG (GM) incorporating the basic linker mutations abrogating 
Vif and A3G interaction with Pr55GAG have already been described in sections 4.2 
and 4.3. The HA-tagged A3G expressing plasmid pcDNA-3.1-A3G-HA has been 
described in section 6.3.2 while the codon-optimised Vif expression plasmid 
pcDNA-hVif has been described in section 6.3.4.  
The GFP-tagged G and GM proteins were visualised by detecting GFP fluorescence. 
Vif was detected using antibody staining with a rabbit HIV-1HXB2 Vif antiserum 
(1:200 dilution) and HA-tagged A3G was detected using the mouse anti-HA 
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antibody (Sigma-Aldrich Cat. No. H9658 used at 1:250 dilution). Red fluorescent 
Alexa Fluor 594 conjugated goat anti-rabbit (Invitrogen Cat. No. A-11012 at 1:3000 
dilution) and goat anti-mouse (Invitrogen Cat. No. A-11005 at 1:500 dilution) 
antibodies were used as secondary antibodies. 
8.4 Assay 
293 T cells were used for the immunofluorescence studies described in this chapter. 
Cells were transfected with the following combinations of plasmids: 
(i) Vif and Pr55GAG                                     (ii) Vif and MutGAG 
(iii) A3G and Pr55GAG                                 (ii) A3G and MutGAG 
The controls for the assay were the following plasmids transfected individually: 
(i) Vif                                                              (ii) A3G 
(iii) Pr55GAG                                                 (iv) MutGAG 
Post-transfection the cells were processed as described in section 2.9 and observed 
under the Leica sp5 confocal microscope. 
8.5 Results 
When 293T cells were co-transfected with Vif and wild-type GAG plasmids, the 
signal for wild-type Pr55GAG (G) was more intense at the cell membrane where it 
accumulates to assemble into virus particles. A diffuse signal was also seen 
throughout the cell (Fig. 8.1 B). The red fluorescent Vif showed diffuse distribution 
throughout the cytoplasm (Fig. 8.1 C). There was a more limited Vif fluorescence 
also observed in the nucleus overlapping the blue signal from nuclear stain DAPI 
(Fig. 8.1 C and D). The signal for Vif was much weaker than that for the G-GFP 
fusion protein. Although a subset of the expressed Vif protein was seen to be 
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overlapping with G at the cytoplasmic membrane, it was not possible to definitively 
conclude from these data that Vif is localising with Pr55GAG at the membrane.  
When 293T cells were co-transfected together with plasmids expressing Vif and 
mutant Pr55GAG, no visible change was seen in cellular localisation of either Vif or 
the Pr55GAG mutant (GM) compared to that seen with G. The signal for GM was 
stronger at the cytoplasmic membrane (Fig. 8.2 B) but some diffuse signal for the 
protein was seen throughout the cytoplasm. The Vif signal was also spread diffusely 
across the cytoplasm but there was some overlap with the blue DAPI signal in the 
nucleus (Fig. 8.2 C and D). A fraction of Vif did overlap with GM at the plasma 
membrane but again this evidence was not sufficient to suggest a colocalisation 
between Vif and GM.  
Thus no visible change was observed in the cellular localisation profiles of Vif and 
the Pr55GAG mutant compared to that seen when Vif and wild type Pr55GAG were co-
expressed in cells (Fig. 8.1 A and 8.2 A). 
 
 
 
 
 
 
 
195 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Localisation of co-expressed Vif and wild-type Pr55GAG (G) proteins:  
293T cells were co-transfected with plasmids expressing Pr55GAG-GFP fusion and 
Vif proteins using the standard lipofectamine transfection protocol detailed in section 
2.5.3. 48 hours post-transfection, the cells were processed and analysed as described 
in section 2.9. GFP fluorescence indicates the position of the GAG-GFP fusion 
proteins. Vif was detected by using a Rabbit HIV-1 HXB2 Vif antiserum as primary 
antibody followed by red fluorescent Alexa Fluor 594 goat anti-rabbit as the 
secondary antibody. Nuclei are stained blue with the nuclear stain DAPI. Panel B 
shows the position of the GAG-GFP fusion protein. Panel C depicts the position of 
the red fluorescent Vif protein and panel D shows the nuclei of cells stained with 
DAPI. Panel A image is the merge of images B, C and D. A magnification bar of 10 
µm is present in the bottom left corner of each image. 
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Figure 8.2 Localisation of co-expressed Vif and basic linker mutant Pr55GAG 
(GM) proteins:  293T cells were co-transfected with plasmids expressing the mutant  
Pr55GAG-GFP fusion and Vif proteins using the standard lipofectamine transfection 
protocol detailed in section 2.5.3. 48 hours post-transfection, the cells were processed 
and analysed as described in section 2.9. GFP fluorescence indicates the position of 
the mutant GAG. Vif was detected by using a Rabbit HIV-1 HXB2 Vif antiserum as 
primary antibody followed by red fluorescent Alexa Fluor 594 goat anti-rabbit as the 
secondary antibody. Nuclei are stained blue with the nuclear stain DAPI. Panel B 
shows the position of the GAG mutant in cells. Panel C depicts the position of the 
red fluorescent Vif protein and panel D shows the nuclei of cells stained with DAPI. 
Panel A image is the merge of images B, C and D. A magnification bar of 10 µm is 
present in the bottom left corner of each image. 
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When the HA-tagged A3G and wild-type Pr55GAG – GFP fusion proteins were co-
expressed in 293T cells, Pr55GAG was again seen to concentrate at the cytoplasmic 
membrane, a diffuse GAG signal was also detected throughout the cell (Fig. 8.3 B).  
By contrast the HA-tagged A3G, localised primarily to the cytoplasmic compartment 
with a subset of the protein co-localising with Pr55GAG at the plasma membrane (Fig. 
8.3 A and C). Also in contrast to Vif which was visibly localised both in the 
cytoplasm and the nucleus, A3G was exclusively observed in the cytoplasm of cells 
(8.1 C, D and 8.3 C, D). 
When HA-tagged A3G was co-expressed with the basic linker mutant of Pr55GAG, 
again no visible change was observed in its localisation compared to that seen when 
co-expressed with wild type Pr55GAG (Fig. 8.3 and 8.4).  
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Figure 8.3 Localisation of co-expressed A3G and wild-type Pr55GAG (G) 
proteins:  293T cells were co-transfected with plasmids expressing Pr55GAG-GFP 
fusion and HA-tagged A3G proteins using the standard lipofectamine transfection 
protocol detailed in section 2.5.3. 48 hours post-transfection, the cells were processed 
and analysed as described in section 2.9. GFP fluorescence indicates the position of 
the GAG-GFP fusion proteins. A3G was detected by using mouse anti-HA as the 
primary antibody followed by red fluorescent Alexa Fluor 594 goat anti-mouse as the 
secondary antibody. Nuclei are stained blue with the nuclear stain DAPI. Panel B 
shows the position of the GAG-GFP fusion protein. Panel C depicts the position of 
the red fluorescent HA-tagged A3G and panel D shows the nuclei of cells stained 
with DAPI. Panel A image is the merge of images B, C and D. A magnification bar 
of 10 µm is present in the bottom left corner of each image. 
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Figure 8.4 Localisation of co-expressed A3G and basic linker mutant Pr55GAG 
(GM) proteins:  293T cells were co-transfected with plasmids expressing the mutant 
Pr55GAG-GFP fusion and HA-tagged A3G proteins using the standard lipofectamine 
transfection protocol detailed in section 2.5.3. 48 hours post-transfection, the cells 
were processed and analysed as described in section 2.9. GFP fluorescence indicates 
the position of GM. A3G was detected by using mouse anti-HA as the primary 
antibody followed by red fluorescent Alexa Fluor 594 goat anti-mouse as the 
secondary antibody. Nuclei are stained blue with the nuclear stain DAPI. Panel B 
shows the position of the mutant GM protein. Panel C depicts the position of the red 
fluorescent HA-tagged A3G and panel D shows the nuclei of cells stained with 
DAPI. Panel A image is the merge of images B, C and D. A magnification bar of 7.5 
µm is present in the bottom left corner of each image. 
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When Vif was expressed alone in cells, it was distributed diffusely across the cell but 
with some concentration in the cytoplasm compared to the nucleus (Fig. 8.5 A and 
B). Thus there was no visible difference found in the localisation of Vif when 
expressed alone or when in combination with Pr55GAG.  
When A3G was expressed alone in cells, it exclusively localised to the cytoplasm 
(Fig. 8.5 D) with no visible signal in the nucleus (Fig. 8.5 C). Thus the localisation of 
A3G in cells was similar in both the presence or in the absence of Pr55GAG. 
When both G and GM proteins were expressed individually in cells, they both 
localised to the cytoplasmic membrane (Fig 8.6 A, B and C, D). In a subset of cells, 
both the G and GM were seen to be diffusely scattered across the cell, mainly in the 
cytoplasm but a small fraction of them was present in the nucleus as well. This 
phenomenon was also observed with co-expression of Pr55GAG with Vif/A3G 
described earlier, where in some cells GAG was seen diffusely spread across the 
cytoplasm and also in the nucleus to some extent in addition to its strong localisation 
at the plasma membrane. The reason for this phenomenon could be the cells being at 
a different stage of GAG protein synthesis and assembly. The cells where GAG is 
present in the cytoplasm are presumably at an earlier stage than the cells where GAG 
has reached its ultimate destination, the plasma membrane, for particle assembly. 
The other possible reason could be due to the over-expression of GAG proteins 
inside cells which might lead to the swamping of some cells and hence non-specific 
localisation of Pr55GAG within the cell. However it is important to note that the 
highest intensity of fluorescent signal obtained with both G as well as GM was still 
from the plasma membrane in all cells. 
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Figure 8.5 Localisation of Vif and A3G proteins expressed singly in cells:  293T 
cells were individually transfected with plasmids expressing Vif and HA-tagged 
A3G proteins using the standard lipofectamine transfection protocol detailed in 
section 2.5.3. 48 hours post-transfection, the cells were processed and analysed as 
described in section 2.9.  Vif was detected by using a Rabbit HIV-1 HXB2 Vif 
antiserum as primary antibody followed by red fluorescent Alexa Fluor 594 goat 
anti-rabbit as the secondary antibody. A3G was detected by using mouse anti-HA as 
the primary antibody followed by red fluorescent Alexa Fluor 594 goat anti-mouse as 
the secondary antibody. Nuclei are stained blue with the nuclear stain DAPI. Panels 
B and D depict the positions of the Vif and A3G proteins respectively. Panels A and 
C are merged images of B and D respectively with nuclear stain DAPI. A 
magnification bar of 10 µm is present for images A and B and 7.5 µm for images C 
and D in the bottom left corner. 
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Figure 8.6 Localisation of wild-type (G) and mutant Pr55GAG (GM) proteins:  
293T cells were individually transfected with plasmids expressing GFP tagged G and 
GM proteins using the standard lipofectamine transfection protocol detailed in 
section 2.5.3. 48 hours post-transfection, the cells were processed and analysed as 
described in section 2.9.  GFP fluorescence indicates the position of the GAG 
proteins G and GM inside cells. Nuclei are stained blue with the nuclear stain DAPI. 
Panels B and D depict the positions of G and GM respectively. Panels A and C are 
merged images of B and D respectively with nuclear stain DAPI. A magnification 
bar of 25 µm is present for images A and B and 10 µm for images C and D in the 
bottom left corner of each image. 
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8.6 Summary 
Both A3G and Vif have been shown to interact at the same site on Pr55GAG, in the 
basic linker region of its nucleocapsid domain (chapter 3). Furthermore, Vif has been 
shown to quench the signal of the CAT reporter in an assay driven by the A3G-
Pr55GAG interaction suggesting that Vif competes with A3G for Pr55GAG binding 
(chapter 5). The experiments described in this chapter were performed to compare 
the localisation of both Vif and A3G in the presence of wild-type Pr55GAG (G) or the 
basic linker GAG mutant (GM).  
No visible change was observed in the localisation pattern of either Vif or A3G in the 
presence of GM when compared to their co-expression with G. However the 
localisation patterns of Vif and A3G were found to differ considerably from each 
other. Vif was diffusely scattered across the whole cell, whereas A3G was 
exclusively compartmentalised to the cytoplasm with no evidence of its presence in 
the nucleus.  
When Vif was co-expressed with either G or GM, there was overlap of a small 
fraction of Vif with G or GM at the plasma membrane. However the extent of this 
localisation was small compared with the amounts of each protein expressed. Hence 
it was not possible on the basis of these data to conclude that there was a specific 
localisation between Vif and Pr55GAG.  In the case of A3G, the overlap of a subset of 
the protein with either G or GM was much more prominent than that seen with Vif, 
allowing it to be argued that a fraction of A3G protein was co-localising with both G 
and GM proteins.  
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However it was not possible to accurately quantify the extent of this colocalisation. 
A better experimental design than that employed with 293T cells would have been to 
infect the non-permissive cells like H9 with wild-type HIV-1 and mutant HIV-1 and 
then probe the various proteins expressed within cells. This approach would have 
mimicked the in vivo infection model of HIV-1 very closely. However one problem 
that could have been encountered in this alternative strategy might be the sensitivity 
of the antibodies used to detect very low levels of endogenous Vif, A3G and Pr55GAG 
proteins. Of note here is the low sensitivity of the primary antibody used in the 
detection of Vif in these studies resulting in very low signal intensity. 
An additional question that these studies were intended to address was to investigate 
if there was any change in the localisation pattern of either Vif or A3G in the 
presence or absence of Pr55GAG. However the experimental controls consisting of 
Vif, A3G, G and GM proteins expressed individually in cells gave similar 
localisation patterns compared to those seen when they were co-expressed with other 
proteins. Thus co-expression with Pr55GAG had no effect on the localisation pattern 
of either Vif or A3G. 
In the light of these results, it becomes important to discuss the proposed model for 
the competition between Vif and A3G for Pr55GAG binding and virion incorporation. 
It is known that different GAG molecules in cells meet with different fates (Klein et 
al, 2007). An immature HIV virion has been estimated to contain ~5000 molecules of 
Pr55GAG (Briggs et al, 2004). However various reports suggest that the number of 
Vif/A3G molecules incorporated into virions is only in the region of ~1% of the total 
GAG molecules (Liu et al, 1995; Xu et al, 2007). Thus not every GAG molecule can 
be interacting with a Vif/A3G molecule. However it is possible that interaction is 
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restricted to a few designated GAG molecules which are marked by the presence of 
some intermediary such as viral RNA, and the competition between Vif and A3G for 
GAG binding occurs at this intermediary. While Vif has been shown to have a strong 
affinity for the HIV-1 RNA in both the 5’ UTR and GAG region sequences 
(Bernacchi et al, 2007; Henriet et al, 2005) , there is controversy about the RNA 
involvement in the packaging of A3G into virions. Whether RNA is involved or not 
and whether if it is involved, is it cellular 7-SL RNA or viral genomic RNA (Bach et 
al, 2008; Khan et al, 2007; Khan et al, 2005; Strebel & Khan, 2008; Svarovskaia et 
al, 2004; Wang et al, 2007a) are all still open to question (section 9.2.2). 
Thus it could be argued from the results obtained in this section that it is more likely 
that the competition between Vif and A3G for Pr55GAG binding requires the presence 
of an intermediary, and viral genomic RNA seems excellently placed to complete 
this jigsaw. 
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CHAPTER 9 
 
Discussion 
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9.1 General summary 
 
The relative importance of the innate immune response in combating virus infections 
has become recognised with the increased understanding of the counter-measures 
that various viruses have evolved to block different facets of this response. The A3G 
based block to lentivirus replication and the Vif accessory protein that acts to block it 
is a good example of the type of innate immune response for which the virus has 
evolved an effective counter-measure. Consequently insights into this mechanism of 
action may provide for the development of novel anti-viral strategies.  
The currently favoured model for Vif’s primary mechanism of action involves it 
promoting the ubiquitination of A3G through stimulating its association with a Cullin 
5 (Cul5) based E3 ligase which in turn leads to the proteasome mediated degradation 
of A3G to lower its intracellular level below the undefined threshold necessary for its 
incorporation into maturing virus particles (Yu et al, 2003). However the failure of 
this model to adequately account for an increasing number of observations is 
prompting its re-evaluation (Ao et al, 2008; Kao et al, 2004; Opi et al, 2007). The 
early recognition that A3G becomes incorporated into maturing virions through a 
specific interaction with Pr55GAG coupled with  in vivo confirmation (Syed & 
McCrae, 2009) of previous reports in vitro (Bouyac et al, 1997a) showing that Vif 
also interacts specifically with Pr55GAG prompted speculation that an alternative 
model of Vif’s primary action may be operating in which it would compete with 
A3G for incorporation into the virus particle. The simplest model for such a 
competition would involve both proteins interacting with the same site on Pr55GAG.  
208 
 
The first observations on the interaction between A3G and Pr55GAG pointed to it 
binding to the I domain located near the amino terminus of the NC region of the 
protein (Luo et al, 2004). However this report was contradicted in a subsequent study 
which indicated that the basic linker region somewhat further along the NC 
component of Pr55GAG was involved in this interaction (Burnett & Spearman, 2007). 
The results reported here in which only the substitution mutations (NCSub) in NC 
affected the interactions are in agreement with these later studies (Chapter 3). 
However Spearman et al. had employed truncated versions of Pr55GAG to study the 
sites of interaction of A3G with GAG. Hence the experiments conducted as a part of 
this thesis employing a full length version of Pr55GAG protein are more accurate than 
any of the previously published reports attempting to analyse the A3G-Pr55GAG 
interaction. Precise localisation of the interaction sites for the Vif- Pr55GAG 
interaction has not been reported previously but the results reported here 
demonstrating that Vif interacts with the same region of NC as A3G provides support 
for a simple competition model since it allows for the binding of one protein to block 
the binding of the other (Chapter 3). As neither Vif nor A3G was able to interact with 
the NC-Sub mutant, it was important to show that this mutated Pr55GAG was still 
functional and this was done by demonstrating that it could still self-assemble into 
virus-like particles (Chapter 4). 
Having increased the probability of competition between A3G and Vif for 
incorporation into maturing virus particles, it was important to show that competition 
between the two proteins for interaction with Pr55GAG occurred in vivo. The 
modification to the two-hybrid assay in which increasing levels of a BD-Vif fusion 
were able to compete with AD-A3G for interaction with BD- Pr55GAG provided clear 
evidence that this is the case (Chapter 5). This observation which indicates that Vif 
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has a higher affinity for Pr55GAG than A3G was confirmed by the finding that 
increasing levels of AD-A3G were not able to block the interaction between BD-Vif 
and AD-Pr55GAG. One possible interpretation of this result could be that increasing 
amounts of BD-Vif was competing with BD-Pr55GAG for the UAS on the reporter 
vector thereby reducing reporter expression. However this was found not to be the 
case by employing the empty BD vector, the hypothesis being that if BD-Vif was 
competing with BD-Pr55GAG for the UAS on the reporter vector, empty BD vector 
would also exert a similar effect and if this was found to be the case there would be a 
uniform reduction in reporter expression across all samples when compared to the 
stepwise reduction seen previously. However increasing the BD-Vif levels in a two-
hybrid assay driven by AD-A3G and BD-Pr55GAG and balancing the total amount of 
DNA with empty BD vector also resulted in a stepwise reduction in reporter gene 
expression implying that the competition was indeed occurring between Vif and A3G 
for Pr55GAG binding. It was also important to ensure that these results were not due to 
the increased levels of BD-Vif leading to the proteasome based degradation of AD-
A3G and hence lower levels of reporter gene expression in the two-hybrid assay. The 
fact that the levels of HA tagged A3G expressed in co-transfected cells remained 
broadly constant across the range of BD-Vif used showed that it was not promoting 
the degradation of A3G under the assay conditions employed (Chapter 5). 
To independently corroborate these competition data, sucrose gradient analysis of 
GAG VLPs was performed (Chapter 6 & 7). However this strategy didn’t yield the 
desired results due to the failure of the positive control to function optimally. The 
most probable cause of this failure could be due to the non-specific incorporation of 
both Vif and A3G into GAG virus-like particles. As all the proteins in this study 
were over-expressed in cells, the high levels of Vif or A3G could have then bound 
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non-specifically to Pr55GAG to get incorporated into the budding GAG VLPs.  This 
made it very difficult to measure the specific incorporation of these proteins in VLPs 
in turn making it impossible to accurately analyse the data obtained from these 
experiments.  
When the localisation patterns of Vif, A3G, Pr55GAG and the basic linker GAG 
mutant were studied using confocal imaging, no visible change in localisation of 
either Vif or A3G was observed when they were co-expressed with the GAG mutant 
when compared to their co-expression with wild type Pr55GAG. Also no change was 
detected in the localisation patterns of both Vif/A3G when expressed individually or 
in combination with Pr55GAG (Chapter 8). These results when analysed together with 
the stoichiometry of both these proteins in the budding HIV virion point towards a 
scenario where the competition between Vif and A3G could be occurring at a few 
designated GAG molecules, the molecules being determined by the presence of an 
intermediary, possibly viral genomic RNA, which mediates these interactions.  
The finding of competition in vivo between Vif and A3G for interaction with 
Pr55GAG allows for the proposition of an alternative model for the action of Vif in 
which it overcomes the A3G based inhibition of virus replication by blocking its 
incorporation into the assembling virus particle. This action of Vif being assisted by 
its well characterised ability to lower the levels of A3G present in infected cells by 
promoting its ubiquitination and subsequent targeting to the proteasome for 
degradation. 
In this new model of Vif action the main observation that remains to be understood is 
how this competition can be achieved in a way that is consistent with the known 
stoichiometry of these proteins in the assembled virion. There are various estimates 
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of the amount of Vif or A3G found in mature virus particles, but none of these 
amounts to more than a small fraction (~1%) of the number of Pr55GAG molecules 
involved in forming a mature virion (Liu et al, 1995; Xu et al, 2007). The following 
could be the probable scenarios where the proposed new model for Vif’s primary 
action could fit within the parameters of existing data available regarding the 
stoichiometry of the interacting components within mature HIV virions: 
(a) The first possibility which seems more likely considering the evidence in its 
favour is the involvement of the same RNA intermediary for the interaction of 
both Vif and A3G with Pr55GAG.  
(b) The second possible explanation would be a direct interaction between Vif and 
Pr55GAG such that every GAG molecule in the cell is bound by Vif thereby 
blocking A3G binding to Pr55GAG and thus preventing its incorporation into 
budding virus particles. This looks unlikely because of the immunofluorescence 
data obtained where not every Pr55GAG molecule was seen to co-localise with co-
expressed Vif/A3G. 
Both these possibilities have been addressed in greater detail in section 9.2.2 later in 
this chapter. Clearly further studies will be needed to provide an explanation of how 
the proposed new model for Vif’s primary action fits with the stoichiometry of the 
interacting components. 
 
 
 
 
 
 
212 
 
9.2 Future work 
 
9.2.1 Validating the conclusions drawn from biochemical assays in this study 
with whole virus based infectivity assays: 
All the results in this study have been obtained from surrogate assay systems due to 
the practical constraints placed on working with infectious HIV. Two important 
limitations of such assays are that they only involve a subset of the HIV gene 
complement and as biochemical assays they lack the dynamic range available in 
biological infectivity assays. Hence the immediate logical step forward would be to 
validate the findings obtained in the mammalian two-hybrid assays with whole virus 
based infectivity assays.  
Hence the aim would be to design virus infectivity assays where the following 
questions would be answered: 
9.2.1.1 Do Vif and A3G interact at the same site on Pr55GAG? 
The NCSub mutant of Pr55GAG which resulted in a huge drop in CAT reporter 
expression with both Vif as well as A3G had two substitution mutations in its 
Pr55GAG sequence whereby two basic amino acids namely Arginine and Lysine in the 
basic linker region of the NC component of the precursor were replaced by two 
acidic amino acids namely two Glutamic acids. These same mutations could be 
possibly incorporated into the Pr55GAG gene sequence in an infectious molecular 
clone of HIV, although of course it must be acknowledged that such a viral mutant 
may not be viable. 
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The hypothesis would be that any virus carrying these NC substitutions would not be 
able to incorporate either Vif or A3G within its budding particles. Theoretically, this 
would mean that the virus would be able to produce fully infectious virus from non-
permissive cells which constitutively express A3G as efficiently as permissive cells, 
even in the absence of a functional Vif protein. 
However this would in effect mean that the resultant mutated virus would be 
potentially more virulent than wild-type HIV-1. Hence it would be prudent to restrict 
the host range of the mutant carrying such mutations by for example incorporating 
deletions in the env gene such that growth would be restricted to cells in which 
complementing env gene product was being expressed. 
9.2.1.2 To study the competition between Vif and A3G for Pr55GAG binding: 
The aim would be essentially to repeat the experiments carried out in Chapter 6, with 
the only difference being that an infectious clone of HIV would be employed instead 
of a Pr55GAG expression plasmid.  
The experiment would entail measuring the infectious viral yield obtained when an 
infectious molecular clone of HIV-1 is allowed to co-express with the degradation-
resistant variant of A3G. The hypothesis would be that inspite of not being able to 
degrade the variant, the Vif protein in HIV will still be able to outcompete A3G and 
prevent its incorporation into newly formed progeny virions thereby preserving the 
normal viral infectivity. Thus the reduction observed in the level of the A3G variant 
in the progeny virions in presence of a functional Vif protein would be roughly 
similar to the decrease in the amount of wild-type A3G observed in virions. 
However, there could still be a potential problem of non-specific incorporation of 
transiently expressed A3G. The more technically correct experimental set-up would 
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mean studying viral infectivity in a cell line which stably expresses the degradation 
resistant variant of A3G instead of transiently expressed protein as this set-up would 
mimic closely the natural course of infection of the virus in non-permissive cells 
constitutively expressing A3G. 
9.2.2 Does a requirement for RNA explain the stoichiometry of the Vif-Pr55GAG 
and A3G-Pr55GAG interaction?  
While the competition hypothesis of Vif action has been demonstrated in the 
mammalian two-hybrid data in this thesis, it is puzzling that only ~1% of the 
Pr55GAG assembled into the maturing virion appears to be interacting with either Vif 
or A3G. One way to account for this is to propose that the interactions between these 
proteins requires a third component, specifically viral RNA, and it is the interaction 
with this third component at a critical time in the virion assembly process that both 
governs the competition between Vif and A3G and determines the amount of either 
protein finally encapsidated into the infectious virion. The overall stoichiometry of 
the process being determined by saturation of the RNA sequence/structure required 
for Pr55GAG –Vif/A3G interaction with one of the interacting proteins, which in vitro 
studies have pointed to being Pr55GAG (Zhang et al, 2000). The area of RNA 
involvement in Vif and/or A3G packaging is currently one of considerable 
controversy, with no clear consensus in the literature concerning the involvement of 
particular RNA species in the packaging of either protein or indeed general 
agreement as to whether any RNA is involved in the interaction between these 
proteins.  
Vif is a basic protein at physiological pH which has intrinsic nucleic acid binding 
activity, but the consensus view is that it has a particular affinity for HIV RNA 
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(Dettenhofer et al, 2000; Khan et al, 2001) and more specifically for the 5’UTR and 
GAG region of the viral genome (Bernacchi et al, 2007; Henriet et al, 2005). 
Interestingly, sequences covering the region of GAG known to be involved in the 
Vif-RNA interaction are present in the Pr55GAG plasmid constructs used in two-
hybrid interaction assays carried out in this study (Chapter 3). Hence it is possible 
that the positive interaction seen between Vif and Pr55GAG is due to the presence of 
the RNA intermediary corresponding to the region of GAG involved in the Vif-RNA 
interaction.  
The picture for A3G is even more complex with no agreement as to whether RNA is 
required for its packaging and further disagreement as to whether it is cellular 7SL 
RNA or viral RNA that is involved (Bach et al, 2008; Khan et al, 2007; Khan et al, 
2005; Strebel & Khan, 2008; Svarovskaia et al, 2004; Wang et al, 2007a).  
To investigate the involvement of RNA in the interaction between Pr55GAG and Vif 
or A3G two in vitro assays can be used.  
9.2.2.1 Qualitative assay 
The expression of GST- Pr55GAG in E.coli and its purification for use in in vitro 
assays has been accomplished successfully at Warwick (Syed, 2008). Expression 
constructs for Vif and A3G have also been made for producing radio-labelled 
proteins in a T7 based coupled transcription-translation system from which all 
endogenous mRNA has been removed post-translationally using micrococcal 
nuclease treatment (Pelham & Jackson, 1976). Using these reagents, assays could be 
set up to (a) investigate the ability of the GST-Pr55GAG to retain radio-labelled Vif or 
A3G on glutathione-sepharose beads, (b) analyse the involvement of specific RNAs 
in this interaction and (c) decipher the order in which these entities need to be mixed 
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in order to facilitate retention. This assay could shed light on the qualitative 
requirement of specific RNAs required for the interaction between these components. 
9.2.2.2 Quantitative assay 
To obtain information on the relative affinities of Vif or A3G for Pr55GAG and the 
effect(s) of specific RNAs on such affinities, surface plasmon resonance (SPR) based 
assays in a Biacore using chips coated with immobilised GST-Pr55GAG fusion protein 
can be employed (Nakadai et al, 2004; Nakajima et al, 2005). In-vitro expression of 
Vif/A3G is unlikely to produce sufficient protein to be used as the analyte in these 
assays. So bacterially expressed and purified GST-Vif and GST-A3G constructs can 
be used from which if necessary the GST tag can be removed using Factor Xa 
cleavage (Syed, 2008). This assay would give quantitative information regarding the 
relative affinities of Vif and A3G for Pr55GAG thus providing indirect supporting 
evidence towards the competition hypothesis of Vif action. In addition, it can also 
give an insight into the involvement of specific RNAs in the Vif/A3G- Pr55GAG 
interaction. 
The aim of both of these experimental approaches will be to assess if and how RNA 
is involved in the interaction between Pr55GAG and Vif/A3G and to confirm the 
nature and location of the sequences/structures necessary for these interactions 
through supplementing the assays with specific RNAs generated from transcription 
vectors. The weight of current evidence does suggest that an RNA intermediary is 
involved in the interaction process. If this is confirmed to be the case then it could 
explain how competition between Vif and A3G occurs in light of the stoichiometry 
of the final amounts of these proteins in the virus particle.  
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It does of course still remain possible that this will not prove to be the explanation, in 
which case an alternative possibility can be investigated. The molar amounts of 
Pr55GAG and Vif synthesised in virus infected cells are broadly similar and so it 
remains possible that every molecule of Pr55GAG is involved in an interaction with 
Vif shortly after its synthesis, blocking any possible interaction with A3G. If this 
occurred then some novel mechanism would be required to break the interaction at 
the cell membrane as Pr55GAG is being assembled into virus particles and thereby 
strip the great majority of the Pr55GAG molecules of their interacting Vif. This model 
of Vif action also demands that none of the A3G present in virus infected cells would 
be able to access Pr55GAG at the cell membrane as molecules stripped of their 
interacting Vif were generated. This hypothesis could be investigated using co-
immunoprecipitation studies which would predict that early in the replication cycle 
prior to virus particle formation, exhaustive immunoprecipitation with anti-Vif sera 
would remove all Pr55GAG from cell lysates meaning that subsequent precipitation of 
the lysate with anti-p24 sera would fail to precipitate any Pr55GAG. 
9.2.3 What is the minimum region of Pr55GAG required for interaction with Vif 
or A3G? 
If competition for interaction with Pr55GAG proves to be the primary mechanism by 
which Vif functions to overcome the A3G based inhibition, then a novel approach to 
antiviral development could be to titrate out the Vif in infected cells by having it bind 
to a peptide analogue of Pr55GAG. This would leave the A3G expressed in the host 
cells to interact with viral Pr55GAG and hence get incorporated into assembling 
virions with its consequent inhibitory effects on subsequent virus replication. For this 
approach to be viable the interaction site for Vif and A3G on Pr55GAG would need to 
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be sufficiently discrete that it can be mimicked in a small peptide capable of being 
efficiently delivered to cells. Our studies on the interaction site have shown that it 
involves the basic linker region of the NC component of Pr55GAG. Subsections of 
Pr55GAG, starting with full length NC (~70 amino acids), can be assayed in the 
mammalian two-hybrid system for their ability to interact with Vif/A3G. If full 
length NC gives positive interaction with Vif and A3G then smaller fragments of NC 
could be used in these experiments with the objective of localising the minimum size 
peptide necessary for positive interaction with Vif. If evidence from experiments in 
section 9.2.2 points towards the involvement of viral genomic RNA in the interaction 
of both Vif and A3G with Pr55GAG then co-expression of HIV RNA covering more 
5’ terminal regions of the HIV genome may be needed in these experiments to 
achieve a positive interaction. After defining the minimum Pr55GAG peptide needed 
for the Vif interaction, the next step would be to examine the feasibility of using 
peptide transfection of virus infected non-permissive cells as a route to blocking the 
action of Vif and hence developing a novel approach to anti-retroviral therapy. 
To date, we are a long way away from finding a satisfactory cure to HIV/AIDS or 
even from the development of an efficacious vaccine against this virus. Hence the 
need of the hour is to study the life-cycle and mechanism of replication of HIV on a 
molecular level and identify new targets which could be potentially used to develop 
novel anti-retroviral drugs. 
Towards the same, the findings in this study are a step forward in this direction. 
Although the research results in this study warrant further detailed analyses, these 
findings have the potential to make a significant impact to the field. Importantly, this 
new hypothesis provides a testable system for the rational development of novel 
antiviral strategies that target Vif function.   
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Figure 1.1 Sequence analysis of the NCDel mutant of Pr55GAG. (A) 
Chromatogram showing the deletion of amino acids 4 to 12 from the N-terminal 
region of the Nucleocapsid domain of Pr55GAG. The beginning of the Nucleocapsid 
sequence has been indicated by arrows and the amino acid number has been 
highlighted alongside the position of the HpaI site. (B) Chromatogram showing the 
in-frame junction of Pr55GAG with pM vector DNA binding domain (BD) separated 
by an EcoRI site in the NCDel mutant of Pr55GAG. 
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Figure 1.2 Sequence analysis of the NCSub mutant of Pr55GAG. (A) 
Chromatogram showing the substitution of amino acids Arginine (R) and Lysine (K) 
with two Glutamic acids (E) in the basic linker region of the Nucleocapsid domain of 
Pr55GAG. The orientation of the Pr55GAG sequence has been indicated by an arrow 
and the respective amino acid position has been depicted with symbols. (B) 
Chromatogram showing the in-frame junction of Pr55GAG with pM vector DNA 
binding domain (BD) separated by an EcoRI site in the NCSub mutant of Pr55GAG. 
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Figure 1.3 Sequence analysis of the GM mutant of Pr55GAG. (A) Chromatogram 
showing the substitution of amino acids Arginine (R) and Lysine (K) with two 
Glutamic acids (E) in the Basic Linker region of the Nucleocapsid domain of 
Pr55GAG. The orientation of the Pr55GAG sequence has been indicated by an arrow 
and the respective amino acid position has been depicted with symbols.  (B) 
Chromatogram showing the end of the Pr55GAG sequence flanked by a BamHI site in 
the GM mutant of Pr55GAG. 
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Figure 1.4 Sequence analysis of the degradation resistant variant of A3G (AM). 
Chromatogram showing the substitution of amino acid Cysteine (C) with Alanine (A) 
at position 97 within the A3G sequence by site-directed mutagenesis of pcDNA3.1-
A3G-HA (A). The orientation of the APOBEC3G sequence has been indicated by an 
arrow and the position of the mutation has been depicted.   
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Figure 1.5 Sequence analysis of HA-pcDNA-HVif (*V). Chromatogram showing 
the 3×HA tags flanked by two EcoRI sites in-frame with the N-terminal beginning of 
the Vif sequence in plasmid pcDNA-HVif (V). The orientation of the Vif sequence 
has been indicated by an arrow.   
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